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Abstract 
Carbohydrate Transporters (GLUTs) are responsible for the transportation of sugars 
into the cell and have been of great interest in research for decades.  Alterations or 
mutations that result in overexpression of GLUTs have been linked to a great number of 
diseases including, obesity, diabetes, and cancer.  Differentiation between transporters 
has been shown to be incredibly difficult due to the highly conserved nature of the 
transporter structure, and thus specific targeting of transporters has proven a difficult 
challenge.   Additionally, the GLUTs have been shown to high flexibility in their 
conformations, so it is difficult to determine what can or cannot pass through the 
transporter, which has led to many failed attempts at targeting these transporters.  So in 
an attempt to gain a better understanding of one transporter specifically, GLUT 5, a 
transporter known to be responsible for fructose transporter, new probes were created by 
conjugating 1-amino-2,5-anhydro-D-mannitol and various fluorescent coumarins. The 
probes were tested in both normal and cancerous cell lines in order to determine their 
uptake kinetics and transport specificity.  To establish transport specificity the probes 
were tested in the presence of various competitive and noncompetitive inhibitors. The 
probe transport was analyzed through various meanings including microplate setting, 
immunostaining, and confocal microscopy.  The combined analysis of the probes has 
shown to be GLUT5 specific which allows for their use as   for biochemical and 




1.1 Sugar Uptake and Metabolism in Health and Disease 
There are currently over one hundred known cancer types that can affect the human 
body, and they all share the common traits of rapid and uncontrolled proliferation.  Sustain 
a rapid state of proliferation requires an increased uptake of nutrients and cancer cells have 
developed a way to rapidly uptake larger amounts of the nutrients available in their 
microenvironment.  In normal cells both nutrient uptake and proliferation are controlled by 
growth factors, whereas cancer cells have overcome this dependence through the alteration 
of receptor-initiated signaling pathways.  Certain pathways are responsible for the 
activation of nutrient uptake and metabolism.  This phenomenon of enhanced nutrient 
glucose uptake by cancer cells was first described by Otto Warburg, which has established 
aberrant metabolism as a cancer characteristic for over 70 years.  The increased nutrient 
uptake is then consumed in cancer cells with a system which shifts the metabolism from 
the standard and efficient oxidative phosphorylation to the much less effective aerobic 
glycolysis, even while there is sufficient oxygen present.  This shift is attributed to defects 
in the mitochondria leading to impaired respiration in cancers, creating a need for an 
alternative pathway for energy generation.  Advances in the understanding of caner 
metabolism has shown that cancers can actively utilize both parts, glycolysis in the cytosol 
and oxidative phosphorylation in the mitochondria, simultaneously.  The notable increase 
in the nutrient uptake in cancer vs normal cells provided the foundation for targeting 
cellular metabolism to diagnose, treat, and monitor cancer.  For example, the enhanced 
2 
glucose uptake in cancers provided a base for targeting cancers with radiolabeled glucose 
and the development of tumor positron emission topography (PET) imaging with 18F-fluro-
2-deoxy-D-glucose (FDG).1  Additionally, enhanced nutrient uptake has been used to direct 
chemotherapeutic agents to cancers through glycoconjugatation.2  Taking advantage of the 
increased nutrient uptake in cancers will be further discussed in later sections.  
1.2 Sugar Transport Mechanism 
Sugars transport across the eukaryotic cellular membrane is mediated by two families 
of glucose transporters, sodium-dependent glucose transporters (SGLTS) and facilitative 
glucose transporters (GLUTS).  Sugar transport by GLUTs is facilitated by a concentration 
gradient while SGLTs use sodium ion co-transportation to deliver glucose against a 
gradient into the cell.  The mechanistic difference in transport is vital due to the one of the 
primary differences in purpose between GLUTs and SGLTS, being that SGLTs are solely 
responsible for glucose reabsorption through the kidneys.   Once reabsorbed from the 
bloodstream through SGLTs the sugars are then redistributed through the body via GLUTs.  
As SGLTs were not the focus of the work discussed in this document, there will be no in-
depth analysis of those transporters.  
3 
GLUTs are… The 
structures of GLUTs are 
highly conserved and 
usually consist of twelve 
transmembrane helixes 
(TMs) split into two 
clusters of six.  
Additionally, they 
usually have from four to 
five intercellular helixes 
(ICs) that are responsible for stabilization.  The transport of sugar substrates through a 
GLUT is concentration gradient dependent, i.e. substrates are moved from areas of high 
concentration, usually outside the cell in the blood stream, to areas of low concentration, 
commonly the inside of the cell.  The transport process starts with the GLUT protein being 
in the outward open conformation, where a substrate is capable of binding to the active 
site.  With the binding of the substrate to the active site, interactions between the TM’s 
trigger a conformational change within the protein that results in the substrate translocation 
inside the cell.  The transport of the sugar through the GLUT can proceed in either 
directions (uniporter), and some GLUTs are also considered to support simultaneous 
transport of a substrate in both directions (antiporter). However, in the condition of active 
sugar phosphorylation, the concentration of sugar inside the cell remains low, resulting in 

























Figure 1. A working alternating access model for GLUT-mediated 
transport. Depicted are the predicted conformations required for a 
complete transport cycle. ICH, TM, transmembrane helix. 
 
4 
phosphorylated counterparts. Thus, overall, transport of a sugar through a GLUTs can be 
considered constant as long as the phosphorylation is being maintained.  
There are currently fourteen known variants of GLUTs which are grouped into three classes 
based upon on their structural, substrate, and genetic sequence similarities (Table 1). Class 
I consist of GLUTs 1-4 and 14 and are primarily responsible for glucose and galactose 
transport.  Class II includes GLUTs 5, 7, 9, and 11, which are primarily fructose 
transporters.  Class III includes GLUTs 6, 8, 10, 12, and 13, which are all unusual members 
of the facilitative transport family. The binding of glucose is highly conserved in the Class 
I transporters, due in part to the fact that GLUTs 2-4 all have high sequence similarity to 
GLUT 1, with them being 83%, 93%, and 85% respectively for GLUTs 2-4. The minor 
Table 1. GLUT transporter expression in healthy tissues and substrate preferences 
Transporter 
and Class 
Expression in Normal Cells Substrate 
I:  GLUT1 erythrocytes glucose, galactose 
GLUT2 renal tubular, intestinal epithelial, liver and 
pancreatic β cells 
glucose, galactose, fructose, 
glucosamine 
GLUT3 neurons and placenta glucose, galactose, mannose 
GLUT4 adipose tissue and striated muscle glucose, glucosamine, galactose, 
mannose, xylose 
GLUT14 testis glucose, galactose 
II: GLUT5 intestinal epithelial, erythrocytes, sperm fructose 
GLUT7 apical membrane in small and large intestine glucose, fructose 
GLUT9 liver, kidney and intestine glucose, fructose 
GLUT11 muscle, heart, fat, placenta, kidney, and 
pancreas 
glucose, fructose 
III: GLUT 6 renal tubular, intestinal epithelial, liver and 
pancreatic β cells 
glucose 
   GLUT 8 testis, brain, fat, liver, and spleen glucose, fructose 
  GLUT 10 heart and lung glucose, galactose 
  GLUT 12 insulin-sensitive tissues glucose, galactose, fructose 
  GLUT 13 brain myoinositol 
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alterations in residue result in the passage of other substrates, in addition to glucose. The 
crystal structure of the human GLUT1, hGLUT1, has shown that helices 1 and 7 as the 
major constituents of the extracellular gate in the inward open conformation. In this state 
TM1 and TM7 are in contact with one and another on the extracellular side, representing 
the major constituents of the extracellular gate. The current proposed interaction that 
facilitate conformational change involve the interactions between the C and N domains, 
and once the substrate is released because of the concentration gradient, the interactions 
between the C and N residues equilibrate and following deprotonation GLUT 1 returns to 
its original extracellular state. GLUT 1 is the most studied and targeted of the GLUT 
transporters as of writing this dissertation and as previously mentioned is currently the key 
target in the use of PET imaging. GLUTs 2, 3, and 4 all share many of the same key 
hydrogen bonding interactions when transporting glucose as GLUTs 2 and 3 both require 
the presence of the C1, C3, and C4 hydroxyls to have effective glucose transport. As was 
shown in GLUT1, C2 substitution is tolerated in GLUTs 2-4 but has negative impact on 
uptake, with GLUT2 being the most impacted by this substitution. Unlike GLUT1, GLUTs 
2-4, are capable of transporting other sugars in addition to glucose, such as D-mannose.  
Some other examples of these variances are that GLUT3 and GLUT4 are both capable 
transporting 3-flouro-D-glucose, GLUT 2 shows marginal transport activity, while not 
transport is observed for GLUT1. These variations in substrate preferences highlight the 
differences within the binding pocket, sensitive towards the alterations in hydrophobicity, 
size, and hydrogen bonding ability of the substrate.   
6 
1.3 Structural Requirements for Substrate Recognition by 
GLUTs 
 Glucose 
At an early stage of GLUT research, it was determined that GLUT1 favored D-
glucose over L-glucose. This observation identified the first bias in substrate selection by 
GLUTs. Two researchers, Kahlenberg and Barnett, independently showed that the GLUT 
preference towards glucose relied primarily on hydrogen bonding with the C1, C3, and C4 
hydroxyl groups, and a hydrophobic interaction with C6. Later, Rees and co-workers 
established the importance of the oxygen atom on C5 for glucose uptake. The binding of 
glucose to GLUTs 1 and 4 was found to be sensitive to alterations in stereochemistry and 
the substitution-induced steric encumbrance at these critical sites. From the various sugars 
tested as inhibitors of 3H-D-glucose uptake, only 2-deoxy-D-glucose and 6-deoxy-D-
glucose proved to be recognized by the protein. These findings suggested the minimal role 
of C2 and C6 hydroxyl groups in the glucose-transporter interaction. It was also found that 
the C2 site of glucose was suitable for substitution or epimerization, which was proven by 
the uptake of 2-chloro-2-deoxy-D-glucose, 2,2-dichloro-2-deoxy-D-glucose, and D-
mannose. However the substituon or stereochemical alterations at the C3 position of D-
glucose led to a significant decrease in the uptake (D-allose, 3-O-alkyl-, 3-chloro-D-
glucose, and 3-deoxy-D-glucose), suggesting a low tolerance from the transporter towards 
any change in steric at the C3 position or loss of the C3 hydroxyl group as a possible 
hydrogen bond acceptor (3-deoxy-D-glucose vs. 3-fluoro-D-glucose). Compared to the 
C3-OH modifications, the chemical changes to the C4-OH group were far better tolerated 
(D-galactose vs  D-glucose), implying that the C3-OH group was vital for binding.  
7 
 
Glucose recognition by the transporter has also been shown to depend strongly on 
the C1-OH group as an H-acceptor and on the hydrophobic interactions with the protein 
through C6. The loss of uptake observed from methylation (methyl α-D-glucose and 
methyl β-D-glucose), removal (1-deoxy-D-glucose) or substitution (1-thio-β-D-glucose) 
of the C1-OH group but not for the 1-flouro-D-glucose analog suggest the vital importance 
8 
of the C1 site as a hydrogen bond acceptor. Additionally, the transporter was found to favor 
the beta-anomer of glucose, but a recent crystal structure report shows the transporter being 
capable of accommodating both anomers, although the relative affinities for these 
substrates are currently unclear. Likewise, increasing the bulk around the C6 position 
through methylation (6-O-methyl-D-galactose) negatively impacted the uptake. In 
contrast, the uptake of 6-deoxy-D-glucose was comparable with that of D-glucose, 
indicating that C6 site does not serve as a hydrogen-bonding site. Colville discovered that 
other class I transporters - Gluts 2 and 3 - employ a model of glucose recognition similar 
to that of Glut 1: that is, they require the presence of the C1-, C3-, and C4-OH groups. The 
presence of the C2-OH group was not needed for high affinity, but substitution at C2 
diminished the uptake, with the Glut 2 transporter being least tolerant to such substitution. 
Gluts 2–4 also appear to be less substrate-specific than Glut 1. Thus, Gluts 2–4 bind d-
mannose (C2-epimer of d-glucose) as efficiently as they do d-glucose or 2-deoxy-d-
glucose. Additionally, there is an apparent difference in substrate recognition between Glut 
2 and Gluts 1, 3, and 4. The loss of affinity observed with 3-deoxy-d-glucose can be 
restored by 3-fluoro-d-glucose for Gluts 1, 3, and 4, but not for Glut 2, thus suggesting that 
for Glut 2 the C3-OH group plays the role of an H-donor. Another notable difference 
amongst Gluts 1–4 is the affinity of 6-O-methyl-d-galactose towards Gluts 2 and 4, but not 
Glut 3, whereas all three transporters similarly accept the 6-fluoro analogue. This 
observation suggested more extended hydrophobic interactions favorable for binding 
within Gluts 2 and 4, and putatively low tolerance for steric interactions for Glut 3. The 
structure–affinity relationship data provided the basis for a simplified schematic of 
glucose–transporter interaction. It was proposed that the sugar enters the binding site of the 
9 
membrane transporter through initial coordination of the ring oxygen atom and the 
anomeric hydroxy group. For all isoforms, some degree of H-bonding was suggested for 
the C1, C3, and C4 hydroxy groups, with the nature of H-bonding at C4 changing from H-
acceptor in Glut 1 to H-donor in Glut 2. For Glut 3, H-bonding at the C4-position was 
proposed to play a relatively minor role, due to the efficient uptake of both glucose and 
galactose. It was also suggested that binding was stabilized by hydrophobic interaction 
with C6 and independent of the C6-OH group. 
1.4 Carbohydrate Uptake and Metabolic Disorders 
Increased carbohydrate consumption is shown to be implicated in diseases, such as 
obesity, type II diabetes, fatty liver disease, gout, sclerosis, and Alzheimer’s. It has also 
been shown that either high glucose or fructose consumption is linked with cancer growth 
and metastasis.  Changes in the GLUT expression and composition were observed upon 
the increased nutritional needs for the uncontrolled growth and division of cancer cells.  
Examples of this phenomena include changes in the expression of the ubiquitous glucose 
transporter GLUT1, with it found to be either overexpressed or downregulated in different 
cancers.  Alterations have been noted not only in the levels of GLUT expression but also 
in the GLUT content. Thus, certain epithelial cancer types gain expression of GLUT13, 
whereas it is normally found being expressed in the brain tissue.  The overexpression of 
GLUTs 5 and 12 are established for the early and late stage breast carcinoma cell lines, 
MCF-7 and MDA-MB-21 respectively. It has also been found that GLUT5 expression is 
active in leukemia, pancreatic, ovarian, and lung cancers.  It is noteworthy that despite a 
substantial bulk of literature on GLUTs, the impact of sugars and sugar consumption on 
10 
cancer development is still not well understood, and that some data are contradicting. For 
example, a high fat and sugar diet have been shown to contribute to the reoccurrence of 
cancer in stage III colon cancer patients. Whereas high sugar consumption has not shown 
to have any effect at all on the risk of colon or any other type of cancer or showed increased 
rick in only a narrow portion of the population. Alternatively, high sugar consumption has 
been definitively linked with obesity and there is a strong connection between this 
metabolic disorder and the formation cancer. Also increased circulation of insulin and 
insulin-like growth factors levels have also been linked with cancer progression, suggesting 
that both obesity and insulin resistance can promote cancer through the activation of 
signaling pathways that drive cell growth. Although some links have been established, 
mapping the road to all sugar-disease connections is long from being complete. 
1.5 GLUTs as Biological Targets 
1.5.1 Imaging Agents 
The discrimination between cancer and normal cells on their differences in sugar uptake 
has been shown to be a practical approach to induce selectivity in imaging application. As 
previously mentioned, position emission tomography (PET) has been very successful in 
taking advantage of this difference in activity in GLUT expression and sugar transport in 
diseased cells, mainly cancer, for beneficial use. PET imaging uses the 18F-labeled analog 
of 2-flouro-2-deoxy-D-glucose (FDG) as a reporter of the enchanced glucose uptake seen 
in cancer cells and as a predicator of tumorigenssi and tumor agressinveness.1  2-18F-FDG 
is readily internalized by the cell through multiple GLUTs and then phosphorylated. The 
phosphorylation of FDG promotes the continuous gradient uptake through the transporter 
11 
which then reflects the metabolism coupled glucose uptake in cells, with those with higher 
metabolic activity having a higher accumulation.  It should be mentioned however that this 
technique is not without faults, as there has been shown for various sites to have a high 
accumulation of the probe, such as inflamed tissues, that are not related to having any 
cancerous activity, leading to false positives.3-4  As FDG uptake is dependent on two 
metabolism coupled factors, sugar uptake and phosphorylation, it has been considered that 
direct evaluation of sugar uptake (independent of phosphorylation) could provide an 
alternate approach for cancer imaging. Among the uptake reporters that have been shown 
not to be phosphorylated, 6-deoxy-6-iodo-D-glucose allowed for the accurate measurement 
of glucose transport rates in insulin-responsive tissues.5-6  However, the rapid efflux from 
the cell  limited the application of this tracer. Rapid excretion was also observed for 6-
deoxy-6-flouro-D-glucose, although the probe did provide an important tool for reflecting 
the glucose uptake not only insulin responsive tissues, but also those that are non-
responsive. Overall, there is still room for exploring new GLUT-targeting probes that could 
carry a radiotracer into the cells and remain in the cell by phosphorylation-unrelated 
mechanisms.   
Development of fluorescent GLUT-targeting probes provided means to recognize cancer 
cells in vitro. While the stringency of GLUTs in substrate selection poses significant 
challenges in transporting modified sugars, several sugar fluorophore combinations were 
shown to produce effective GLUT-targeting probes. Among those, the green-fluorescent 
7-Nitrobenzofurazan (NBD) has been shown to pass efficiently through GLUTs in the form 
of D-glucose (NBDG). Targeting of fructose GLUTs has also gathered attention due to the 
12 
recent understanding of direct links between high fructose uptake and cancer. Respectively, 
D-fructose (NBDF) and 2,5-anhydro-D-mannitol (NBDM) conjugates of NBD were 
developed for targeting fructose transport.7-8 Othe sugar analogs have also been tested as 
carriers of NBD, with alterations in stereochemistry shifting the uptake between fructose 
and glucose transporters.9 Recent developments also highlight the applicability of 
coumarins and resorufin as fluorophores for GLUT probes. Glucose conjugates of 7-
aminocoumarins (CDGs, Fig. 2) are taken up by the cells through glucose-dependent 
transport.10 However, a significant drop in the uptake with increase in fluorophore size 
poses a new aspect to consider for designing GLUT-specific reporters.  
1.5.2 Drug Delivery Agents 
Alterations in the expression levels of various GLUTs in cancer has highlighted sugar 
transporters for potential targeted drug delivery. Consequently, glycoconjugation has 
emerged as a strategy to direct chemotherapeutic agents to cancerous cells for achieving 
enhanced cancer specificity and improved drug safety. With higher glucose uptake in 
cancers becoming clearly evident, glucose transporters became the target of various sugar 
drug conjugates, particularly for targeting glucose transporter GLUT1. One of the pioneer 
compounds was glufosfamide, a glucose conjugate of the DNA alkylating agent ifosamide 
mustard.  Following glufosfamide, conjugation to different sugars has been used to 
improve the cytotoxic properties of chlorambucil. The studies included the development of 
the 63-member library of compounds (conjugates of glucose, mannose, galactose, xylose 
and other), among which D-threose conjugate showed the most significant improvement 
in potency (8-fold more potent in reducing cell growth than chlorambucil). However, 
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whether the improved cytotoxicity was a result of alterations in mechanism of action or 
was induced by enhanced cellular accumulation of the probe, or whether glycoconjugation 
resulted in GLUT-mediated uptake was not addressed. Since then, the glycoconjugation 
strategy has been widely applied to various anticancer drugs and imaging agents 
(chlorambucil, azinomycin, clioquinol, adriamicyin, warfarin, cyclopamine, platinum and 
palladium-based chemotherapy drugs, and nano materials).2 The C2-glucose conjugates of 
platinum and palladium  complexes of glucose were tested in cisplatin-sensitive and 
cisplatin resistant gastric cancer cell lines and in vivo models.11 Tested in the gastric cancer 
cell lines, both Pd and Pt conjugates were found to induced DNA double strand breaks 
similarly to cisplatin but have lesser cytotoxicity. The preference of GLUTs towards C2 
glucose-platinum conjugation was established for oxaliplatin-glucose conjugates. In 
addition, conjugation of glucose to oxaliplatin through C6 was also observed to be tolerated 
by the GLUT1. The corresponding conjugates varied in the length of the linker between 
oxaliplatin and glucose showed cytotoxicity comparable to that of an aglycone, with 
ovarian cancer cells showing the highest sensitivity. All compounds were found to platinate 
DNA leading to cell apoptosis, with the number of platinated residues relatively similar to 
oxaliplatin. Glycoconjugation has also been explored with inhibitors of lactate 
dehydrogenase (LHD) in an attempt to improve the anticancer efficiency of 
photosensitizers, as well as to deliver drugs to the brain through GLUT1 expressing brain 
barriers. In particularly among the latter, the conjugation of glucose to ibuprofen resulted 
in a three-fold higher concentrating of the drug in the brain that maintained stability for 4h. 
All of these findings highlight the possibility of using pro-drugs as a delivery strategy to 
the brain.  While multiple efforts have been made to target GLUTs in biomedical research, 
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the majority of studies (or conjugates made) failed to provide a significant levels of 
discrimination between normal and metabolically-compromised cells. These outcomes 
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Facilitative glucose transporters (GLUTs) perform gradient dependent influx and 
efflux of carbohydrates to sustain the nutritional needs for cell proliferation.  Metabolic 
deregulations in cells induce alterations in the cellular GLUT composition, resulting in 
overexpression of intrinsic or expression of extrinsic GLUTs. Among GLUTs, glucose-
transporting GLUT1 attracted attention for half a century as a target for cancer therapy and 
diagnostics, and other GLUTs started to gather much interest recently because of their 
direct relationship with cancer.1 Particular attention is drawn by fructose-transporting 
GLUTs and the fructose-specific transporter GLUT5 due to the links between fructose 
uptake and cancer development, progression, and metastasis.2 Consequently, the fructose 
transport-targeting probes are of interest as biochemical and biomedical tools. 
Analyses of GLUT expression and activity as means to assess the metabolic state 
of the cell have been approached through the development of GLUT-targeting radiolabeled 
sugar analogs, as well as affinity labels.3 Among radiolabeled analogs, halogenated sugar 
derivatives were accessed to evaluate glucose and fructose transport efficiency in 
conjunction with and independently of phosphorylation. The development of fluorescently 
labeled GLUT probes has been approached to alleviate the practical limitations associated 
with radiolabeling and to obtain high affinity probes. Among fluorescent GLUT probes, 7-
nitrobenzofurazan (NBD) has been utilized for GLUT transport analysis in the form of 
sugar conjugates.  Among those, fructose and 2,5-anhydro-D-mannitol were accessed as 
probes to target fructose transport providing a precedent for distinguishing GLUT5- 
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expressing vs. GLUT5-deficient cell lines. Recently, coumarin and resorufin conjugates of 
glucose have been evaluated as probes for glucose GLUTs. The probes showed a limited 
passage through GLUTs, and accumulated in cells through non-GLUT-mediated transport. 
The challenge in passing a non-natural moiety through GLUTs is also reflected by the loss 
of GLUT-mediated uptake for glucose–drug conjugates, with the position of 
functionalization and possible change in transporter–probe interaction due to alterations in 
H-bonding being key players. Considering the need in GLUT-specific molecular tools, we 
have explored the feasibility to develop such tools using GLUT5 as model transporter. The 
choice of GLUT5 has been prompted by the unique specificity of this protein to one 
substrate (majority of other GLUTs are promiscuous). A direct link between GLUT5 and 
various diseases provided additional reasoning to targeting this transporter.  
It should be noted that structural requirements for fructose transport are not 
thoroughly understood, primarily due to the existence of the natural fructose as a mixture 
of structural isomers – furanose and pyranose. In early studies by Colville et al.,4-5 
selectivity of GLUT2 towards the furanose form of fructose has been proposed based on 
the ability of L-sorbose (C5-epimer of fructofuranose) and 2,5-anhydromannitol (C2-
deoxy analog of fructofuranose) to inhibit 2-deoxy-D-glucose uptake (Scheme 1).5 
Inhibition constant for 2,5-anhydromannitol (Ki = 26 mM) was relatively similar to that of 
2-deoxyglucose (Ki = 26 mM) and 6-8 times lower than Ki for L-sorbose or D-fructose. 
However, considering that in aqueous solutions D-fructose exists predominantly in 
pyranose form and that GLUT2 takes up other pyranoses, the plausibility of fructose uptake 
in both forms is to be verified.  
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Series of studies by Holman and coworkers6-9 have focused of designing 
carbohydrate probes to reveal structural features responsible for fructose-specificity of 
GLUT5 in view of accessing GLUT5-specific affinity probes. Studies were based on 
evaluating competitive inhibition of fructose uptake in the presence of fructose analogs and 
derivatives and, in analogy to other GLUTs, revealed the dependence of uptake via GLUT5 




































Ki = 12 mM
Ki = 16 mM











R = methyl, Ki
 = 15.0 mM           allyl, Ki = 28.5 mM
R-β-D-fructofuranose
R = methyl, Ki








Ki = 32.4 mM  
Scheme 2.1. Conformer ratios and inhibitory constants for 2-deoxyglucose uptake via 
GLUT2 for D-fructose, D-sorbose and 2,5-anhydromannitol. Comparison of interaction of 
C2-derivatives of furanose and pyranose ring forms of fructose with GLUT5. Inhibitory 
constants were derived by monitoring inhibitory effect of analogs on the uptake of [14C]-
D-fructose into CHO cells expressing GLUT5. 
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The uptake of fructose via GLUT5 was found to favor β-anomers over α-anomer, 
as was shown by testing C2-methylated fructopyranose and fructofuranose analogs 
(Scheme 1).6 Small changes in the sterics around C2 induced by methyl group did not 
impact the uptake. In contrast, increase in the size of C2-substitution, tested with allyl 
derivatives, significantly diminished the affinity of a furanose analog, while had a minor 
impact on the affinity of the pyranose analog. Further testing of 2,5-anhydro-D-mannitol 
revealed that anomeric hydroxyl does not play any role in fructofuranose uptake and 
confirmed that GLUT5 effectively takes up fructose in its furanose form.7 Fructose uptake 
also requires the presence of cyclic oxygen as H-acceptor, since 6-fold loss in the uptake 
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Scheme 2.2. Conformer ratios and inhibitory constants for fructose uptake via GLUT5 for D-
fructose, D-psicose and D-tagalose. 
The affinity of fructose to GLUT5 also diminishes upon alteration in 
stereochemistry of ring hydroxyls or their alkylation (except for C2-OH).6 Thus, the 
affinity of fructose epimers D-picose (C3-epimer), D-tagalose (C4-epimer) and L-sorbose 
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(C5-epimer) was up to 9-fold lower than that of fructose (Scheme 2). Allylation of C1, C3-
5 hydroxyls of fructose resulted in 7-9-fold drop in affinity compared to fructose (Table 4). 
The observed loss in affinity upon alkylation could suggests the importance of these 
hydroxyls as H-donors or the data could reflect the impact of steric interaction on uptake. 
The observed sensitivity of fructose analog binging towards sterics is reminiscent of that 
observed with glucose analogs.  
 
Table 2.1. Effect of hydroxyl alkylation on fructose uptake via GLUT5a 
Substrate 
Pyranose/furanose ratio Ki, mM 
αP, βP αF, βF  
1-O-allyl-D-fructose 14, 67 Trace, 19 106±19 
3-O-allyl-D-fructose 15, 38 12, 35 90±31 
4-O-allyl-D-fructose 55, 18 18, 9 106±20 
5-O-allyl-D-fructose 73, 27 no F 153±37 
6-O-allyl-D-fructose no P 100, 0  20±8 
aUptake determined relative to the uptake of [14C]-D-fructose. The Ki values 
calculated by lest square fitting to Eqn: V0/V1 = 1 + 1/Ki, where V0 and V1 are tracer 
uptake rates in the absence and presence of inhibitor, respectively, I is the inhibitor 
concentration and Ki is the half maximal inhibition constant of affinity constant.  
 
Deriving more complete understanding of binding requirements for fructose is 
somewhat complicated by the fact that allylated fructose analogs exist as a mixture of 
conformers and anomers and ratios of those differ (Table 1). Thus, C1-O-allyl and C3-O-
allyl analogs are predominately in the β-anomer form (86% and 72%, respectively), while 
C4 or C5 analogs exist prevalently as α-amoners (72% and 73%, respectively). Alterations 
in pyranose/furanose ratios could also influence affinities of analogs. Overall, the 
heterogeneity of the probes limits interpretation of the data, leaving room for further 
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studies. Probes where hydroxyls are substituted with H-acceptors, such as fluorine, and 
analogs with altered size of substituents could be of interest to assess whether diminished 













fructopyranose fructofuranose  
Figure 2.1. Simplified diagram of fructose binding to GLUT5. Fructose conformers modeled in 
Spartan ’14 (Molecular Mechanics, MMFF). Visualization was carried out in PyMol. Red, 
oxygen; green, carbon; white, hydrogen. 
Structure-affinity studies carried out by Holman and coworkers led to tentative 
binding models for fructofuranose and fructofuranose (Figure 1). For fructopyranose, 
effective binding and uptake relies on H-bonding of the C1-OH (as H-donor) and cyclic 
oxygen with the exofacial binding site of GLUT5. Binding mode for fructofuranose relies 
on H-bonding interaction between one of the primary hydroxyls (also as H-donor) and the 
cyclic oxygen and, in addition, involves a stabilizing interaction with the transporter from 
the second primary hydroxyls (as H-acceptor). The orientation of hydroxymethylene 
groups at C2 and C5 stereocenters appears to favor anti relationship for effective uptake 
(based on the loss of GLUT5-mediated uptake of L-sorbose). Due to C2 pseudo-symmetry 
and the lack of binding interactions between C2-OH and GLUT5, fructofuranose could 
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interact with exofacial binding site either by C1 or C6, as long as the binding proton is 
present. 
The Holman team further speculated that analogs locked in a favored for uptake 
conformation can result in a new class of compounds that interact with GLUT5. Several 
glycol-1,3-oxazolidin-2-thiones and oxazolidin-2-ones were prepared to test this 
hypothesis.9 Two major scaffolds were evaluated: one included compounds maintaining 
both C1 and C6 hydroxyls (I, Figure 4) and the other lacked C1-OH (II, Figure 2). All 
substrates of scaffold I were active as inhibitors of [14C]-D-fructose uptake via GLUT5 in 
CHO cells regardless of whether C1 was a free hydroxyl or an ether.9 GLUT5 affinities 
were ~4-fold higher for carbonyl than thiocarbohyl derivatives, suggesting an additional 
binding interaction of the carbonyl oxygen with the transporter. In addition, while L-
sorbose was a poor GLUT5 substrate,6 bicyclic derivatives of L-sorbose were more 
effective GLUT5 probes than derivatives of fructose, plausibly due to the better positioning 
of the C6-OH and the amide of the cycle in the active site for H-bonding. In contrast, 
substrates of scaffold II did not impact the uptake of [14C]-D-fructose regardless of the 
stereochemistry, further supporting the importance of complimentary C1 and C6 bonding 
for the effective uptake.9 Whether the entry of fructofuranose or derivatives I into the 
binding site occurs with C1 or C6 remains elusive, due to the absence of the probes testing 
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Figure 2.2. A. Bicyclic furanose analogs as GLUT5-mediated uptake probes. B. 3-D structures of 
β-D-fructofuranose and 1,3-oxazolidin-2-one derivative of β-D-fructofuranose (MMFF, 
Spatran’14). Graphical data visualization by PyMol. Red, oxygen; green or magenta, carbon; white, 
hydrogen. 
The obtained understanding of substrate election by GLUT5 provided the basis for 
us to explore new molecular probes for specific targeting of this transporter for biochemical 
and biomedical applications. 
2.2 Development of GLUT5 Specific Probes 
To approach the development of GLUT5 probes we have explored 2,5-anhydro-D-
mannitol8 as a sugar template that can be specifically recognized by GLUT5. With the goal 
of developing tools for real-time monitoring and assessment of GLUT5 activity, we have 
explored the ability of GLUT5 to transport fluorescent moieties. Coumarins have been 
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selected due to their relatively small size and good fluorescent properties.  Furthermore, 
the reported ability to tune fluorescence color for coumarins through functionalization 
provided additions point of attraction and added the feasibility to produce probes of 























Scheme 2.3. Synthesis (A) and fluorescence properties (B) of mannitol-coumarin conjugates 
ManCou1-3. 
The passage of 7-aminocoumarin in the form of a glucosamine conjugate through 
glucose GLUTs has been demonstrated,11 providing a basis for testing this fluorophore as 
a substrate for GLUT5. Thus, as a proof-of-principle, we have investigated the uptake of a 
7-aminocoumarin as a conjugate of GLUT5-targeting 2,5-anhydro-D-mannose. We have 
targeted three coumarins that differed in the substitution at C4. The 7-aminocoumarin 
(Cou1) was synthesized from 7-hydroxycoumarin according to the established procedure.12 
The 7-amino-4-methylcoumarina and 7-amino-4-trifluoromethyl coumarin were 
purchased (Sigma Aldrich). These tree fluorophores were then conjugated to 2,5-anhydro-
26 
D-mannitol (Man) through reductive amination with 2,5-anhydro-2-carbaldehyde-D-
mannitol to produce the fluorescent-D-mannitol–coumarin conjugates ManCous (Scheme 
1, ManCou 1, R = H; ManCou2, R = CH3; ManCou3, R = CF3). 
Fluorescence measurements (Scheme 3B) have shown that ManCous 1 has a strong 
emission in the “blue” region of the spectrum (λmax = 461 nm). The fluorescence data has 
clearly reflected the impact of substitution on coumarin fluorescence.  Thus, the electron-
withdrawing effect of fluorine atoms induced a red-shift in the emission for ManCou3 
towards the “green” region of the spectrum (λmax = 511 nm). The electron-donating effect 
of the methyl group, in turn, induced a blue-shift in the fluorescence emission of a coumarin 






Figure 2.3. ManCou probes induce fluorescence in MCF7 cells. ManCou1 (A) and 
ManCou2 (B) can be observed under the blue filter (exc/em 405 nm/560 nm); ManCou3 
(C and D) can be observed under blue or green (exc/em 405 nm/525 nm) filter.  E) Co-
staining of cells with nuclear dye (Red Dot, exc/em 635/ 655 nm) and ManCou1; D) co-
staining of cells with RedDot and ManCou3. Images taken with 60X objective after treating 




Figure 2.4. Concentration-dependent uptake of ManCous 1-3 at 37 °C. Data obtained using 
fluorescent plate reader exc/em 385 nm/460 nm. All uptake data are measured in triplicates 
in 96-well plate after 10 min incubation of cells, removal of the probe and repeated cell 
wash. 
With new ManCou conjugates in hand, we moved into testing them as GLUT5 
probes. For this part, we have used breast cancer MCF7 cells known to express GLUT5.  
After treating MCF7 cells with various concentrations of ManCou1, a significant 
accumulation of the coumarin-induced blue fluorescence was observed after a short 10 min 
incubation.  We found that concentrations of 20 µM were sufficient to monitor the probe 
accumulation through microscopy (Figure 3A). Accumulation of ManCous 1 and 2 could 
be easily detected under blue filter. In contrast, ManCou3 could be imaged under both, blue 
and green filter, which fits the observed ref-shift the in the corresponding emission 
spectrum (Scheme 3B). Interestingly, the Z-stack images have shown that there is a 
significant difference in the cellular distribution between three probes. Thus, while 
ManCou1 and ManCou2 are distributed throughout the cell (including cell nucleus), 
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ManCou3 accumulates preferentially in the cytosol. The nuclear accumulation was 
confirmed through co-staining the cell with the nuclear dye (Figure 3, E and D).  
Further evaluations of probe uptake in cells revealed additional differences between 
probes. Thus, we have observed that increase in probe concentration has differential impact 
on probe’s accumulation in the cell. For example, while linear-type uptake has been 
measured for ManCou1 probes at 10-500 µM concentrations, the uptake of ManCou2 
deviated from the linear trend  and the uptake of ManCou3 completely saturated after 200 
µM (Figure 4). The differences in accumulation of probes parallel the differences in their 
cellular distribution. Considering that GLUT-mediated uptake is coupled with sugar 
phosphorylation, it is feasible to surmise that the observed saturation reflects the lack of 
phosphorylation for ManCou3 probe. Hence, cellular distribution also appears to depend 
on phosphorylation status of the probe, reflecting that ability of the cell nucleus to absorb 
only phosphorylates ManCou conjugates. 
With the uptake of ManCou probes in MCF7 cells confirmed, we have moved 
towards assessing their particular uptake pathway. Considering that the ManCou conjugate 
represents a merging of a hydrophilic sugar and a hydrophobic fluorophore, we have 
investigated the contribution from GLUTs vs. passive diffusion to the observed cellular 
accumulation of this probe. For the analysis, MCF7 cells were incubated with the 
unconjugated 7-aminocoumarin at 37 °C and fluorescence was recorded. Two major 
differences were observed between ManCous and unconjugated coumarins. First, 
unconjugated coumarin showed >10-fold lower accumulation in cells, highlighting a 
significant contribution from the sugar moiety to the observed ManCou uptake. Analysis 
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of coumarin-treated cells through microscopy has revealed that the acquired fluorescence 
was primarily from the coumarin association with the cell membrane (Figure 5, Z-stack 
images). 
While the ManCou1 uptake was concentration-dependent, the uptake levels for the 
unconjugated coumarin Cou1 were not affected by the concentration. The concentration-
dependent uptake and the unambiguous contribution from the sugar moiety to the enhanced 
uptake provided a basis to consider the GLUT-mediated transport as a primary uptake 
mechanism for ManCou1. The GLUT participation became further evident from the loss 
of ManCou1 uptake after incubating MCF7 cells at 4 °C conditions known to decrease cell 
metabolism and thereby GLUT-mediated uptake. In contrast, low temperatures did not 
impact the uptake of Cou1, highlighting its passive diffusion through the membrane into 
the cell. The loss of the uptake at low temperature was also observed for higher 




Figure 2.5. Assessing participation of passive diffusion on ManCou uptake. A) Comparative 
uptake of ManCous vs. corresponding coumarins (Cou) at 20 µM concentration (37 °C); B) Z-
stack imaged of MCF7 cells treated with 7-aminocoumarin (Cou1) at 37 °C; C) Comparative 
analysis of ManCou1 vs. Cou1 uptake at varied concentrations (37 °C); D) Comparative analysis 
of ManCou1 uptake at 37 °C vs. 4 °C. All uptake data are measured in triplicates in 96-well plate 
after 10 min incubation of cells, removal of the probe and repeated cell wash. Data represents the 
Gained Fluorescence measured exc/em 385 nm/460 nm. Confocal images obtained with 60X 
objective using exc/em 405 nm/461 nm. 
We have further used a series of competitive uptake and inhibition analyses to 
verify the uptake of ManCou1 through GLUTs, and particularly through GLUT5. We have 
observed that the uptake of ManCou1 and ManCou2 is effectively inhibited by fructose 
(Figure 6A) suggesting the probe to be taken through fructose-transporting GLUT(s). 
When glucose (Figure 6B) or glucosamine (specific for GLUT213, Figure 6C) were used 
as competitive inhibitors, no alterations in the ManCou1 uptake were observed, indicating 






















Curve fit - ligand binding one site
f = Bmax*abs(x)/(Kd + abs(x))
Rsqr = 0.9964





Figure 2.6. Analysis of ManCou uptake in the presence of fructose (A); glucose (B); 
glucosamine (C); cytochalasin B (D); and MSNBA E). Data in graphs was obtained for 20 
µM ManCou1-3 probes in triplicates. Plots represents average data, error bars represent 
standard deviation. Data are collected after 10 min incubation of cells with ManCou in 96-
well plates, removal of the probe, and cell wash (exc. 360 nm, em. 430 nm for ManCous 1 
and 2, and em. 500 nm for ManCou3 and 4). Cell imaging (Z-stack) was done with confocal 
microscope using 60X objective exc/em 405 nm/461 nm.  Blue/green correspond for 
ManCou1; Red corresponds to nuclear RedDot stain. F) Analysis of binding affinity for 
fructose in the presence of 20 µM ManCou1. Data analyzed by Sigmaplot13 using uptake 
values from (A).Competitive inhibition of 20 µM ManCou1 uptake with fructose in 
concentrations 10-50 mM allowed to derive the Kd = 3.1 mM measured for fructose (Figure 
6F). This data relates well with other reported binding affinity values between GLUT5 and 
fructose ranging from 6-9 mM.8, 15  Considering that no saturation was observed for 
ManCou1 uptake even at elevated 500 mM concentrations, we used a fructose:ManCou1 
ratio measured to induce 50% ManCou1 uptake inhibition to estimate that ManCou1 bind 
GLUT5 ~9-fold stronger than fructose, allowing us to derive Kd ~330 µM. Interestingly, 
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the impact of fructose on ManCou3 was minimal. Using the concentration-dependent 
uptake data (Figure 4), we have found that ManCou3 exhibits ~20-fold higher affinity (Kd 
= 52.45 mM) that ManCou1. Significant enhancement in affinity suggests that additional 
interactions with the protein are presented by the presence of potentially H-binding 
fluorides on the coumarin. 
The lack of ManCou1 inhibition in the presence of cytochalasin B (Figure 6D), the 
established inhibitor of the uptake through GLUTs 1–4 (IC50 = 2–6 mM) but not GLUT5, 
further ruled out non-specific transport, highlighting GLUT5-mediated uptake. The results 
further highlighted high fructose-dependence for the uptake of these probes, allowing us to 
indicate fructose-specific transporter GLUT5 as the mode of ManCou transport. Further 
the complete inhibition of ManCou1 uptake in the presence of GLUT5-specific inhibitor 
MSNBA14 (Figure 6E) have validated the specificity of these conjugates to GLUT5.  
2.3 Exploring the Structural Basis for ManCou-GLUT5 Binding 
 
To gain insight into the ManCou interaction with GLUT5, molecular docking of 
DFT-optimized structures of coumarin conjugates into the exofacial cavity of a mammalian 
fructose transporter GLUT5 (PDB code: 4YB9) using Autodock415 was carried out. For 
each ManCou probe, the resulting complexes were ranked, and the complexes were 
analyzed to identify the position/binding of conformers.  
Overall, the analysis of complexes showed the ManCous to bind with the uptake relevant 
residues through the 1-AM moiety but accommodate different orientations of the 
fluorophore (Figure 2.7). All three probes were found to H-bond with Tyr32, Gln167, 
Gln289, and the Glut5-specific Asn294 – residues also found to be involved in fructose 
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uptake through GLUT5.15 While the binding of 1-AM between three complexes involved 
the same residues, the H-bonding sites at 1-AM were altered to accommodate the change 
in the position of the fluorophore. For ManCou1, the large population of conformers was 
found to orient the coumarin moiety towards His419 and Trp420 – residues found to be 
critical for fructose uptake (Figure 2.7A).15 For ManCou3, nine out of ten conformational 
isomers had the coumarin moiety oriented away from these residues into the more open 
space (Figure 2.7C). Interestingly, for ManCou2 (Figure 2.7B), conformations similar to 
those of ManCou1 and ManCou3 were detected, suggesting the probe to have duality, as 
sensed by malignant cells. However, a higher level modeling would be required to assess 
a true binding site(s) for these probes and further identifying key interactions contributing 




Figure 2.7. Docking analysis of ManCou1-3. Docking analysis performed with 
Autodock4. Models visualized with PyMol. 
Following these preliminary assessment, the analysis of GLUT5-ManCou 
interactions was carried out using molecular dynamics. In addition, simulations were run 
to assess the correlations between GLUT5 binding to ManCous vs fructose in a furanose 
conformer. The work was done in collaboration with Dr. Christov (MTU).16 For MD 
simulations, the inward-open conformation of GLUT5 from Bob Taurus (pdb code 4YB915) 
was used and calculations were carried out using AMBER16 code17 and ff14SB 
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forcefield.18 The substrates were docked within the central binding site of GLUT5 and the 









Gln167, Gln289 - weaker 
Tyr412, Gly416, Ala396, 
Val399, and Ala415
Asn294 – strong H-bonding
 
Figure 2.8. Molecular dynamic simulation of GLUT5-ManCou interactions. Images 
represent MD snapshots. 
Docked fructose was used as control and has shown stable interactions with Tyr32, 
Gln167, Q287, S392, and H418. These interactions have been previously observed within 
the crystal structure reported by Nomura et al19 and conformed through fluorescence and 
mutagenesis studies. Additional weak interactions with residues Tyr279 and Gln288 are 
also seen. Gln167 was experimentally suggested to contribute to the fructose-specificity of 
GLUT5 as its substitution to glutamate seems to add the capacity to transport glucose for 
GLUT7.15, 19 The interaction with Gln167 has also been found essential for the 
conformational change allowing the substrate translocation through the protein.15 
Comparative analysis of fructofuranose vs. ManCous revealed a significant impact 
of the hydrophobic fluorophore moiety on the ligand binding geometry (Figure. 2.8.). The 
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simulations indicated that interactions with Gln167, and Gln289 are also present for the 
sugar moiety of ManCou-H, although the ligand is positioned differently from 
fructofuranose (Figure 2.8). The change in the ligand position appears to be driven by 
additional interaction between the C=O of coumarin and Asn325, plausibly contributing to 
the experimentally observed higher affinity of ManCou-H to GLUT5.20  
The binding of ManCou-CF3 is accompanied by the additional change in the 
position of the fluorophore, while the interactions of the sugar with Gln167, and Gln289 
are conserved. This change appears to be due to F-H-C and F-H-N interactions with 
Tyr412, Gly416, Ala396, Val399, and Ala415 residues (Figure 2.8) and could be 
contributing to stronger binding of ManCou-CF3 to GLUT5.20 Furthermore, ManCou-CF3 
appears to induce specific interaction with Asn294 that is not present for ManCou-H or 
fructofuranose complexes. It should be noted that the interaction with Asn294 has been 
previously suggested to contribute to inhibition of GLUT5.14  
Overall, the average number of hydrogen bonds during 1 μsec MD simulations was 
found highest in the ManCou-CF3 complex (1.7) followed by the ManCou-H complex (1.2) 
and then by the fructose complex (1.1). The differences in binding interactions were is a 
good agreement with the free energies of binding. Thus, -43.3 kcal/mol, -39.7 kcal/mol, 
and -19.6 kcal/mol calculated for GLUT5 complexes with ManCou-CF3, ManCou-H, and 
fructose, respectively, agree with the experimental binding affinity trend.20  
2.4 Development of Multicolor GLUT5 Probes 
With the successful delivery of a blue-fluorescent 7-aminocoumarin into the cell 
through GLUT5, we moved forward to testing ManCou analogues to gauge the tolerance 
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of GLUT5 to coumarin fluorophores and gain access to probes of different fluorescence 
colors. The substitution at the C4 position of the 7-aminocoumarin had been shown to 
impact the fluorescence emission.21 Thus, we constructed a focused library of ManCous by 
synthesizing Cous bearing various electron withdrawing groups at C4 (C4-EWG),22-24 
including new amides (Cou10-12), 2-furyl (Cou13), and 2-pyridyl (Cou14) C4-analogs. 
We have completed the library by adding 6-aminocoumarin (Cou8) and the C3-substituted 
analogue of 7-aminocoumarin Cou9 to assess the impact of alterations in the position of 
sugar conjugation on the ManCou uptake. 
The Cous 5, 13 and 14 were synthesized through Pechmann condensation,22-23, 25 
and Cous 10–12 were obtained from Cou5 through amidation with the corresponding 
amine.22  Except for ManCou9, all ManCous were obtained through reductive amination 
of the corresponding Cous with 2,5-anhydro-2-carbaldehyde-D-mannitol. ManCou9 was 
obtained through EDCI/HOBt-mediated amidation with 1-amino-2,5-anhydro-D-mannitol. 
Fluorescent analysis of the obtained coumarins has shown that C4-substitution 
indeed highly impacts fluorescence emission while allowing to maintain the excitation at 
a low wavelength (405 nm). Overall, C4-substitution allowed to shift the emission maxima 
from 462 nm (ManCOu1) to 564 nm (ManCou10). The fluorescence intensity of ManCous 
varies with the substitution position and type, with ManCou13 and ManCou8 showing the 
highest and the lowest fluorescence intensity, respectively. The absolute quantum 
efficiency for all ManCou conjugates reflects the quenching effect of electron 






















































Scheme 2.4. C-4 functionalized coumarins as fluorophores for multi-color GLUT5 probes. 
 
We have also observed that the absorption maxima of ManCou conjugates have 
red-shifted 8–22 nm compared to the unconjugated coumarin. In an effort to explain the 
changes in the absorption, density functional theory was employed. The structures of 7-
aminocoumarins and the corresponding ManCou conjugates were first geometrically 
relaxed, and then single point energy calculations were performed. The analysis of the 
HOMO and LUMO energies revealed a reduction of the energy gap upon alkylation of the 




 λmax, nm 
Fluorescence, a  
λmax, nm 




Yield,b ΦF  
1 366 452 86 0.26 
2 360 461 101 0.30 
3 387 508 121 0.1 
4 376 506 130 0.44 
5 398 558 160 0.09 
6 371 538 167 0.21 
7 365 460 95 0.37 
8 384 459 75 0.08 
9 430 481 51 0.27 
10 382 564 182 0.06 
11 385 549 164 0.22 
12 383 554 171 0.12 
13 (2-furyl) 368 531 163 0.29 
14 (2-pyridyl) 374 535 161 0.21 
aAll data measured in water/ethanol (70:30 v/v) mixture. bAbsolute quantum yield was derived 
with respect to the anthracene as fluorescence standard.  
Through confocal imaging, we have observed that MCF7 cells gained fluorescence 
after treatment with all ManCous except for ManCous 6 and 7 – both bearing carboxylic 
acid moieties. The gained cell fluorescence for ManCous 2, 8 and 9 (blue filter) highlighted 
the tolerance of GLUT5 towards positional isomers of coumarin–mannitol conjugates. 
ManCous 3 and 4 were visible under both green and blue filters; ManCou5 was visible 
under orange/red filters and ManCous 10–14 were visible under red, yellow, and green 
filters (Figure 2.9). The GLUT5-specificity of these new analogs was supported by the lack 
of uptake inhibition in the presence of cytochalasin B, and decline in the uptake in the 
presence of fructose (Figure 2.9.J). The inhibitory effect of fructose was strong for 
ManCous 2, but decreased for EWG-substituted ManCous. 
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Table 2.3. Comparative analysis of UV λmax and HOMO/LUMO contribution for 














1 366 -445/-186 259 1 352 -459/-190 269 
2 360 -440/-177 263 2 347 -453/-180 273 
3 387 -468/-232 236 3 372 -486/-253 233 
4 376 -441/-193 248 4 358 -453/-196 257 
5 398 -467/-217 250 5 377 -482/-223 259 
13 374 -438/-209 219 13 366 -449/-213 236 
aData provided for probes showing the uptake through GLUT5; bHOMO/LUMO orbital 
energies were calculated with Spartan ’14 V1.1.2 (Wavefunction Inc.) using Density 
Functional, BLYP, 6-31G* 
The Z-stack analysis of ManCou-treated MCF7 cells revealed an apparent impact 
of coumarin substitution on the cellular distribution of the probe. Namely, while ManCous 
1 and 2 were distributed throughout the cell, C4-EWG ManCous and ManCous 8 and 9 
accumulated in the cytosol (Figure 2.9). The cytosolic distribution could be readily 
delineated through the labelling of the cell nucleus and the cell membrane with dyes of 







Figure 2.9. Fluorescence confocal Z-stack images of MCF7 cells treated with: A) 
ManCou2; B) and C) ManCou3; D) ManCou4 (blue and green merge); E) ManCou5; F) 
ManCou9; G-I) ManCou 11. Blue fluorescence measured at 461 nm; green fluorescence 
measured at 525 nm; red fluorescence measured at 585 nm. ManCous were excited with 
405 nm laser. Yellow color assigned considering the fluorescence maxima for ManCous 
10-12. Images taken with 60X objective after treating cells with 20 µM ManCous over 10 
min. Images recorded at the same laser intensity and exposure time.  
The differences in cellular accumulation of ManCous paralleled the differences in 
their uptake. Thus, while linear uptake was observed for ManCous 1 and 2 at 1–500 mM 
concentrations, the uptake for all other ManCous saturated after 200 mM (Figure 2.10, A). 
Considering that the continuity of the uptake through GLUTs is coupled with 
phosphorylation, it is feasible that the differences in the uptake behavior between ManCous 
could be reflecting the impact of coumarin substitution on the phosphorylation of 2,5-
anhydro-D-mannitol by cellular kinases. All saturable ManCous showed Kd in the 54–75 
mM range (Figure 2.10, B). 
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Curve fit - ligand binding one site
Rsqr = 0.9723
KD = 64.97 ± 15.67 uM
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Curve fit - ligand binding one side
Kd = 74.84 ± 14.8 uM
Rsqr = 0.9818
f = Bmax*abs(x)/(Kd + abs(x))
Concentration, uM















Curve fit - ligand binding one site
Rsqr = 0.9905
KD = 71.3255 ± 10.0 uM
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Figure 2.10. Uptake (A) and binding affinity (B) for C4-functionalized ManCou probes. 
Overall, the presence of EWG groups at the coumarin appears to contribute to the 
strength of the ManCou–GLUT5 interaction as well as uptake rates. This contribution is 
manifested by the apparent inhibition of ManCou1 uptake in the presence of ManCou3. 
Namely, incubating MCF7 cells with the equimolar mixture of ManCous 1 and 3 resulted 
in the loss of nuclear accumulation of the blue fluorescence, a feature characteristic for 
ManCou1. To explore this effect further, we have employed the GLUT5-targeting green 
fluorescent NBDM probe (Kd = 22 mM).26 After incubating MCF7 cells with the 
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equimolar mixture of ManCou3 and NBDM, a trace of NBDM-induced green fluorescence 
was observed inside the cell. In contrast, ManCou3-induced blue fluorescence was 
abundant. For the ManCou1–NBDM mixture, the uptake of both was observed, although 




Figure 2.11. ManCous as competitors for NBDM and NBDG uptake in MCF7 cells 
(Confocal, Z-stack images). A) Equimolar NBDM and ManCou3; B) Equimolar NBDM 
and ManCou1; C) Equimolar ManCou1 and NBDG; D) Equimolar ManCou3 and NBDG; 
E) NBDM; F) NBDG. Z-stack images taken after 10 min treatment and cell wash. Cells 
imaged with 60X objective using exc/em. 405 nm/425-525 nm for ManCous, and exc/em 
450 nm/565 nm for NBDM and NBDG (eGFP, green fluorescence). All images obtained 
at the same laser intensity and exposure time.Overall, the differential effect of ManCous 1 
and 3 on NBDM appears to reflect the differences in the strength of the GLUT5–ManCou 
interaction. It should be noted that the uptake of the glucose-GLUT-targeting green 
fluorescent NBDG probe (NBD conjugate of glucose7) was not impacted by any of the 
ManCou conjugates. This observation further validates the GLUT5-specificity of ManCou 
conjugates. It should be noted that the uptake of glucose-GLUT-targeting green fluorescent 
NBDG probe (NBD conjugate of glucose7) was not impacted by any of the ManCou 
conjugates (Figure 2.10, C and D). This observations further validates the GLUT5-
specificity of ManCou conjugates. 
2.5 Conclusion 
In conclusion, we have shown that fructose-specific transporter GLUT5 is capable 
of passing coumarins as an imaging cargo, emphasising a capacity for these facilitative 
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transporters to pass non-native moieties in the form of a proper sugar or sugar mimic 
conjugate. The focused coumarin library conjugated to the 1-amino-2,5-anhydro-D-
mannitol (ManCous) includes fluorescent probes that emit at different parts of the 
fluorescence spectrum, while maintaining the same excitation. As GLUT5 reporters, the 
probes allow for a visual discrimination between GLUT5-proficient and GLUT5-deficient 
cells. The structure-uptake relationship established with ManCou analogs revealed that the 
presence of a carboxylate moiety compromises GLUT5-mediated uptake, while ester, 
amide, and free amine functionalities are well tolerated. Also, a strict relationship of uptake 
saturation and cytosolic accumulation with coumarin substitution was observed. The 
spectral versatility of ManCou probes allows for combination studies through mismatching 
fluorescence colors of different reporters, such as nuclear and membrane dyes. 
Furthermore, variations of fluorescent colors within the ManCou library provides an 
opportunity for co-analysis of GLUT5 and other GLUTs (or other cellular targets). 
Considering a direct impact from ManCous on fructose uptake, further evaluation is in 
work to identify the cellular fate of ManCous and reveal their processivity by cellular 
kinases and their potential role as kinase inhibitors.  
2.6 Materials and Methods 
All reagents were used as received unless otherwise stated from Sigma-Aldrich, TCI 
America, Alfa Aesar, Ark Pharm, AK Scientific, Combi-Blocks or Chem-Impex 
International. Commercially available coumarins were purchased from: 7-amino-4-
methylcoumarin (Cou2), Sigma-Aldrich; 7- amino-4-(trifluoromethyl)coumarin (Cou3), 
Alfa Aesar; 2-(7-amino-2-oxo-2H-chromen-4-yl)acetic acid (Cou7), Ark Pharm; 6-amino-
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2H-chromen-2-one (Cou8), Enamine; 7-(diethylamino)-2-oxo-2H-chromene-3-carboxylic 
acid (Cou9), Combi-Blocks. N,N-Dimethylformamide (DMF) was dried and stored over 
CaH2 before use. Dry tetrahydrofuran was dispensed from an automated Innovative 
Technology Pure-Solv 400 Solvent Purification System. Analytical TLC was carried out 
on commercial SiliCycle SiliaPlate® 0.2 mm F254 plates. Preparative silica 
chromatography was performed using SiliCycle SiliaFlash® F60 40-63 μm (230-400 
mesh). Final purification of compounds was achieved with Agilent-1200 HPLC (high-
pressure liquid chromatography) using reversed phase semi-preparative column 
(Phenomenex® Luna® 10 μm C18(2) 100 Å, LC Column 100 x 10 mm, Ea). 1H and 13C 
NMR spectra were recorded at room temperature with a Varian Unity Inova 400 MHz 
spectrometer. CD3OD, DMSO-d6, and D2O were used as solvents and referenced to the 
corresponding residual solvent peaks (3.31 and 49.0 ppm for CD3OD, respectively; 2.50 
and 39.52 ppm for DMSO-d6, respectively; 4.79 ppm for D2O).  The following 
abbreviations are used to indicate the multiplicity: s - singlet; d - doublet; t - triplet; q - 
quartet; m - multiplet; b - broad signal; app - approximate. The coupling constants are 
expressed in Hertz (Hz). The highresolution (HR) MS data (ESI) were obtained using a 
Thermo Fisher Orbitrap Elite™ Hybrid Ion Trap-Orbitrap Mass Spectrometer at Chemical 
Advanced Resolution Methods (ChARM) Laboratory at Michigan Technological 
University. UV-vis spectra were recorded on a Cary 100 Bio-spectrophotometer from 
Agilent Technologies. Fluorescence spectra were obtained with FluoroMax-4 
spectrophotometer. 96-well plate analysis of cell fluorescence was carried out with Victor3 
fluorescence plate reader (excitation at 385 nm). Confocal images were taken with 
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Olympus FluoViewTM FV1000 using the FluoView software. Fluorescence imaging was 
done with EVOS FL Auto inverted microscope 
RPMI-1640, Penicillin/Streptomycin, FBS (Fetal Bovine Serum), 25% Trypsin-EDTA 
(1X), and PBS (phosphate buffered saline solution) were purchased from Life 
Technologies, USA. MEM Non-Essential Amino Acids 100X were purchased from 
Quality Biological, USA. Sterile DMSO (25-950-CQC, 250mL) was purchased from 
Sigma. MCF7 and Hep G2 cells were purchased from ATCC, USA and cultured according 
to the suggested growth methods. 










Scheme S1: Synthesis of 2,5-anhydro-2-carbaldehyde-D-mannitol 2. 
(2S,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carbaldehyde 
(2):26 D-Glucosamine hydrochloride 1 (4.00 g, 18.5 mmol) was dissolved in water (100 
ml) and stirred at room temperature for 5 h. Sodium nitrite (3.19 g, 45.3 mmol) was then 
added, followed by cautious addition of Amberlite 120 H+ resin (90 g) by portion, 
maintaining the temperature of ice bath for 4 h. After the reaction, the resin was removed 
by filtration and the solution was then neutralized by adding sodium carbonate. The 
remaining solution was vacuum dried and then methanol was added to the residue to 
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precipitate the inorganic salts. After removing the salts by filtration, the solution was 
vacuum dried to get the compound 2 as a yellow sticky solid (2.49 g, 70%) that was used 















ManCou1-7, 10-14Cou1: R = H
Cou2: R = CH3
Cou3: R = CF3
Cou4: R = Ph
Cou5: R = CO2Et
Cou6: R = CO2H
NaBH3CN
MeOH/AcOH
Cou7: R = CH2CO2H
Cou10: R = C(O)NH2
Cou11: R = C(O)NHMe
Cou12: R = C(O)NHPh
Cou13: R = 2-furyl







































Scheme S2: Synthesis of ManCous1-14. 
General procedure for the synthesis of ManCous1-8, 10-14:27 Typically, (2S,3S,4S,5R)-
3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carbaldehyde26 (up to 1 mmol) and 
the corresponding coumarin (0.8 equiv.) were dissolved in methanol (10 ml). AcOH (1 ml) 
was used to adjust the pH to <6, followed by portionwise addition of NaBH3CN to the 
reaction mixture (3 X 0.8 equiv, every 20-30 minutes). Water could also be added to 
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improve solubility of some coumarin substrates (up to 20% v/v). The solutions were stirred 
at room temperature for up to 24 h. The mixtures were then concentrated to dryness under 
reduced pressure and purified by column chromatography on silica gel using CH2Cl2 : 
MeOH (up to 90 : 10), EtOAc : MeOH (up to 80 : 20) or water : isopropanol : EtOAc (1 : 
2 : 7 up to 2 : 4 : 4) mixtures. The final purification was achieved by semi-preparative 
HPLC using water-acetonitrile gradient starting with 2-20% acetonitrile to obtain the final 
products as yellow solids or semi-solids, 10-30 mg samples. No attempts were made to 
optimize the yields of the products, which could be estimated as 30-40% average. The 
composition and purity of the final products was confirmed by HRMS, 1H-NMR, and 13C-
NMR. 
7-((((2R,3S,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-
yl)methyl)amino)-2H-chromen-2-one (ManCou1): 1H-NMR (400 MHz, CD3OD): δ, 
7.76-7.36 (d, J = 9.2, 1H), 7.32-7.30 (d, J = 8.4, 1H), 6.68-6.65 (dd, J1 = 2.4, J2 = 8.4, 1H), 
6.53 (d, J = 2.4, 1H), 6.01-5.99 (d, J = 9.2, 1H), 4.02-3.98 (m, 2H), 3.95-3.92 (m, 1H), 
3.88-3.85 (m, 1H), 3.73-3.69 (app dd, J1 = 3.2, J2 = 12.0, 1H), 3.66-3.61 (app dd, J1 = 5.6, 
J2 = 12.0, 1H), 3.48-3.44 (app dd, J1 = 3.6, J2 = 13.6, 1H), 3.38-3.32 (app dd, J1 = 6.8, J2 
= 13.6, 1H) ppm. 13C-NMR (100 MHz, CD3OD): δ, 164.7, 158.1, 154.5, 146.5, 130.2, 
112.3, 110.6, 109.1, 98.0, 85.3, 83.2, 80.3, 78.9, 63.3, 46.2 ppm. HRMS (ESI): m/z [M + 
Na]+ calcd for C15H17NNaO6: 330.09539; found 330.09434. 
7-((((2R,3S,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-
yl)methyl)amino)-4-methyl-2H-chromen-2-one (ManCou2): 1H-NMR (400 MHz, 
CD3OD): δ, 7.48-7.45 (dd, J1 = 3.2, J2 = 8.8, 1H), 6.71-6.67 (dt, J1 = 2.4, J2 = 8.8, 1H), 
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6.52-6.51 (t, J = 2.4, 1H), 5.93 (m, 1H), 4.02-3.98 (m, 2H), 3.96-3.93 (m, 1H), 3.88-3.85 
(m, 1H), 3.73-3.69 (app dd, J1 = 3.6, J2 = 11.6, 1H), 3.66-3.61 (app dd, J1 = 5.6, J2 = 12.0, 
1H), 3.48-3.43 (app dd, J1 = 3.6, J2 = 13.6, 1H), 3.37-3.32 (app dd, J1 = 6.8, J2 = 13.6, 1H), 
2.38 (d, J = 0.8, 3H)  ppm. 13C-NMR (100 MHz, CD3OD): δ, 164.7, 157.3, 156.5, 154.4, 
126.9, 112.1, 111.1, 108.6, 98.2, 85.3, 83.2, 80.3, 78.9, 63.3, 46.2, 18.5 ppm. HRMS (ESI): 
m/z [M + Na]+ calcd for C16H19NNaO6: 344.11104; found 344.11043. 
7-((((2R,3S,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-
yl)methyl)amino)-4-(trifluoromethyl)-2H-chromen-2-one (ManCou3): 1H-NMR (400 
MHz, CD3OD): δ, 7.44-7.41 (dd, J1 = 2.0, J2 = 9.2, 1H), 6.74-6.71 (dt, J1 = 2.4, J2 = 9.2, 
1H), 6.60-6.59 (d, J = 2.4, 1H), 6.37 (s, 1H), 4.02-3.98 (m, 2H), 3.95-3.92 (m, 1H), 3.89-
3.85 (m, 1H), 3.73-3.69 (app dd, J1 = 3.6, J2 = 11.6, 1H), 3.66-3.61 (app dd, J1 = 5.6, J2 = 
12.0, 1H), 3.50-3.46 (app dd, J1 = 3.6, J2 = 14.0, 1H), 3.40-3.35 (app dd, J1 = 6.4, J2 = 13.6, 
1H) ppm. 13C-NMR (100 MHz, CD3OD): δ, 162.2, 158.6, 155.0, 143.3, 143.0, 124.8, 
122.1, 112.8, 108.3, 104.1, 98.5, 85.4, 83.2, 80.2, 78.8, 63.3, 46.1 ppm. HRMS (ESI): m/z 
[M + H]+ calcd for C16H17F3NO6: 376.10082; found 376.09955.  
7-((((2R,3S,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-
yl)methyl)amino)-4-phenyl-2H-chromen-2-one (ManCou4): 1H-NMR (400 MHz, 
CD3OD): δ, 7.50-7.48 (m, 3H), 7.42-7.39 (m, 2H), 7.15-7.13 (d, J = 8.8, 1H), 6.59-6.56 
(m, 2H), 5.90 (s, 1H), 4.03-3.99 (m, 2H), 3.97-3.94 (m, 1H), 3.90-3.86 (m, 1H), 3.74-3.70 
(app dd, J1 = 3.6, J2 = 11.6, 1H), 3.66-3.61 (app dd, J1 = 5.6, J2 = 12.0, 1H), 3.47-3.43 (app 
dd, J1 = 3.6, J2 = 14.0, 1H), 3.37-3.32 (app dd, J1 = 6.8, J2 = 13.6, 1H) ppm. 13C-NMR (100 
MHz, CD3OD): δ, 164.2, 158.7, 157.9, 154.2, 137.2, 130.4, 129.7, 129.3, 128.8, 112.0, 
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109.6, 108.2, 98.4, 85.2, 83.1, 80.2, 78.8, 63.2, 46.2 ppm. HRMS (ESI): m/z [M + Na]+ 
calcd for C21H21NNaO6: 406.12669; found 406.12520.  
Ethyl 7-((((2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-
2-yl)methyl)amino)-2-oxo-2H-chromene-4-carboxylate (ManCou5): 1H-NMR (400 
MHz, CD3OD): δ, 7.84-7.82 (d, J = 8.8, 1H), 6.64-6.61 (dd, J1 = 2.4, J2 = 8.8, 1H), 6.49-
6.48 (d, J = 2.4, 1H), 6.36 (s, 1H), 4.43-4.38 (q, J = 7.2, 2H), 4.03-3.99 (m, 2H), 3.96-3.94 
(m, 1H), 3.90-3.86 (m, 1H), 3.74-3.70 (app dd, J1 = 3.6, J2 = 11.6, 1H), 3.66-3.62 (app dd, 
J1 = 5.6, J2 = 12.0, 1H), 3.47-3.43 (app dd, J1 = 3.6, J2 = 14.0, 1H), 3.38-3.32 (app dd, J1 
= 6.8, J2 = 14.0, 1H), 1.42-1.38 (t, J = 7.2, 2H) ppm. 13C-NMR (100 MHz, CD3OD): δ, 
165.8, 163.6, 158.3, 154.5, 145.3, 128.6, 112.5, 111.0, 106.9, 98.2, 85.3, 83.1, 80.3, 78.8, 
63.30, 63.25, 46.1, 14.4 ppm. HRMS (ESI): m/z [M + H]+ calcd for C18H22NO8: 380.13458; 
found 380.13345.  
7-((((2R,3S,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-
yl)methyl)amino)-2-oxo-2H-chromene-4-carboxylic acid (ManCou6): 1H-NMR (400 
MHz, D2O): δ, 7.47-7.45 (d, J = 8.8, 1H), 6.73-6.70 (d, J = 8.8, 1H), 6.53 (s, 1H), 6.07 (m, 
1H), 4.07 (bs, 3H), 3.96-3.93 (m, 1H), 3.80-3.76 (app dd, J1 = 3.2, J2 = 12.4, 1H), 3.73-
3.68 (app dd, J1 = 6.0, J2 = 12.0, 1H), 3.48-3.36 (m, 2H) ppm. 13C-NMR (100 MHz, D2O): 
δ, 172.6, 165.9, 156.4, 155.4, 152.8, 127.7, 112.1, 106.7, 103.4, 97.7, 82.7, 81.0, 78.4, 76.8, 




yl)methyl)amino)-2-oxo-2H-chromen-4-yl)acetic acid (ManCou7): 1H-NMR (400 
MHz, D2O): δ, 7.48-7.45 (d, J = 8.8, 1H), 6.77-6.74 (dd, J1 = 2.4, J2 = 8.8, 1H), 6.59 (d, J 
= 2.4, 1H), 6.06 (s, 1H), 4.10 (bs, 2H), 3.98-3.94 (m, 1H), 3.81-3.65 (m, 5H), 3.54-3.46 
(m, 2H) ppm. We were not able to obtain satisfactory 13C-NMR data in D2O. HRMS (ESI): 
m/z [M + H]+ calcd for C17H20NO8: 366.11893; found 366.11771. 
6-((((2R,3S,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-
yl)methyl)amino)-2H-chromen-2-one (ManCou8): 1H-NMR (400 MHz, CD3OD): δ, 
7.84-7.82 (d, J = 9.2, 1H), 7.13-7.11 (d, J = 8.8, 1H), 6.99-6.96 (dd, J1 = 2.4, J2 = 9.2, 1H), 
6.80-6.79 (d, J = 2.4, 1H), 6.36-6.33 (d, J = 9.2, 1H), 4.03-3.96 (m, 3H), 3.89-3.85 (m, 1H), 
3.74-3.70 (app dd, J1 = 3.6, J2 = 12.0, 1H), 3.66-3.62 (app dd, J1 = 5.6, J2 = 11.6, 1H), 3.42-
3.38 (app dd, J1 = 3.6, J2 = 13.6, 1H), 3.30-3.32 (app dd, J1 = 6.4, J2 = 13.6, 1H) ppm. 13C-
NMR (100 MHz, CD3OD): δ, 163.7, 147.59, 147.56, 146.1, 120.8, 119.9, 118.0, 116.7, 
109.4, 85.2, 83.2, 80.4, 78.9, 63.3, 47.3 ppm. HRMS (ESI): m/z [M + H]+ calcd for 




(ManCou9): This compound was synthesized according to the reported general 
procedure.28 To a solution of 1-amino-2,5-anhydro-D-mannitol26 (100 mg, 0.61 mmol), 7-
(diethylamino)-2-oxo-2H-chromene-3-carboxylic acid (120 mg, 0.46 mmol), 1-
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hydroxybenzotriazole monohydrate (HOBt; 93 mg, 0.69 mmol) and diisopropylethylamine 
(DIEA; 0.24 ml, 1.4 mmol) in dry DMF (4 ml), N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDCI; 132 mg, 0.69 mmol) was added and the mixture 
was stirred at room temperature for 12 h. It was diluted with EtOAc (100 ml), washed with 
brine (3 X 20 ml), and dried with MgSO4. After filtration and concentration, the residue 
was purified by column chromatography on silica gel, eluting with 0-100% EtOAc in 
hexanes, followed by 20% MeOH in EtOAc. The final purification was achieved by semi-
preparative HPLC using water-acetonitrile gradient starting with 50% acetonitrile. A 
sample of compound was obtained as a yellow semi-solid (~20 mg). 1H-NMR (400 MHz, 
CD3OD): δ, 8.60 (s, 1H), 7.53-7.51 (d, J = 9.2, 1H), 6.81-6.78 (dd, J1 = 2.4, J2 = 9.2, 1H), 
6.54-6.53 (d, J = 2.4, 1H), 4.04-3.86 (m, 4H), 3.75-3.62 (m, 4H), 3.54-3.49 (q, J = 7.2, 4H), 
1.25-1.21 (t, J = 7.2, 6H) ppm. 13C-NMR (100 MHz, CD3OD): δ, 165.4, 163.8, 159.0, 
154.4, 149.2, 132.5, 111.6, 109.9, 109.4, 97.2, 85.0, 82.7, 79.8, 78.4, 63.2, 46.0, 42.3, 12.8 
ppm. HRMS (ESI): m/z [M + H]+ calcd for C20H27N2O7: 407.18187; found 407.18109. 
7-((((2R,3S,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-
yl)methyl)amino)-2-oxo-2H-chromene-4-carboxamide (ManCou10): 1H-NMR (400 
MHz, CD3OD): δ, 7.52-7.50 (d, J = 8.8, 1H), 6.70-6.68 (dd, J1 = 2.4, J2 = 8.8, 1H), 6.57-
6.56 (d, J = 2.4, 1H), 6.08 (s, 1H), 4.02-3.98 (m, 2H), 3.95-3.92 (m, 1H), 3.88-3.84 (m, 
1H), 3.73-3.69 (app dd, J1 = 3.6, J2 = 12.0, 1H), 3.65-3.61 (app dd, J1 = 5.6, J2 = 12.0, 1H), 
3.49-3.45 (app dd, J1 = 4.0, J2 = 13.6, 1H), 3.39-3.34 (app dd, J1 = 6.4, J2 = 13.6, 1H) ppm. 
13C-NMR (100 MHz, CD3OD): δ, 170.0, 163.8, 158.3, 154.7, 151.7, 128.2, 112.4, 106.9, 
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98.2, 85.3, 83.1, 80.2, 78.8, 63.2, 46.2 ppm. HRMS (ESI): m/z [M + H]+ calcd for 
C16H19N2O7: 351.11927; found 351.11826. 
7-((((2R,3S,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-
yl)methyl)amino)-N-methyl-2-oxo-2H-chromene-4-carboxamide (ManCou11): 1H-
NMR (400 MHz, CD3OD): δ, 7.46-7.44 (d, J = 8.8, 1H), 6.69-6.66 (dd, J1 = 2.4, J2 = 8.8, 
1H), 6.56 (d, J = 2.4, 1H), 6.04 (s, 1H), 4.02-3.92 (m, 3H), 3.88-3.84 (m, 1H), 3.73-3.69 
(app dd, J1 = 3.6, J2 = 11.6, 1H), 3.65-3.61 (app dd, J1 = 5.6, J2 = 11.6, 1H), 3.49-3.45 (app 
dd, J1 = 3.6, J2 = 13.6, 1H), 3.39-3.33 (app dd, J1 = 6.4, J2 = 13.6, 1H), 2.92 (s, 3H) ppm. 
13C-NMR (100 MHz, CD3OD): δ, 168.4, 163.9, 158.4, 154.8, 151.9, 128.3, 112.4, 107.1, 
98.3, 85.3, 83.2, 80.3, 78.8, 63.3, 46.2, 26.5 ppm. HRMS (ESI): m/z [M + H]+ calcd for 
C17H21N2O7: 365.13492; found 365.13368. 
7-((((2R,3S,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-
yl)methyl)amino)-2-oxo-N-phenyl-2H-chromene-4-carboxamide (ManCou12): 1H-
NMR (400 MHz, CD3OD): δ, 7.70-7.67 (m, 2H), 7.50-7.47 (d, J = 9.2, 1H), 7.40-7.35 (m, 
2H), 7.21-7.16 (m, 1H), 6.71-6.68 (dd, J1 = 2.4, J2 = 8.8, 1H), 6.59-6.58 (d, J = 2.4, 1H), 
6.18 (s, 1H), 4.02-3.98 (m, 2H), 3.95-3.93 (app dd, J1 = 5.2, J2 = 6.0, 1H), 3.88-3.85 (m, 
1H), 3.73-3.69 (app dd, J1 = 3.6, J2 = 12.0, 1H), 3.65-3.61 (app dd, J1 = 5.6, J2 = 12.0, 1H), 
3.50-3.45 (app dd, J1 = 3.6, J2 = 14.0, 1H), 3.40-3.34 (app dd, J1 = 6.8, J2 = 14.0, 1H) ppm. 
13C-NMR (100 MHz, CD3OD): δ, 165.7, 163.7, 158.3, 154.7, 151.7, 139.0, 129.9, 128.0, 
126.0, 121.6, 112.4, 107.01, 106.95, 98.3, 85.3, 83.1, 80.2, 78.8, 63.2, 46.2 ppm. HRMS 
(ESI): m/z [M + H]+ calcd for C23H23N2O7: 427.15057; found 427.15000. 
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7-((((2R,3S,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-
yl)methyl)amino)-4-(furan-2-yl)-2H-chromen-2-one (ManCou13): 1H-NMR (400 
MHz, CD3OD): δ, 7.92-7.90 (d, J = 8.8, 1H), 7.81-7.80 (dd, J1 = 0.4, J2 = 1.6, 1H), 7.17-
7.16 (dd, J1 = 0.4, J2 = 3.6, 1H), 6.70-6.67 (m, 2H), 6.54-6.53 (d, J = 2.4, 1H), 6.24 (s, 1H), 
4.04-4.00 (m, 2H), 3.97-3.44 (app dd, J1 = 5.2, J2 = 6.0, 1H), 3.90-3.87 (m, 1H), 3.74-3.70 
(app dd, J1 = 3.6, J2 = 12.0, 1H), 3.67-3.62 (app dd, J1 = 5.6, J2 = 12.0, 1H), 3.49-3.44 (app 
dd, J1 = 3.6, J2 = 14.0, 1H), 3.39-3.34 (app dd, J1 = 6.8, J2 = 14.0, 1H) ppm. 13C-NMR (100 
MHz, CD3OD): δ, 164.5, 158.1, 154.1, 150.2, 146.5, 144.6, 128.4, 115.5, 113.3, 112.3, 
107.0, 104.3, 98.5, 85.3, 83.1, 80.2, 78.8, 63.3, 46.2 ppm. HRMS (ESI): m/z [M + H]+ calcd 
for C19H20NO7: 374.12401; found 374.12338. 
7-((((2R,3S,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-
yl)methyl)amino)-4-(pyridin-2-yl)-2H-chromen-2-one (ManCou14): 1H-NMR (400 
MHz, CD3OD): δ, 8.71-8.69 (ddd, J1 = 1.2, J2 = 1.6, J2 = 5.2, 1H), 8.02-7.98 (dt, J1 = 1.6, 
J2 = 8.0, 1H), 7.66-7.64 (d, J = 8.0, 1H), 7.56-7.53 (ddd, J1 = 0.8, J2 = 5.2, J2 = 8.0, 1H), 
7.30-7.28 (d, J = 8.8, 1H), 6.63-6.60 (app dd, J1 = 2.4, J2 = 8.8, 1H), 6.59 (d, J = 2.4, 1H), 
6.09 (s, 1H), 4.02-3.99 (m, 2H), 3.96-3.93 (m, 1H), 3.89-3.85 (m, 1H), 3.73-3.69 (app dd, 
J1 = 3.6, J2 = 12.0, 1H), 3.66-3.61 (app dd, J1 = 5.6, J2 = 12.0, 1H), 3.48-3.44 (app dd, J1 
= 3.6, J2 = 14.0, 1H), 3.38-3.33 (app dd, J1 = 6.8, J2 = 14.0, 1H) ppm. 13C-NMR (100 MHz, 
CD3OD): δ, 164.0, 158.2, 155.7, 155.6, 154.3, 150.3, 139.0, 128.8, 125.6, 125.5, 112.2, 
109.0, 108.8, 98.3, 85.2, 83.1, 80.2, 78.8, 63.2, 46.2 ppm. HRMS (ESI): m/z [M + H]+ calcd 
for C20H21N2O6: 385.14000; found 385.13907. 
Synthesis of Coumarins 
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4 5 6 Cou4: Ar = Ph
Cou13: Ar = 2-furyl




Scheme S3: Synthesis of C4-aryl coumarins Cou4 and Cous13-14. 
(3-Hydroxyphenyl)carbamic acid ethyl ester (6):29 This compound was synthesized 
according to the reported procedure.29 3-Aminophenol 4 (10.0 g, 91.6 mmol) and ethyl 
acetate (350 ml) were refluxed for 1 hour with vigorous stirring.  Ethyl chloroformate 5 
(11.92 g, 109.9 mmol) was then added via addition funnel over a 30 minute period.  The 
reaction mixture was refluxed for an additional hour and then allowed to cool to room 
temperature. Upon cooling a grey/white precipitate formed within the flask. The precipitate 
was removed via filtration, and washed with ethyl acetate (3 x 150 ml). The combined 
filtrates were concentrated to afford 6 as a grey solid (9.46 g, 57%) that was used without 
further purification. 1H-NMR (400 MHz, DMSO-d6): δ, 9.45 (s, 1H), 9.29 (bs, 1H), 7.04-
7.00 (m, 2H), 6.86-6.84 (m, 1H), 6.39-6.36 (ddd, J1 = 1.2, J2 = 2.4, J3 = 8.0, 1H), 4.12-4.07 
(q, J = 7.2, 2H), 1.24-1.21 (t, J = 7.2, 3H) ppm.  
7-Amino-4-phenyl-2H-chromen-2-one (Cou4):23 This compound was 
synthesized according to the reported procedure.23 6 (1.00 g, 5.52 mmol) and ethyl 
benzoylacetate (1.27g, 6.62 mmol) were added to a 100 ml round-bottom flask equipped 
with a stir bar. 70% H2SO4 (30 ml) was added and the mixture was stirred at room 
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temperature. More 70% H2SO4 was added until the reaction mixture turned from 
yellow/cloudy to amber/clear and then stirring was maintained overnight at room 
temperature. The reaction mixture was then poured over 100 ml of crushed ice to give a 
bright yellow precipitate. The solid was filtered and recrystallized from hot methanol to 
afford clear large crystals of Cou4-precursor (0.717g, 42%). 1H-NMR (400 MHz, DMSO-
d6): δ, 10.14 (s, 1H), 7.62-7.61 (d, J = 2.4, 1H), 7.54-7.48 (m, 5H), 7.36-7.30 (m, 2H), 6.20 
(s, 1H), 4.18-4.13 (q, J = 7.2, 2H), 1.27-1.24 (t, J = 7.2, 3H) ppm.  
Cou4-precursor (0.408 g, 1.32 mmol) was added to a 50 ml round-bottom flask, 
followed by H2SO4 conc. (5 ml) and glacial AcOH (5 ml). The reaction mixture was heated 
to 125 ̊ C for 2 hours under reflux condenser, after which it was cooled to room temperature 
and poured over 50 ml of crushed ice. The resulting suspension was neutralized till weakly 
basic using 4M NaOH, affording a yellow precipitate.  The precipitate was filtered and 
recrystallized from hot methanol to give Cou4 as a fine yellow powder (0.175 g, 56%). 1H-
NMR (400 MHz, DMSO-d6): δ, 7.54-7.46 (m, 5H), 7.09-7.07 (d, J = 8.8, 1H), 6.54-6.51 
(app dd, J1 = 2.0, J2 = 8.8, 1H), 6.50 (d, J = 2.0, 1H), 6.24 (bs, 2H), 5.90 (s, 1H) ppm. 13C-
NMR (100 MHz, DMSO-d6): δ, 160.3, 156.0, 155.6, 153.1, 135.5, 129.2, 128.6, 128.1, 
127.6, 111.3, 107.2, 107.0, 98.8 ppm. HRMS (ESI): m/z [M + H]+ calcd for C15H12NO2: 
238.08681; found 238.08597. 
7-Amino-4-(furan-2-yl)-2H-chromen-2-one (Cou13): This compound was 
synthesized according to the reported general procedure.30 6 (1.00g, 5.52 mmol) and 3-
furan-2-yl-3-oxo-propionic acid ethyl ester (1.27 g, 6.62 mmol) were added to a 50 ml 
round-bottom flask equipped with a stir bar. Methanesulfonic acid (10 ml) was added and 
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the mixture was stirred at room temperature for overnight while the colour turned from 
clear/amber to black. The reaction mixture was then poured over 50 ml of ice water. It was 
then extracted with ethyl acetate (3 x 75 ml), and the combined organics were washed with 
brine (2 x 50 ml) and dried over Na2SO4. After filtration and concentration, a brown solid 
was obtained which was then recrystallized from hot methanol to afford Cou13-precursor 
as grey-black crystals (0.446 g, 27 %). 1H-NMR (400 MHz, DMSO-d6): δ, 10.18 (s, 1H), 
8.16-8.14 (d, J = 8.8, 1H), 8.05-8.04 (d, J = 1.6, 1H), 7.59 (d, J = 2.0, 1H), 7.47-7.46 (d, J 
= 3.6, 1H), 7.44-7.42 (dd, J1 = 2.0, J2 = 8.8, 1H), 6.80-6.78 (dd, J1 = 1.6, J2 = 3.6, 1H), 6.53 
(s, 1H), 4.20-4.14 (q, J = 7.2, 2H), 1.28-1.25 (t, J = 7.2, 3H) ppm. 13C-NMR (100 MHz, 
DMSO-d6): δ, 159.8, 154.6, 153.1, 147.6, 146.2, 142.8, 140.9, 127.0, 115.3, 114.3, 112.7, 
110.0, 107.6, 104.7, 60.7, 14.4 ppm. 
Cou13-precursor (1.00 g, 3.34 mmol) was added to a 50 ml round-bottom flask, 
followed by H2SO4 conc. (5 ml) and glacial AcOH (5 ml). The reaction mixture was heated 
to 125 ̊ C for 2 hours under reflux condenser, after which it was cooled to room temperature 
and poured over 50 ml of crushed ice. The resulting suspension was neutralized till weakly 
basic using 4M NaOH, extracted with ethyl acetate (3 x 75 ml) and dried over Na2SO4. 
After filtration and concentration, the residue was purified by column chromatography on 
silica gel (dry loading), eluting with 40-100% EtOAc in hexanes, followed by 5% MeOH 
in EtOAc. The residue was triturated with hexanes containing little CH2Cl2. The product 
was filtered, washed with hexanes and dried in air to obtain Cou13 as a yellow-brown 
powder (0.11 g, 14%). 1H-NMR (400 MHz, DMSO-d6): δ, 8.02 (s, 1H), 7.92-7.90 (d, J = 
8.4, 1H), 7.36 (s, 1H), 6.76 (s, 1H), 6.63-6.61 (d, J = 8.4, 1H), 6.48 (s, 1H), 6.26 (bs, 2H), 
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6.24 (s, 1H) ppm. 13C-NMR (100 MHz, DMSO-d6): δ, 160.7, 156.4, 153.2, 148.6, 145.9, 
142.0, 127.5, 114.7, 112.6, 111.6, 104.6, 103.3, 99.1 ppm. HRMS (ESI): m/z [M + H]+ 
calcd for C13H10NO3: 228.06608; found 228.06500. 
7-Amino-4-(pyridin-2-yl)-2H-chromen-2-one (Cou14): This compound was 
synthesized according to the reported general procedure.30 6 (2.00 g, 11.03 mmol) and ethyl 
3-oxo-3-(pyridin-2-yl)propanoate (2.56 g, 13.24 mmol) were added to a 50 ml round-
bottom flask with a stir bar. Methanesulfonic acid (10 ml) was added and the mixture was 
stirred at room temperature for overnight while the color turned from clear/amber to black. 
The reaction mixture was then poured over 50 ml of ice water. It was then extracted with 
ethyl acetate (3 x 75 ml), and the combined organics were washed with brine (2 x 50 ml) 
and dried over Na2SO4. After filtration and concentration, a grey solid was obtained which 
was then recrystallized from hot methanol to afford Cou14-precursor as fine white 
crystals of 1 : 1 MeOH solvate (1.403 g, 41 %). 1H-NMR (400 MHz, DMSO-d6): δ, 10.17 
(s, 1H), 8.78-8.76 (ddd, J1 = 1.2, J2 = 2.0, J2 = 8.8, 1H), 8.03-8.00 (dt, J1 = 2.0, J2 = 8.0, 
1H), 7.77-7.75 (m, 1H), 7.70-7.68 (d, J = 8.8, 1H), 7.64-7.63 (d, J = 2.0, 1H), 7.58-7.54 
(m, 1H), 7.36-7.34 (dd, J1 = 2.0, J2 = 8.8, 1H), 4.19-4.14 (q, J = 7.2, 2H), 4.11-4.07 (q, J = 
5.2, 1H), 3.18-3.16 (d, J = 5.2, 3H), 1.28-1.24 (t, J = 7.2, 3H) ppm. 13C-NMR (100 MHz, 
DMSO-d6): δ, 159.8, 154.6, 153.3, 153.1, 152.2, 149.3, 142.8, 137.5, 127.8, 124.4, 124.2, 
114.1, 112.7, 112.0, 104.6, 60.7, 48.6, 14.4 ppm. 
Cou14-precursor (0.50 g, 1.61 mmol) was added to a 50 ml round-bottom flask, 
followed by H2SO4 conc. (5 ml) and glacial AcOH (5 ml). The reaction mixture was heated 
to 125 ̊ C for 2 hours under reflux condenser, after which it was cooled to room temperature 
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and poured over 50 ml of crushed ice. The resulting suspension was neutralized till weakly 
basic using 4M NaOH, affording a beige precipitate. The precipitate was filtered and 
recrystallized from hot methanol to give Cou14 as fine yellow crystals (0.162 g, 68%). 1H-
NMR (400 MHz, CD3OD): δ, 8.72-8.70 (ddd, J1 = 1.2, J2 = 1.6, J2 = 4.8, 1H), 8.04-8.00 
(dt, J1 = 2.0, J2 = 8.0, 1H), 7.69-7.66 (dt, J1 = 1.2, J2 = 8.0, 1H), 7.58-7.54 (ddd, J1 = 0.8, 
J2 = 4.8, J2 = 8.0, 1H), 7.29-7.26 (app dd, J1 = 3.2, J2 = 6.4, 1H), 6.60-6.57 (m, 2H), 6.11 
(s, 1H) ppm. 13C-NMR (100 MHz, CD3OD): δ, 164.1, 158.2, 156.0, 155.8, 155.0, 150.5, 
139.2, 129.2, 125.7, 125.6, 113.2, 109.2, 109.1, 100.7 ppm. HRMS (ESI): m/z [M + H]+ 
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Scheme 4: Synthesis of Cou5. 
Ethyl 7-amino-2-oxo-2H-chromene-4-carboxylate (Cou5):31 3-Aminophenol 
(4) (5.00 g, 45.8 mmol), diethyl oxaloacetate sodium salt (8) (14.4 g, 68.7 mmol) and EtOH 
(20 ml) were heated at reflux overnight. The mixture was cooled and concentrated to 
dryness and the residue was purified by silica gel chromatography (50% EtOAc in 
hexanes). Cou5 was obtained as an yellow-orange solid (4.17 g, 39%). 1H-NMR (400 
MHz, DMSO-d6): δ, 7.69-7.66 (d, J = 8.8, 1H), 6.60-6.57 (dd, J1 = 2.4, J2 = 8.8, 1H), 6.46-
6.45 (d, J = 2.4, 1H), 6.37 (bs, 2H), 6.31 (s, 1H), 4.39-4.33 (q, J = 7.2, 1H), 1.35-1.31 (t, J 
= 7.2, 1H) ppm. 13C-NMR (100 MHz, DMSO-d6): δ, 164.3, 160.3, 156.5, 153.6, 143.8, 
59 
127.4, 111.8, 109.2, 104.4, 98.8, 62.0, 13.9 ppm. HRMS (ESI): m/z [M + H]+ calcd for 
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Scheme 5: Synthesis of Cou6 and Cous10-12. 
7-Amino-2-oxo-2H-chromene-4-carboxylic acid (Cou6): Ethyl 7-amino-2-oxo-
2H-chromene-4-carboxylate (Cou5) (1.00 g, 4.30 mmol) and 2M KOH solution (25 ml) 
were added to the flask and refluxed for 4 h. After cooling, the reaction mixture was washed 
with AcOEt (25 ml, discarded). AcOH was used to neutralize the solution that was 
concentrated to dryness. The residue was purified by column chromatography on silica gel, 
eluting with water: isopropanol: EtOAc mixtures (1 : 2 : 7 to 2 : 4 : 4). The residue was 
triturated with CH2Cl2 containing little EtOH, and then refluxed in CHCl3 overnight. The 
product was filtered, washed with CHCl3 and dried in air to obtain orange solid (0.38 g, 
43%) in satisfying purity. 1H-NMR (400 MHz, DMSO-d6): δ, 7.73-7.70 (d, J = 8.8, 1H), 
6.53-6.50 (dd, J1 = 2.0, J2 = 8.8, 1H), 6.40 (d, J = 2.0, 1H), 5.93 (s, 1H) ppm. 13C-NMR 
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(100 MHz, DMSO-d6): δ, 167.1, 161.6, 156.3, 152.6, 128.6, 111.0, 106.2, 104.8, 98.4 ppm. 
HRMS (ESI): m/z [M + H]+ calcd for C10H8NO4: 206.04535; found 206.04487. 
7-Amino-2-oxo-2H-chromene-4-carboxamide (Cou10): This compound was 
synthesized according to the modified general procedure.32 Cou5 (1.00 g, 4.30 mmol) was 
placed in the flame-dried flask under the flow of Ar. Then 7N NH3 in absolute MeOH (20 
ml) was added and the mixture was allowed to react at room temperature under Ar for 24 
h. Then the mixture was concentrated to dryness. The residue was purified by column 
chromatography on silica gel, eluting with 100% CH2Cl2 to 100% EtOAc, followed by 10-
40% MeOH in EtOAc. The residue was triturated with CH2Cl2, and filtered washing 
sequentially with CH2Cl2, water, ethanol, again CH2Cl2 and dried in air. The product was 
obtained as a yellow solid (0.12 g, 14%). 1H-NMR (400 MHz, DMSO-d6): δ, 8.16 (bs, 1H), 
7.83 (bs, 1H), 7.43-7.41 (d, J = 8.8, 1H), 6.57-6.55 (dd, J1 = 2.0, J2 = 8.8, 1H), 6.44 (d, J = 
2.0, 1H), 6.27 (bs, 2H), 5.99 (s, 1H) ppm. 13C-NMR (100 MHz, DMSO-d6): δ, 166.8, 160.8, 
156.4, 153.5, 150.2, 127.6, 111.6, 105.5, 105.0, 98.7 ppm. HRMS (ESI): m/z [M + H]+ 
calcd for C10H9N2O3: 205.06134; found 205.06064. 
7-Amino-N-methyl-2-oxo-2H-chromene-4-carboxamide (Cou11): This 
compound was synthesized according to the modified general procedure.32 Cou5 (1.00 g, 
4.30 mmol) was placed in the flame-dried flask under the flow of Ar. 33 wt. % CH3NH2 in 
MeOH (20 ml) was added and the mixture was allowed to react at room temperature under 
Ar for 24 h. Then the mixture was concentrated to dryness. The residue was purified by 
column chromatography on silica gel, eluting with 50-100% EtOAc in hexanes, followed 
by 10% MeOH in EtOAc. The residue was stirred overnight in CH2Cl2/EtOAc, filtered, 
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washed with CH2Cl2 and dried in air. The product was obtained as a yellow solid (0.08 g, 
9%). 1H-NMR (400 MHz, DMSO-d6): δ, 8.66 (d, J = 4.0, 1H), 7.38-7.36 (d, J = 8.8, 1H), 
6.56-6.54 (d, J = 8.8, 1H), 6.44 (s, 1H), 6.28 (bs, 2H), 5.98 (s, 1H), 2.77 (d, J = 4.0, 3H) 
ppm. 13C-NMR (100 MHz, DMSO-d6): δ, 165.0, 160.5, 156.2, 153.4, 150.0, 127.5, 111.5, 
105.6, 105.0, 98.6, 25.8 ppm. HRMS (ESI): m/z [M + H]+ calcd for C11H11N2O3: 
219.07699; found 219.07602. 
7-Amino-2-oxo-N-phenyl-2H-chromene-4-carboxamide (Cou12): This 
compound was synthesized according to the modified general procedure.33 A solution of 
aniline (0.729 ml, 8 mmol) in dry THF (20 ml) was cooled to 0 ˚C under Ar and a 
commercial 2.0 M solution of trimethylaluminum in hexanes (10 ml, 20 mmol) was added 
dropwise over 10 minutes. Then, to the resulting mixture a solution of Cou5 (0.932 g, 4 
mmol) in dry THF (40 ml) was added dropwise over 20 minutes at 0 ˚C. The mixture was 
allowed to warm to rt and stirred for overall 22 h. It was diluted with EtOAc (100 ml) and 
carefully neutralized with aq. NH4Cl (100 ml) with vigorous stirring. The phases were 
separated, and the aqueous phase was additionally extracted with EtOAc (100 ml). The 
combined organic extracts were washed with brine (50 ml) and dried over MgSO4. After 
filtration and concentration, the residue was purified by column chromatography on silica 
gel, eluting with 0-80% EtOAc in hexanes. The product was further purified by 
recrystallization from EtOAc and filtered washing copiously with CH2Cl2 to obtain an 
orange solid (0.165 g, 14%). 1H-NMR (400 MHz, DMSO-d6): δ, 10.7 (bs, 1H), 7.74-7.72 
(d, J = 8.0, 2H), 7.39-7.36 (m, 3H), 7.16-7.13 (t, J = 7.2, 1H), 6.60-6.58 (d, J = 8.0, 1H), 
6.49 (s, 1H), 6.34 (bs, 2H), 6.20 (s, 1H) ppm. 13C-NMR (100 MHz, DMSO-d6): δ, 163.2, 
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160.5, 156.2, 153.5, 149.6, 138.2, 128.7, 127.2, 124.2, 119.9, 111.7, 105.8, 104.8, 98.6 
ppm. HRMS (ESI): m/z [M + H]+ calcd for C16H13N2O3: 281.09264; found 281.09189. 
Cell Imaging 
For confocal microscopy cells were plated (100,000/plate) in 35 mm glass-bottom confocal 
dishes (MatTek) and allowed to grow in their respective growth media for 24 hours. For 
optical microscope analysis cells were plated in a 6-well plates (3 x 105) and allowed to 
adhere and grow for 24 h. For treatment, cell media was removed and ManCou solution in 
PBS (1 ml) was added. Cells were incubated with ManCous at 37 Co for 10 min. After 
incubation, probe solution was removed, and cells were washed with warmed PBS (3 x 1 
ml) and leaving 1 ml of PBS for imaging. Cell images were taken using Olympus 
FluoViewTM FV1000 using the FluoView software. 60X oil suspended lens was used to 
observe fluorescent activity with the following conditions: DAPI (ManCous) and eGFP 
(NBDM and NBDG) filters; lasers 405 nm (45% intensity), 450/490 nm (30% intensity); 
10 µs/pixel. Z-stacking was done using FluoView software and depth command.  
Microplate uptake and inhibition assays 
For microplate assays, at ~80% confluence cells were collected and plated in 96-well flat 
bottom plates (20,000 cells/well) and allowed to grow for 24 hours. Cells were then washed 
with warmed (37 ˚C) PBS solution, treated with ManCou probes (concentration varies) in 
PBS and incubated at 37 ˚C and 5% CO2 for 10 min. After incubation, cells were carefully 
washed with warmed PBS (3 x 100 µl). Fluorescent data were immediately collected using 
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Victor3 plate reader and using WallacTM umbelliferone (excitation 355 nm, emission 460 
nm, 1.0 s) protocol. All trials were done in triplicate on each plate. 
Uptake Inhibition studies were carried out in microplate format. Using 96-well 
plate method fluorescence of ManCou probes in cells was measured in the presence of 
varying concentrations of fructose, glucose, glucosamine, and cytochalasin B. For this part, 
PBS solution containing 20 µM ManCou and the specific concentration of a sugar were 
prepare and introduced to cells. Separately, complete culture media were used to establish 
the impact of nutrients on ManCou uptake. Cell incubation, and data collection were 
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3 Metabolism-driven High Throughput Cancer 
Identification with GLUT5-specific Molecular Probes 
3.1 Introduction 
Point of care (POC) and POC-healthcare technologies (POCHT) that monitor changes in 
the intracellular mechanisms to report disease development have gained prominence in 
clinical and consumer implementations owing to the ease of access to information, low 
cost and self-management of health and wellbeing [1-5]. The marked improvement in in 
microfluidics, molecular diagnostics, and nucleic acid chemistries [6-8] to identify cancer-
relevant biomarkers [9] has led to an increased interest in POC/POCHT for cancer. 
However, the relatively low concentration of the biomarkers poses constrains on sensing, 
limiting the identification of the metastatic capability of the tumor, when present. The 
diagnosis currently heavily relies on various radiological techniques. Despite the advances 
to improve the resolution of radiological approaches, pathology reports of biopsy samples 
remain the sole means to identify cancer type and stage [10]. There exist discrepancies in 
diagnosis for the same sample owing to the highly heterogeneous nature of the tissue, subtle 
morphological changes, and the interpretation by the observer particularly when the sample 
deviates from key criteria used to classify breast tumors [11]. Any approach capable of 
identification of cancer cell population in the heterogeneous environment of the tumor is 
expected to be based on error-free cancer detection and diagnosis for development of 
cancer relevant POC technologies. Within this communication, a metabolism-driven 
approach for detection and identification of breast cancers is described. The difference in 
carbohydrate demands among different cells and cancer sub-populations forms the basis 
for the approach presented here.   
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The long-recognized higher energy demands in cancer cells [12,13] have led to the 
development of metabolism-based approach to detect cancer, with 18F-2-deoxy-glucose 
being a widely used as PET-imaging cancer agent [14]. Until recently the major efforts in 
identifying cancer through metabolism changes have focused on targeting glucose uptake 
and the facilitative glucose transporter GLUT1 [15,16]. However, the global physiological 
need for glucose and ubiquitous presence of GLUT1 limits this strategy in sensitivity, 
selectivity, and specificity [17]. Targeting glucose transport is in particular limited for 
breast cancers, known to exhibit insignificant changes in glucose uptake with respect to 
their normal counterparts [18-20]. Recently, strong links between cancer and enhanced 
fructose uptake have been established, bringing forth fructose transport as a promising 
target to identify cancer on the basis of fructose uptake and metabolism [21]. For example, 
triple-negative breast cancer phenotypes have been reported to exhibit 8-10-fold higher 
fructose uptake than other phenotypes, with minimal fructose uptake measured for normal 
breast cells [22-24]. A particular dependence of cancer cells on fructose for growth and 
progression identified for breast cancers [25-27] has justified targeting fructose uptake as 
means to detect breast cancer. Moreover, the possibility to achieve high levels of specificity 
in detection is provided by the specific expression of fructose transporter GLUT5 in breast 
cancer cells but not normal breast cells [28], owing the availability of proper detection 
tools. 
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Targeting GLUTs has led to only a few molecular probes showing transporter-
specificity [16,29]. Fructose transporters have been specifically targeted with fluorescent 
7-nitrobenzofurazan conjugates of fructose (NBDF) and 1-amino-2,5-deoxy-D-mannitol 
(NBDM) [30,31], with NBDM showing unique specificity towards GLUT5. Interestingly, 
epimers or regio-isomers of NBDM were shown to gain uptake through glucose GLUTs 
with loss of uptake through the fructose GLUTs [32,33]. Among various fructose analogs, 
1-amino-2,5-anhydro-D-mannitol (1-AM) has shown specificity towards GLUT5 and high 
affinity could be achieved upon fuctionalization of 1-AM with aromatic moieties 
[30,34,35]. Among those, NBD conjugate (NBDM) provided fluorescent GLUT-specific 
probes for direct analysis of GLUT5 activity in different cell lines. While NBDM provided 
feasibility for discriminating between normal and cancer cells on the basis of the uptake 
through GLUT5 [30], the probe had limited accumulation in cells (uptake saturation at 50 
µM concentration measured), resulting in the unfavorable background fluorescence. Here 
we report GLUT5-targeting 
probes with improved cancer 
detection capability. The two 
probes described, differ in their 
uptake profile and reflect the 
metabolic capacity of the cell and 
GLUT5 activity. Considering the 
recognized differences between 
cells in their metabolic efficiency 
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Figure 3.1. Fluorescence-based identification of breast 




allow for discrimination of pre-malignant cells from differentiated epithelial cells and 
normal cells under in vitro setting (Figure 1). 
3.2 Materials and Methods 
 All reagents were used as received unless otherwise stated from Sigma-Aldrich. 
The 7-aminocoumarin was synthesized according to the reported literature [36] and 7-
amino-4-(trifluoromethyl)coumarin was procured from Alfa Aesar. Analytical TLC was 
carried out on commercial SiliCycle SiliaPlate® 0.2 mm F254 plates. Preparative silica 
chromatography was performed using SiliCycle SiliaFlash® F60 40-63 μm (230-400 
mesh). Final purification of compounds was achieved with Agilent-1200 HPLC (high-
pressure liquid chromatography) using reversed phase semi-preparative column 
(Phenomenex® Luna® 10 µm C18(2) 100 Å, LC Column 100 x 10 mm, Ea). 1H and 13C 
NMR spectra were recorded at room temperature with a Varian Unity Inova 400 MHz 
spectrometer. CD3OD was used as a solvent and referenced to the corresponding residual 
solvent peaks (3.31 and 49.0 ppm, respectively) The following abbreviations are used to 
indicate the multiplicity: s - singlet; d - doublet; t - triplet; q - quartet; m - multiplet; b - 
broad signal; app - approximate. The coupling constants are expressed in Hertz (Hz). The 
high-resolution (HR) MS data (ESI) were obtained using a Thermo Fisher Orbitrap Elite™ 
Hybrid Ion Trap-Orbitrap Mass Spectrometer at Chemical Advanced Resolution Methods 
(ChARM) Laboratory at Michigan Technological University. 96-well plate analysis of cell 
fluorescence was carried out with Victor3 fluorescence plate reader (excitation at 385 nm). 
Confocal images were taken with Olympus FluoViewTM FV1000 using the FluoView 
software. Fluorescence imaging was done with EVOS FL Auto inverted microscope. 
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3.2.1 Synthesis of ManCou Conjugates 
ManCou1: R = H


















up to 24 h
30-40% yield
 
Figure 3.2: Synthesis of ManCou analogs. 
General procedure: (2S,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-
carbaldehyde [30] (up to 1 mmol) and the corresponding coumarin (0.8 equiv.) were 
dissolved in methanol (10 ml). The pH of the solutions was adjusted to <6 by acetic acid 
(1 ml), and NaBH3CN was added portion-wise to the reaction mixture (3 X 0.8 equiv., 
every 20-30 minutes). The reaction solutions were stirred at room temperature for up to 24 
h. The mixtures were then concentrated to dryness under reduced pressure and purified by 
column chromatography on silica gel using methanol in dichloromethane (0-10%) 
mixtures. The final purification was achieved by semi-preparative HPLC using water-
acetonitrile (2-20%) gradient, with the 30-40% average yield after final purification. 
Structures of ManCous were verified through spectroscopic analysis. 
7-((((2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-
yl)methyl)amino)-2H-chromen-2-one (ManCou1): 1H NMR (400 MHz, CD3OD): δ, 7.76-
7.36 (d, J = 9.2, 1H), 7.32-7.30 (d, J = 8.4, 1H), 6.68-6.65 (dd, J1 = 2.4, J2 = 8.4, 1H), 6.53 
(d, J = 2.4, 1H), 6.01-5.99 (d, J = 9.2, 1H), 4.02-3.98 (m, 2H), 3.95-3.92 (m, 1H), 3.88-
3.85 (m, 1H), 3.73-3.69 (app dd, J1 = 3.2, J2 = 12.0, 1H), 3.66-3.61 (app dd, J1 = 5.6, J2 = 
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12.0, 1H), 3.48-3.44 (app dd, J1 = 3.6, J2 = 13.6, 1H), 3.38-3.32 (app dd, J1 = 6.8, J2 = 
13.6, 1H) ppm. 13C NMR (100 MHz, CD3OD): δ, 164.7, 158.1, 154.5, 146.5, 130.2, 112.3, 
110.6, 109.1, 98.0, 85.3, 83.2, 80.3, 78.9, 63.3, 46.2 ppm. HRMS (ESI): m/z [M + Na]+ 
calc’d for C15H17NNaO6: 330.09539; found 330.09434. 
7-((((2R,3S,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-
yl)methyl)amino)-4-(trifluoromethyl)-2H-chromen-2-one (ManCou2): 1H NMR (400 
MHz, CD3OD): δ, 7.44-7.41 (dd, J1 = 2.0, J2 = 9.2, 1H), 6.74-6.71 (dt, J1 = 2.4, J2 = 9.2, 
1H), 6.60-6.59 (d, J = 2.4, 1H), 6.37 (s, 1H), 4.02-3.98 (m, 2H), 3.95-3.92 (m, 1H), 3.89-
3.85 (m, 1H), 3.73-3.69 (app dd, J1 = 3.6, J2 = 11.6, 1H), 3.66-3.61 (app dd, J1 = 5.6, J2 = 
12.0, 1H), 3.50-3.46 (app dd, J1 = 3.6, J2 = 14.0, 1H), 3.40-3.35 (app dd, J1 = 6.4, J2 = 
13.6, 1H) ppm. 13C NMR (100 MHz, CD3OD): δ, 162.2, 158.6, 155.0, 143.3, 143.0, 124.8, 
122.1, 112.8, 108.3, 104.1, 98.5, 85.4, 83.2, 80.2, 78.8, 63.3, 46.1 ppm. HRMS (ESI): m/z 
[M + H]+ calc’d for C16H17F3NO6: 376.10082; found 376.09955.  
3.2.2 Tissue culture  
Normal breast cells (MCF 10A/ ATCC® CRL-10317™), adenocarcinoma (MCF-
7/ATCC® HTB-22™) cells and hepatocellular carcinoma (Hep G2/ ATCC® CRL-
10317™) cells were procured from American Type Cell Culture. The pre-malignant breast 
cancer cells MCF10AneoT was purchased from the Animal Model and Therapeutics 
Evaluation Core (AMTEC) Karmanos Cancer Institute, Wayne State University. All cells 
were maintained at 37°C, at 65% relative humidity and under 5% CO2 in their respective 
culture medium (see Appendix A). All cultures were supplemented with 10,000 I.U./mL 
Penicillin and 10,000μg/mL Streptomycin to lower chances of bacterial contamination. 
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3.2.3 Microplate uptake and inhibition assays 
For microplate assays, cells at ~80% confluence were collected and plated in 96-well flat 
bottom plates (20,000 cells/well) and allowed to grow for 24 hours. Cells were then washed 
with warm (37 ˚C) PBS solution, treated with ManCou probes (concentration varies) in 
PBS and incubated at 37 ˚C and 5% CO2 for 10 min. After incubation, cells were carefully 
washed with warm PBS (3 x 100 µl). Fluorescent data was immediately collected using 
Victor3 plate reader and using WallacTM umbelliferone (excitation 355 nm, emission 460 
nm, 1.0 s) protocol. All trials were done in triplicates. The corresponding errors were 
derived as standard deviation.  Uptake inhibition studies were carried using 96-well plate. 
Fluorescence of ManCou probes in cells was measured in the presence of varying 
concentrations of fructose and glucose. For this part, PBS solution containing 20 µM 
ManCou and the specific concentration of a sugar was prepared and introduced with the 
cells. In parallel, complete culture media was used to establish the impact of nutrients on 
ManCou uptake. Cell incubation, and data collection were conducted as stated above. 
3.2.4 Immunostaining 
The GLUT5 (Slc2a5) primary antibody (sc-271055) was obtained from Santa Cruz 
Biotechnology, Inc and the secondary antibody (ab6787) was obtained from Abcam, plc. 
The primary antibody was used with incubation buffer at a 1:200 dilution while the 
secondary antibody was used at a dilution of 1:1000 as recommended. All the cells were 
fixed in 4% paraformaldehyde and blocked for 1 hour at room temperature. Incubation for 
primary and secondary antibodies was 2 hours and 1 hour respectively, at room 
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temperature. PBS rinse was carried out between each step. Imaging was carried out 
immediately.   
3.2.5 Imaging 
The individual cell lines in culture were incubated with ManCou1 and 2 for 10 minutes at 
a concentration of 20µM across all tests. The test concentration was established after 
evaluation of the imaging efficiency within a range of concentrations (5-100 µM). 20 µM 
concentration was selected as the lowest at which steady fluorescence readout was 
achieved using a confocal microscope (Olympus FluoViewTM FV1000). Imaging was 
carried out using EVOS FL Autoimaging with the EVOS software (Figure 2). All images 
were taken at a constant gain setting. From the grayscale images, the corrected total cell 
fluorescence (CTCF) was calculated as described in our previous work [35]. Briefly, using 
ImageJ, comparing the average fluorescence with the background of the same image, the 
fluorescence signal only in the region of interest was obtained as described here [37]. The 
process was repeated five times for each image captured to obtain an average fluorescence. 
The average CTCF obtained was then normalized to the average CTCF obtained for the 
normal control sample. The normalized average CTCF (with respect to MCF10A) was then 
plotted in Microsoft Excel (Figure 4B). The advantage of using CTCF for images obtained 
along a z-plane with best focus as presented by McCloy et al [37] demonstrates that the 
information thus obtained eliminates errors due to localized higher levels. 
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3.3 Results and Discussion 
3.3.1 Design and evaluation of fluorescent fructose mimic as GLUT5-
specific probes 
Two blue-fluorescent GLUT5 probes were designed on the basis of the established GLUT5 
preference for 1-amino-2,5-anhydro-D-mannitol (Man) [30,34] and the capacity of GLUTs 
to pass coumarin (Cou) fluorophores [38], to enable significant accumulation in the cell 
through GLUT5. The resulting sugar-coumarin conjugates – ManCous – bearing H or CF3 
at the C4 position of the coumarin ring (ManCou1 and ManCou2, respectively, Figure 2A) 
were evaluated for the uptake and GLUT5 specificity in cell culture. For this part, MCF-7 
cells, previously studied for GLUT5-mediated uptake [22,24,31] and Hep G2 cells which 
lack GLUT5 [39] were used.  
For the initial uptake analysis, MCF7 cells were treated in a 96-well plate with 
ManCou probes at different concentrations and the cell fluorescence was measured with a 
fluorescence plate reader. At concentrations exceeding 100 µM, the fluorescence readout 
for ManCou2 showed signs of saturations and leveled off at 200 µM concentration (Figure 
3A). The fluorescence signal from ManCou1 gradually increased and showed no saturation 
even at 500 µM concentration. The Z-stack analysis of ManCou-treated cells showed a 
prominent accumulation of probes inside the cell. While both probes are internalized by 
the cell, they show a marked difference in cellular distribution. ManCou1 is evenly 
distributed throughout the cell, including the nucleus, while ManCou2 is localized in the 
cytosol (Figure 3B). The differences in the cell distribution parallel those in the ManCou 
uptake profile. To delineate the contribution of the sugar in the uptake of ManCous a direct 
79 
comparison of ManCou uptake with that of the non-conjugated coumarin was carried out. 
At the same concentrations, we have observed up to 6-fold and 5-fold lesser uptake for 
unconjugated coumarins (Cou1 is coumarin of ManCou1, Cou2 is coumarin of ManCou2, 







Figure 3.3. ManCou uptake analysis. A) concentration-dependent uptake in MCF-7 cells 
in 96-well plate; B) Brightfield and fluorescence (DAPI) overlay of Confocal Z-stack 
images of MCF7 with ManCou1 and ManCou2 C) Brightfield and fluorescence (DAPI) 
overlay of Confocal Z-stack images of Hep G2 cells with ManCaou1 and ManCou2. 
Images taken for 20 µM ManCous at 405 nm excitation, 461 nm emission, (60X for MCF7 
cells and 40X for HepG2 cells).  
It also appears that the uptake of ManCou1 is nearly twice as much as ManCou2. 
The uptake of both ManCous was inhibited by fructose (Figure 4B), although to a greater 
extent in the case of ManCou1. Glucose, however, had no effect on the uptake as evident 
from the equally efficient internalization of the probes in buffer and complete high glucose 
culture medium (Figure 4C). Finally, we have tested ManCou uptake in GLUT5-deficient 
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HepG2 cells to delineate any contribution from non-specific binding to the observed gained 
fluorescence. While some basal fluorescence has been observed for whole cell images, the 
Z-stack analysis (Figure 3C) showed no internalization of the probe, suggesting no active 
uptake of ManCous. Overall, the lack of inhibition from glucose in conjunction with the 
lack of uptake observed with Hep G2 cells supports the GLUT5 specificity of ManCous.  
    
Figure 3.4. Analysis of sugar impact on ManCou uptake. A) Comparative uptake of 
ManCous (black bars) vs. non-conjugated (grey bars) coumarins; B) Fructose-induced 
inhibition of ManCou uptake; C) ManCou uptake is independent of glucose concentration 
and is equally effective in the buffer and complete culture medium. All data obtained in 
96-well plate format. Each data point constitutes an average of two independent 
experiments in triplicate. Error bars represent standard deviation. 
It is noteworthy that the uptake through GLUTs is loosely coupled with 
phosphorylation. In the uptake of sugars through GLUTs, phosphorylation promotes 
removal of the sugar buildup in the cell, thus facilitating continuous uptake. With the 
GLUT-mediated uptake for ManCou sestablished, the apparent differences in the uptake 
between ManCou1 and ManCous appear to suggest the difference in their connection with 
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cell metabolism. Thus, is it plausible that the linearity in the uptake of ManCou1 through 
GLUT5 is promoted by the efficient removal of the probe gradient through 
phosphorylation, considering an effective phosphorylation of the base 2,5-anhydro-D-
mannitol [40-43]. On the other hand, saturable uptake for ManCou2 implies gradient build-
up, precluding continuous uptake of the probe, and thus, the lack of phosphorylation. It is 
then plausible that only phosphorylated species are further taken up by the cell nucleus. 
While the established mannitol phosphorylation allows to consider a direct connection 
between ManCou1 and cell metabolism, alternations in the coumarin structure appear to 
alter the cellular processing of ManCous (as reflected by the change induced by the CF3 
group of ManCou2). Further analyses are needed to establish cellular fate of ManCou 
probes and link nuclear accumulation with ManCou phosphorylation.  
3.3.2 Profiling fructose uptake efficiency and GLUT5 in cells for cancer 
detection. 
We analyzed ManCou uptake in normal and cancer cell lines to evaluate the 
feasibility of cancer cell detection on the basis of the probe uptake through GLUT5. The 
comparative analysis of normal MCF10A, adenocarcinoma MCF7 and premalignant 
MCF10AneoT (ANeoT) cells was carried out through imaging. After treating cells with 20 
µM concentration of ManCous for 10 min, the accumulated fluorescence was recorded and 
fluorescence intensity analyzed. We have observed minimal to no accumulation of probes 
in the normal MCF10A breast cells (comparable to that in HepG2 cells). The ManCous 
have excitation and emission maxima of 405 nm/465 nm respectively. The fluorescent 
images were captured in the blue channel.  
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As indicated by the grayscale fluorescent images in Figure 5A, the level of probe-induced 
fluorescence in the normal MCF10A cells is comparable to that of the Hep G2 cells. The 
background fluorescence appears to originate from the residual association of probes with 
the membrane as no fluorescence could be detected inside of MCF10A or Hep G2 cells by 
Z-stack analysis. Thus, the data implicates that the uptake of ManCou probes in MCF7 and 
AneoT cells proceeds through GLUT5, resulting in a facile imaging of cancer cells. It is 
important to note that fructose uptake in the healthy tissues is limited to the liver and 
intestines and fructose-specific GLUT5 is upregulated in cancer cells [23,24,31,44,45] 
supporting our approach to using fructose-based detection. This was further confirmed by 
immunostaining the cells treated with probes for GLUT5 as shown in Figure 6.  
Using the normalized average CTCF with respect to the control MCF10A, the 
relative levels for each of the cells lines and treatment conditions can be directly assessed. 
As shown in Figure 4B, the fluorescence intensity observed for AneoT treated with 
ManCou1 was nearly 70-times higher than that for MCF10A and Hep G2 cells for the same 
concentration and incubation period. Under the same conditions, AneoT had nearly 7-times 
higher response compared to MCF-7 clearly distinguishing the pre-malignant AneoT from 
the adenocarcinoma cells MCF-7 (statistically significant data). The differences in the 
uptake of ManCou1 provides a one point discrimination between normal and cancer cells. 
Under identical conditions, ManCou2 probe had nearly 65-times higher uptake in the MCF-
7 than HepG2 cells, and nearly 3-times higher uptake than in AneoT cells. The differences 
in the uptake of ManCou2 provide a second point for discriminating between cancer and 
normal cells and add to a better discrimination between cancer subtypes.  
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Figure 3.5 ManCou uptake in cells. A) Grayscale fluorescence images of ManCou uptake 
in cells used to determine relative fluorescence using EVOS FL Auto at 20X. B) Relative 
differences in ManCou uptake (normalized for MCF10A cells). Data obtained for normal 
breast cells MCF 10A, hepatocellular cancer cells Hep G2 (negative control), pre-
malignant breast cancer cells AneoT and breast adenocarcinoma cells MCF7 after 10 
minutes of incubation with 20µM of ManCous1 and 2. The t-tests (p<0.05) was performed 
after F-test (F<=Fcritical one-tail). For ManCou1, MCF7 was statistically significant 
compared to AneoT, HepG2 and MCF10A while AneoT was statistically significant 
compared to HepG2 and MCF10A. For ManCou2, only MCF7 was statistically significant 
compared to AneoT, HepG2 and MCF10A. 
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It should be noted that the ManCou1:ManCou2 ratios increases with the 
concentration of probes as ManCou2 approaches uptake saturation. Thus, for MCF7 cells, 
the ratios of 0.9, 1.3, 1.7, and 2.5 were measured for ManCou1:ManCou2 at 20 µM, 50 
µM, 100 µM, and 200 µM concentrations, respectively. For AneoT, using higher 
concentration of ManCous induced rapid cell detachment. Overall, the expectations would 
be that in heterogeneous populations, treating cells with ManCou1 and ManCou2 and 
analyzing the CTCF will provide a visual discrimination of normal, pre-malignant and 
adenocarcinoma cells. The two-point analysis would take the form of the analysis shown 
in Table 1. The disparity in the signal makes this approach also ideal for spectrophotometric 
analysis in a micro-plate or flow formats. 
Reported evidence suggests that Hep G2 cells lack the fructose-specific transporter 
GLUT5 [39], while breast cancer cells express it in significant levels. In order to assess the 
relation between uptake of the probe and the presence of the fructose-specific transporter 
GLUT5 in the cells tested, we carried out immunostaining of the cells for GLUT5 (Texas 
Red ®. Ex: 596nm, Em: 620nm) following a 10-minute incubation with 20µM of the 
respective probes. Cells without the probes were used as controls. The differential 
expression of GLUT5 in the cellular membrane is evident from the GLUT5 
immunostaining depicted in Figure 5 (control panel). As can be seen, there is little to no 
GLUT5 in MCF10A and HepG2 cells. In contrast, MCF7 cells and AneoT cells presented 
detectable levels of GLUT5. The lack of probe uptake (DAPI) in MCF10A and HepG2 is 
represented well by the absence of GLUT5. Similarly, the probe uptake in MCF7 and 
AneoT cells are accompanied by the presence of GLUT5 (Figure 5, ManCou panels). The 
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differences in GLUT5 levels appear to parallel the differences in the accumulation of 
ManCou probes in the corresponding cells, with the overall levels of uptake increasing 
with malignancy.  
 
Figure 3.6 Immunostaining of cells for GLUT5 without and with ManCous. Optical 
microscopy, 20X. Control panel represents GLUT5 staining. ManCou1 and ManCou2 
panels represent GLUT5 staining after 10 min treatment of cells with the respective probes. 
The red fluorescence represents GLUT5 (Texas Red ®. Ex: 596nm, Em: 620nm) and blue 
(DAPI) represents the probe. The cells were incubated with 20µM of the respective probes 
for 10 minutes, fixed in paraformaldehyde before immunostaining. Images were captured 
using EVOS FL Auto immediately following immunostaining.   
The correlation is particularly observable for ManCou1, showing visible difference 
blue fluorescence between MCF7 and AneoT cells with the latter having higher uptake 
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despite the lower levels of GLUT5. Overall, the ManCou uptake correlates with the 
presence of GLUT5, providing further evidence for GLUT5-directed visualization of 
cancer cells. Further detailed analysis of GLUT5 expression and relation to fructose will 
be required to develop a better understanding of the relationship between the fructose-
specific transporters and uptake of the fructose-like probes.      
 Table 3.1: Example two-point analysis demonstrating identification of normal, 






















Overall, due to the correlations observed for the uptake of the ManCous and the 
presence of GLUT5 as well as significant differences in accumulation of the ManCous in 
cancer cells, optical screening of breast cancer using the fluorescent-labeled fructose 
analogs in a multi-plate format or flow settings is feasible. Further analysis and 
experimentation is needed to quantify the relative abundance of GLUT5 to establish the 
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correlations with ManCou uptake, as well as evaluate the contribution from the cell 
population densities in a given sample to improve the detection system and hence the 
diagnosis. Combined with fluorescent response, the two-point, two-metric system has the 
potential to clearly discriminate cancer cells and its subtypes. Future work will involve 
screening heterogeneous cultures derived from breast cancer biopsy samples for advancing 
the approach to POC technology. 
3.4 Conclusion 
We have successfully demonstrated effective discrimination of premalignant and 
adenocarcinoma cancer cells using fluorescently labeled fructose analogs in vitro. The 
rapid response from the 10 minutes incubation and the observably different response 
between the cancer cells with the two fructose analogs highlight the use of this technique 
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4 Coumarins: Spectroscopic Measurements and First 
Principles Calculations of C4-substituted 7-
Aminocoumarins 
4.1 Introduction 
Coumarins are plant metabolites that are known for their biological properties, including 
antimicrobial, antiviral, anti-inflammatory, antidiabetic, antioxidant, and enzyme 
inhibitory activity.1 Among the coumarin family, 7-aminocoumarins have gained the most 
attention, as evidenced by the extensive study of their fluorescent properties.2 The large 
Stokes shifts and emissions in the visible spectral range upon proper functionalization led 
to the widespread use of 7-aminocoumarins as analytical and biological sensors.2-5 
Recently, application of coumarins as fluorescent sensors was extended to the labeling of 
proteins,6 evaluation of sugar transport capacity in mammalian cells,7-8 and detection of 
cancer cells.9 Substitution at coumarins is known to alter their fluorescence and absorption 
properties. A particular impact on coumarin fluorescence has been observed upon 
substitution at C4 position. In general, the addition of the electron-withdrawing group at 
the C4 position induces a strong red-shift in the coumarin fluorescence spectrum, with a 
relatively small effect on the absorption spectrum.10 For example, ~50 nm red-shift is 
measured for the C4-trifluoromethyl and C4-phenyl analogs of 7-aminocoumarin, and 
~100 nm red-shift for the C4-methylcarboxy analog.10 In contrast to the electron 
withdrawing groups, the presence of an electron donor, such as a methyl group, induces a 
blue-shift in the fluorescence spectrum. It was suggested that modifications in the 
fluorescence properties of C4-substituted coumarins depend on the presence of the 
substituent capable of rotating in the excited state.10 Considering the variability of the 
impact that C4-substitution has on the fluorescence properties of coumarins, the task of 
this investigation was to get an atomistic-level understanding of the electronic interactions 
that define spectroscopic properties in the coumarin family.  Here, we employ the time-
dependent (TD) density functional theory (DFT)11 method to determine the ground state 
and excited state properties of the coumarin family. Absorption and fluorescence 
calculations were performed for eight coumarins with substituents including H-, CH3-, 
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CF3-, Ph-, COOEt-, CONH2-, CONHMe- and the CONHPh- groups at the C4 position of 
the coumarin aromatic ring. The theoretical findings were correlated to the experimental 
data produced with chemically-obtained coumarin analogs. Although analysis of few 
members of this set has been previously investigated,10, 12-14 this is a systematic 
experimental/theoretical study of a set of C4-substituted 7-aminocoumarin analogs.  
4.2 Methods 
DFT calculations were performed with GAUSSIAN0915 using Becke’s 3 parameter hybrid 
functional B3LYP16-17 with the non-local correlation provided by the Lee, Yang, and Parr 
(LYP) expression.16 The 6-311+(2d,p) basis sets were used for C, O, N, and H atoms 
associated with the coumarin family of molecules. The use of the B3LYP functional is well 
established in the literature. On the other hand, it is also known that for charge transfer 
excitations which involve electron-hole separations over larger distances (extended π 
systems, intermolecular charge transfer) long-range corrected (range-separated) hybrid 
functional forms like CAM-B3LYP are essential. They give a qualitatively correct 
description for large charge separations, but usually higher excitation energies then 
calculated using B3LYP.  Comparative test calculations for coumarin 4 showed that the 
intramolecular charge transfer separation is not large enough to mandate CAM-B3LYP: 
B3LYP and CAM-B3LYP yield the same qualitative UV spectrum but the B3LYP value 
of 349 nm is closer to the experimental value of 358 nm than the CAM-B3LYP value of 
318 nm for the first excitation energy. Therefore, B3LYP was used for further analysis of 
the coumarin set.  For the optical properties, calculations of the ground state and excited 
states were performed. Absorption is calculated as the difference between ground and 
excited state energies at the optimized ground state geometry, and the fluorescence is 
calculated as the difference between ground and excited state energies at the optimized 
excited state geometry. Since the experimental spectra of the coumarin series were taken 
in solution, the effect of the solvent is approximated by employing the Polarizable 
Continuum Model (PCM).18 The total energy of the molecule in solution is calculated by 
making the solvent reaction field self-consistent with the solute electrostatic potential 
which is generated from the computed electron density.15 Dielectric constants for water, 
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methanol and ethanol (ε = 78.35, 24.85 and 32.61, respectively) were used for a 
comparative analysis of the solvent effect for coumarin 2 absorption. The calculated results 
(Table 2) show that the solvent induced red shift is independent whether water, methanol, 
and ethanol were used, warranting further use of water as a solvent for the calculations.  
Table 4.2. Calculated first singlet excitation energy (π → π*) for Coumarin 2 (R = 
CH3) – solvent effect 
Coumarin 2 (R = CH3) Singlet S1 excitation (nm) 
Gas phase - This work (theory) 314 
Gas phase – Ref. 14 (theory) 308 
Solvent (water) -   This work (theory) 332 
Solvent  (methanol ) - This work (theory)  332 
Solvent  (methanol ) - This work (exp.) 347 
Solvent (ethanol) - This work (theory) 332 
Solvent (ethanol) – Ref. 14 (theory) 334 
Solvent (ethanol) – Ref. 14 (exp.) 353 
When calculating the excited state properties of molecules in solution by using PCM as a 
self-consistent reaction field (SCRF) method, different solvation approaches can be used 
within GAUSSIAN09. In this paper, we use the vertical absorption and emission PCM 
approach for which solvation of the excited state is taken into account via a linear response 
formalism.15, 19  The absorption and emission results will be labeled PCMa and PCMe, 
respectively. A summary of the main effects of the solvent on the electronic structure in 
terms of the difference between the highest occupied molecular orbital (HOMO) and the 
lowest unoccupied molecular orbital (LUMO) is given in Supplementary Information, 
Table S1. The inclusion of the solvent effect in calculations leads to a consistent red shift 
of the HOMO-LUMO gap by an average value of 0.18 eV or 15 nm (~5%).  
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4.3 Results and Discussion 
4.3.1 Synthesis and spectroscopic properties of C4-substituted coumarins  
Table 1 lists the members of the coumarin family bearing different substituents at the C4 
position in the coumarin aromatic ring (Figure 1). The H-substituted molecule is labeled as 
Coumarin 1, CH3-substituted as Coumarin 2, CF3-substituted as Coumarin 3, Ph-
substituted as Coumarin 4, COOEt-substituted as Coumarin 5, CONH2-substituted as 
Coumarin 6, CONHMe-substituted as Coumarin 7, and the CONHPh-substituted molecule 
is labeled as Coumarin 8. Coumarins 1, 2 and 3 were obtained from commercial sources. 
Coumarins 4 and 5 were synthesized through the established procedure of Pechmann 
Condensation.20-21 Coumarin 5 was used as a starting material to access coumarins 6, 7 and 
8 (Figure 1A). The structures of the coumarin molecules were confirmed through standard 
analytical techniques including nuclear magnetic resonance and mass spectroscopic 
methods. The absorption (Figure 1B) and fluorescence (Figure 1C) spectra of the coumarin 
family were measured in methanol and water as solvents. Less than 1 nm difference was  














1 (H) 352 463 111 
2 (CH3)** 347 452 105 
3 (CF3) 371 508 136 
4 (Ph) 358 509 151 
5 (COOEt) 377 566 189 
6 (CONH2) 364 567 203 
7 (CONHMe) 362 552 190 
8 (CONHPh) 362 398, 560 36, 198 
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observed between aqueous and methanolic samples. In Coumarin 1, the absorption and 
fluorescence peaks are located at 352 and 463 nm, respectively. With reference to 
Coumarin 1, the methyl substitution in Coumarin 2 is the only substitution that leads to a 
blue shift of the absorption and fluorescence peaks, all other substitutions lead to a red shift 
in the corresponding optical spectra. A significant shift (≈115 nm) in the fluorescence peak 
positions is observed in going from H- to CONHPh-group at the C4-position, which is 
accompanied with a smaller shift (≈30 nm) in the absorption peak positions. The calculated 
Stokes shift (i.e. difference between absorption and fluorescence peak positions) is also 
noticeable ranging from 105 nm in Coumarin 2 to 203 nm in Coumarin 6 (Table 1). 
4.3.2 Theory: Electronic Properties 
The use of 7-aminocoumarins as sensors of biological processes and protein function 
brings forth the need of understanding the impact that C4-substitution has on their electron-
densities. First, through the Bader charge analysis22 we identified that altering the type of 
the functionality at the C4 site does not seem to have a noticeable influence on the electron 
density of the coumarin family. The Bader’s charge associated with the R functional group 
is calculated to be 0.08e (-H), 0.11e (-CH3), -0.12e (-CF3), 0.06e (-Ph), -0.09e (-COOEt), 
0.01e (-CONH2), 0.02e (-CNHMe) and 0e (-CONHPh).  Interestingly, subtle changes 
induced by a specific substituent can be seen in the electrostatic potential surface plots 
displayed in Figure 2.  In contrast to the cases of  –CH3 (i.e. Coumarin 2) and –CF3 (i.e. 
Coumarin 3), substitution of the carbonyl group (-C=O) for coumarins 5 to 8 induces the 
electron-excess regions around the carbonyl group which is aligned in the same direction 
in coumarins 6, 7, and 8 but rotated in coumarin 5 with the -OEt group. The relative absence 
of electrons around the second amino group (-NH-R) creates another high potential area 





Figure 4.1. Calculated electrostatic potential maps of the representative C4-substituted 
coumarins. Regions with the electron-excess density (low potential) and the electron-
deficient (high potential) are represented by the red and blue regions with the contours 
ranging from -0.083 to + 0.083 Hartree/e. 
Coumarin 2 (R=-CH3) Coumarin 3 (R=-CF3)
 Coumarin 5 ((R=COOEt)   Coumarin 7 (R=CONHMe)
 
4.3.3 Theory: Optical Properties 
We begin with the calculations of the optimized ground state configurations of the C4-
substituted coumarins in gas phase, which are then used as initial configurations for the 
geometry optimization of the molecules in aqueous-phase using PCM and subsequent TD-
DFT calculations to determine the optical properties of the coumarin family. Note that a 
review and discussion of a large number of benchmark studies about the performance of 
the TD-DFT method to reproduce vertical (geometry of initial and final states is the same) 
and adiabatic (geometry of final states differs from initial state) valence electron transitions 
can be found in a recent analysis of the absorption spectra of four other 7-
aminocoumarins.12  In Table 2 we provide a comparison of our results with the previously 
reported results for Coumarin 2.  
We find that an inclusion of the solvent effect for water with ε = 78.35 induces a red shift 
of about 18 nm for the first 1→1' singlet S1 excitation. This red shift is found to be 
independent of the nature of the solvent. Previous DFT calculations using a Dunning cc-
pVDZ basis23 reported a red shift of 26 nm in ethanol for Coumarin 2.14 
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4.3.4 Absorption: DFT calculations 
In general, the measured absorption peak of a given molecule can be approximated by the 
calculated difference between the highest occupied molecular orbital (HOMO) and the 
lowest unoccupied molecular orbital (LUMO). Interestingly, we find that the relative 
ordering of the calculated HOMO-LUMO gap values with respect to Coumarin 1 is the 
same as the relative ordering of the measured absorption peaks (Figure 3).  This observation 
should be an indication that the HOMO-LUMO (1 → 1') transition can be expected to be 
the dominant configuration in the first excited state calculation of the C4-substituted 
coumarin family. 
Figure 2. Calculated HOMO-LUMO gap vs. measured absorption peaks for C4-
substituted coumarins. Numbers on x-axis refer to coumarins listed in Table 1. The 
experimental absorption spectra are measured for coumarin solutions in methanol. 
 
4.3.5 Absorption: TD-DFT calculations 
The results of the TD-DFT calculations of the vertical excitation energy of the C4-
substituted coumarin family in the aqueous phase are summarized in Table 3. 
 
Table 4.3. The calculated vertical excitation energies and the measured absorption 
peak positions of the C4-substituted coumarins. The orbitals labeled as 1, 2, 1’, and 2’ 
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For all eight coumarins, the first few singlet excited states were calculated using the PCM 
model. The first excited state will be the state of interest whose geometry will be optimized 
to calculate the emission (fluorescence) spectrum below.  The associated absorption spectra 
obtained with a broadening factor (σ) of 0.25 eV (peak half-width at half-height) are 
displayed in Figure 4a.  A comparison of the calculated and experimental absorption peak 
positions is made in Figure 4b showing that the TD-DFT calculations describe the trend 
observed in experiments very well.  For the C4-substituted coumarins, the first excited 
singlet S1 has the largest oscillator strength (by at least an order of magnitude; the only 
exception is coumarin 8 where the second singlet excited state S2 has ~1/3 of the S1 
oscillator strength) as shown in Table 3. S1 is the HOMO→LUMO (1→1') transition 
between the π→π* orbitals that have the same primary character in all eight derivatives 
(see discussion below and Figure 5).  The second singlet excitation S2 also has a similar 
character in all eight derivatives: it is dominated by the HOMO-1→LUMO (2→1') 
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transition with some HOMO→LUMO+1 (1→2') admixture. In coumarin 8, S2 is a pure 
2→1' excitation and is associated primarily with an intramolecular state transferring charge 
from the -CONHPh group at C4 to the coumarin aromatic system (Figure 5). The other 
exception is coumarin 4 (also a phenyl group at C4) for which S2 has some additional 
admixture from a 1→4' excitation. To understand the nature of orbitals associated with the 
optical properties, the frontier molecular orbitals, namely HOMO, HOMO-1, LUMO, and 
LUMO+1 are displayed in Figure 5. In the ground state of the C4-substituted coumarin 
family, HOMO is a π-orbital delocalized over the coumarin aromatic system with 
significant contributions from the benzene rings and the nitrogen atom but not from the 
carbonyl group and the R-group substitutions at C4. On the other hand, LUMO is a π*-
orbital with contributions from the carbonyl group and the R-group substitutions. A unique 
feature found only in coumarin 8 is the composition of the HOMO-1: it is completely 
localized on the -R substitution (-CONHPh) at the C4 site. Here, we restrict ourselves to 
the lowest excitations in the optical spectra since the experiments do not explore the region 
below 300 nm. Calculations exploring the <300 nm region have been reported elsewhere 
for coumarin 2,14 showing the next transition with significant oscillator strength to be at 
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Figure 4.2 (A) Calculated absorption spectra of coumarins 
listed in Table 1. (B) Calculated vs. measured absorption peak 




4.3.6 Fluorescence: TD-DFT calculations 
To calculate the fluorescence spectra, the geometry optimization calculations for the first 
excited singlet state (S1) of coumarins were performed using the PCMe model. The 
noticeable effects seen in the TD-DFT results can be summarized as follows:  
1. Planarity of the amino group: In the ground state configuration, the amino group is 
pyramidal with the sum of the three C-N-C angles being ≈350°.  The optimization 
of the excited state configuration yields the sum to be ≈360° making the amino 
group to be more planar (see Table S2, supplementary information).  
2. Rotation of –R group:  In the optimized first excited state, the calculated dihedral 
angle between the coumarin aromatic ring and the side group R is significantly 
modified relative to its value in the ground state configuration. Figure S1 displays 
the changes in the dihedral angle for the cases of phenyl ring substitution (e.g. 
Coumarins 4 and 8) or the COOEt substitution (e.g. Coumarin 5). This significant 
photoexcited rotation can be associated with larger Stokes shifts that was also 
discussed for a series of 14 fluorophores.10  
1 2 3 4 5 6 7 8
Figure 3.3 The frontier molecular orbitals associated with the ground states of C4-
substituted coumarins.  Numbers on the x-axis refer to coumarins listed in Table 1 
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3. Increase in dipole moment: Table 4 shows an enhancement of the dipole moment 
values in the optimized first excited state configuration relative to the 
corresponding values in the ground state. This is consistent with the fact that the 
first excited state is an excitation from HOMO (π-orbital delocalized over the 
coumarin aromatic system but not on the substituted R-group) to LUMO (π* orbital 
with contributions from the R-group and the carbonyl group of the coumarin). 
Subsequently, this transition yields asymmetric charge distribution in the first 
excited state leading to higher dipole moments. Our results are similar to the results 
of ab initio excited-state molecular dynamics calculations for Coumarin 3 (or 
coumarin 151)  reporting the significant increase in the gas-phase dipole moment 
of the excited state.24       
Table 4.4 Calculated (aqueous phase) dipole moments for the ground state and the 




Dipole Moment (Debye) 
Ground State Excited State 
Coumarin 1(R=H) 9.4 14.9 
Coumarin 2(R=CH3) 9.6 15.0 
Coumarin 3(R=CF3) 9.1 15.6 
Coumarin 4(R=Ph) 9.7 16.3 
Coumarin 5(R=COOEt) 11.4 17.9 
Coumarin 6(R=CONH2) 7.4 12.5 
Coumarin 7(R=CONHMe) 8.4 11.7 
Coumarin 8(R=CONHPh) 8.2 14.2 
 
Table 5 lists values of the vertical emission energy obtained using the PCMe model for the 
C4-substituted coumarins in the aqueous phase. Note that most of the S2 transitions are 
now associated with single 2 → 1' (HOMO-1 → LUMO) configurations. For Coumarins 4 
and 8 with –R group having a phenyl group, significant oscillator strength is found for the 
second excited state (S2) which leads to a double peak structure in their emission spectra 
(Figure 6a). This is affirmed by the measured fluorescence spectra for Coumarin 8 as 
























Exp [nm] PCMe [nm]
(A) 
(B) 
Figure 4.4 a) Calculated fluorescence spectra. b) 
Calculated vs. measured fluorescence peak positions. 
Numbers on x-axis refer to coumarins listed in Table 1 
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Table 4.5 Experimental and Calculated vertical transition energies associated with the 
florescence spectra obtained using the PCMe model for coumarins in the aqueous 
phase. The transition states are labeled as 1, 2, 1’, and 2’ for HOMO, HOMO-1, 
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The theoretical fluorescence spectra for Coumarins 1-8 and the comparative analysis of 
experimental vs. calculated emission maxima are depicted in Figure 6. The TD-DFT results 
for the two lowest singlet states compared to the fluorescence peak positions of the 
experimental spectra suggest that the calculated peak positions follow the experimental 
trend but with the larger discrepancy: an average shift Δe = 60 nm was found for 
fluorescence maxima (Figure 6b) vs. Δa = 8 nm for absorption maxima (Figure 4b) between 
theoretical and experimental results. These larger discrepancies are not due to states 
crossing during the excited state optimization but seem to indicate that the excited state 
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optimization in solution using PCM is more sensitive to the specific approach used to 
describe the solvent-solute interaction: optimization with equilibrium linear response 
solvation describe the experimental trend; when using the state-specific external iteration 
solvation approach19 for the coumarin series we find that it sometimes under- and 
sometimes overestimate the change in solvent-solute interaction. 
The calculated Stokes shifts follow the experimental Stokes shifts (see Table 1) but shifted 




Coumarins as fluorescent sensors play an ever-increasing role in many biological 
applications, including the labeling of proteins, evaluation of sugar transport capacity in 
mammalian cells, and detection of cancer cells. The aim of this investigation was to get a 
fundamental understanding of the role of the C4 substitution on the electronic interactions 
that define coumarin fluorescence. Eight coumarins bearing different substituents at the C4 
position were analyzed. Coumarins 1-3 were obtained from commercial sources, 
coumarins 4 - 8 were synthesized. TD-DFT methods were used to theoretically analyze the 


















Figure 4.5 Comparison of calculated and experimental 
Stokes shifts. 
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HOMO→LUMO transition between the π→π* orbitals that have the same primary 
character in all eight derivatives:  HOMO is a π orbital delocalized over the coumarin 
aromatic system with significant contributions from the benzene rings and the nitrogen 
atom; LUMO is a π* orbital with contributions from the carbonyl group and the -R-group 
substitutions. That is, the photoexcitation leads to an asymmetric charge distribution with 
a large increase in dipole moment and geometry relaxation in the first excited states of 
coumarins. TD-DFT results for the absorption and emission spectra describe the trend of 
the experimental spectra well. The larger red shifts for the fluorescence peaks are found if 
the substituent contains a carbonyl (C=O) group which may be associated with significant 
change in rotation of the –R group relative to the coumarin rings of these C4-substituted 
coumarins. Considering the ever-growing interest in fluorescent probes of different colors, 
the methods provided here could be used for predicting the impacts of various substituents 






5 Tuning Cross-Coupling Approaches to C3 
Modification of 3- Deazaurines 
5.1 Introduction 
Purines are important building blocks used effectively across various disciplines. 
Functionalization and modification of purines have been of interest for synthetic organic 
chemistry, medicinal chemistry, and toxicology as reflected by the half-century application 
and development of purine-based anticancer or antiviral agents.1-4 Purines are also of 
interest as detection probes,5-9 and as mechanistic probes for understanding cellular 
responses to DNA and RNA modification.10,11 Approaching these highly functionalized 
heterocycles often requires tuning of existing or development of new synthetic routes. 
Overcoming challenges associated with the reactivity of 3-deazaadenine derivatives, in 
particular, has been approached through de novo construction of 3-deaza-3-substituted 
purine backbone or functionalization of nucleosides. Several modifications such as 3-
methyl, the related protected 3-hydroxymethyl and methylenethiol or nitro groups were 
reported.12-15 3-Deaza-3-fluoroadenosines had to be synthesized stepwise, but other 3-halo 
derivatives could also be obtained through direct halogenation of the non-substituted 3-
deazaadenosines.16-22 The use of cross-coupling reactions in C3-modification of purines is, 
however, limited. Examples of palladium-catalyzed methylations of 3-deaza-3-
bromoadenosine analogs through Kumada coupling have been demonstrated.17,20 Recently, 
the modification of adenosine nucleosides through Sonogashira cross-coupling have been 
reported, providing access to 3-deaza-3-alkyne adenosine derivatives.8,9,23 However, the 
use of nucleosides as substrates for cross-coupling reactions can be challenging due to the 
presence of potentially labile glycosidic bonds or nucleophilic functional groups that have 
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to be protected to achieve the compatibility with many organometallic reagents, as reflected 
by the reported examples of Negishi and Kumada reactions for introduction of alkyl or 
benzyl substituents.24-27 Given the importance of modified nucleobases itself, the method 
that would allow a direct access to C-3 modified purine scaffolds would be therefore of 
interest. Here we describe a general strategy that allows the deliberate synthesis of various 
3-deaza-3-substituted purine analogs through metal-catalyzed cross-coupling reactions. 
5.2 Results and Discussion 
En route to 3-deazaadenine analogues of purines we first investigated the reactivity of the 
readily available 3-deazaadenine 1 (Scheme 1) in cross-coupling reactions.15 In direct 
attempts to utilize it as a cross-coupling partner we were able to obtain the 3-iodo-3-
deazadenine 2, and observe its acceptable reactivity in Suzuki cross-coupling conditions 
using the Pd(OAc)2/TPPTS catalyst system, a general method developed for aqueous 
coupling reactions of halogenated purine/pyrimidine nucleobases and nucleosides.4,26,28 
The reactions of 2 with phenylboronic acid and trans-2-phenylvinylboronic acid afforded 
compounds 3a and 3b with 65 and 58% yield, respectively (Scheme 1). 
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Despite the sufficient results obtained for Suzuki cross-coupling of 2 with model aryl/vinyl 
boronic acids, this conditions failed in the attempt to produce an alkyl analog with model 
ethylboronic acid, similarly as reported by other authors.26 The reactivity of 2 can be 
hampered by its low solubility in organic solvents and the presence of active nucleophilic 
nitrogens. When the amino group at C6 was protected as an isobutyryl amide (the 
established purine protecting group),  the more soluble N-(7-bromo-1H-imidazo[4,5-
c]pyridin-4-yl)isobutyramide 4 was obtained (Scheme 1).15 Various Suzuki coupling 
conditions of 4 with phenyl- and isobutylboronic acids were investigated, involving metal 
catalysts such as Pd(PPh3)4, Pd2(dba)3, PddppfCl2 and NiCl2(dme), ligands such as PCy3, 
(t-Bu)2PMeHBF4 and SPhos, and bases such as K2CO3, Cs2CO3, K3PO4 and KOt-Bu in 
ethereal or alcoholic solvents.29-33 Typically, the unreacted starting material was recovered 
from the reaction mixtures, highlighting the lack of reactivity of 4. Also, the liability of 
amide protecting group prohibited the use of aqueous coupling conditions utilizing bases 
such as carbonates. 
We have also evaluated the possibility to use a commercial C6-chloro (5) and the known 
C6-azide34 (5b) purines as a starting materials amenable for further amination or reduction, 
respectively, to access 3-deazaadenine. However, the attempts to install a halide at the C3 
(Compound 6, Scheme 1) have failed, precluding further evaluation. 
As the electron withdrawing groups at C6 (chloride, amide or azide) were shutting off the 
reactivity of C3 position, we hypothesized that the use of electronically more neutral 
protecting groups will promote the solubility of 1, and retain its reactivity towards cross-
coupling reactions. Unfavorably, the direct attempts to react 5 with bisbenzylamines to 
produce the desired cross-coupling partner of type 13 (Scheme 2) failed even under harsh 
conditions (e. g., 140 ˚C, neat or DMF/K2CO3), reflecting the evident low reactivity of this 
substrate towards direct displacement of chlorine atom.12,34 We decided to investigate the 
catalytic aminations with bis(4-methoxybenzylamine) ((PMB)2NH) on 5. In parallel, the 
catalytic amination of PMB-protected analog was investigated, considering the reported 
challenges for modifications of unprotected imidazoles.35 It should be noted that PMB 
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protection of 5 (PMBCl, K2CO3, DMA, 45 ˚C, 24 h, 96% yield) yielded a ~1.6:1 mixture 
of N9- and N7-PMB protected products that was used directly.36 Several literature 
conditions applicable for chloroarenes, 6-halopurines and their nucleosides were 
investigated.37-42 RuPhos and its Pd-bound precatalyst in the presence of NaOt-Bu in 
THF,41 have been shown to be particularly successful for the reactions of non-activated 
heretoaryl chlorides with secondary amines. In these conditions, up to 19% of N9-PMB 
protected product (identical to 13-H, Experimental Section) was obtained, albeit with 
higher catalyst loading (6 mol%) and prolonged reaction time (43 h). However, a 
significant decomposition was observed. The use of LiHMDS instead of NaOt-Bu led to 
the exclusive decomposition of both protected and non-protected 5. Next, Pd(OAc)2 was 
tested in combination with ligands such as BINAP, SPhos and XPhos in the presence of 
Cs2CO3 or NaOt-Bu in solvents such as toluene, THF, dioxane and DMF.37-40,42 Significant 
decomposition was observed in the majority of cases, and no product formation. Some 
level of success was achieved with the combination of Pd(OAc)2 (0.1 eq.) and SPhos (0.2 
eq.) in the presence of NaOt-Bu in toluene (110 ˚C, 22 h). 13-H was isolated in 21% yield, 
reflecting the low reactivity of heteroaryl chlorides with secondary amines.40,41 For 
practical purposes, we have not investigated this reaction further.  
To overcome hurdles posed by the limited reactivity of the tested substrates, we decided to 
construct the fully protected 3-deazadenenine analog from the cheap, available precursors, 
using a similar route as reported in the literature.15,43 The highly regioselective sequential 
substitutions of 4- and 2-chloro atoms of the known derivative 943 with 4-
methoxybenzylamine (PMBNH2), followed by (PMB)2NH produced the compound 11 
(Experimental Section) and upon further reduction of the nitro group and cyclization, we 
were able to obtain the target 3-deazaadenine precursor (13) with the exclusive N9-PMB 
protection and 26% overall yield in 6 steps from a commercial 3-nitropyridine-2,4-diol 7 
(Scheme 2). The length of the synthetic route is similar to that of 115 but offers the access 
to the fully protected soluble starting material amenable to functionalization. 
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1) (PMB)2NH, Et3N, n-BuOH
130 °C, 24 h, 92%
2) Na2S2O4, EtOH/H2O
reflux, 4.5 h, 59%
3) HC(OMe)3
110 °C, 24 h, 94%
PMBNH2, Et3N
 
Gratifyingly, a variety of different coupling conditions involving 13 were successfully 
demonstrated as shown in Table 1, including the examples of reactions such as Suzuki43,44 
(entries 1-5), Heck45 (entries 6 and 7), Sonogashira8,23 (entry 8), Kumada46 (entries 9 and 
10), Negishi (entries 11-14)47 and the nickel-catalyzed reductive couplings of alkyl halides 
recently developed by the Weix group (entry 15).48 
The Suzuki couplings could be accomplished with aromatic, alkenyl and alkyl boronic 
acids (entries 1-5). Both electron-rich and electron-deficient alkenes were tolerated under 
the Heck conditions (entries 6-7). Sonogashira coupling with phenylacetylene proceeded 
with high efficiency (89%, entry 8).  
The formation of alkyl derivatives, with the challenging substrates containing β-hydrogens, 
such as alkylboronic acids or ethyl 4-bromobutyrate was less efficient (29-35%, entries 3-
5 and 15) and accompanied by a significant hydrodebromination reaction, indicating the 
extent of the undesired β-H elimination. This byproduct (13-H) could be subjected to 
halogenation, e. g. by the treatment of crude reaction mixtures with NBS/NIS, facilitating 
a chromatographic separation of the cross-coupled product 14, while the haloderivative 
13/13-I could be recovered (see Experimental Section). The iodo analog 13-I obtained this 
way offered no selectivity enhancement for alkylations using conditions B or F. 
Propitiously, simple alkyl derivatives could be obtained with improved yields (45-87%) 
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through Kumada-type couplings with substrates such as trimethylaluminum and 
benzylmagnesium chloride (entries 9 and 10). Ultimately, modified Negishi conditions 
allowed the access to a variety of primary alkyl derivatives with notably higher yields than 
those obtained through Suzuki protocol (entries 11-13 versus 3-5). In the case of 
challenging isopropyl derivative, we observed up to 20% of the known isopropyl to n-
propyl isomerization (entry 14).49 Interestingly, our Negishi protocol provided satisfying 
and consistent results only when an excess of Grignard reagent against an 
overstoichiometric amount of zinc chloride was used, which helped to improve the 
solubility of the intermediate organozinc species. This observation seems to be in accord 
with the works by the Organ group that unveiled the mechanisms involving organozinc 























Entry Substrate Cond.a Product Yield (%) 
1 PhB(OH)2 A 14a, R=Ph 91 
2 PhCH=CH2B(OH)2 A 14b, R=(E)-styryl 79 
3 Ph(CH2)2B(OH)2 B 14c, R=(CH2)2Ph 35 
4 EtB(OH)2 B 14d, R=Et 31 
5 i-BuB(OH)2 B 14e, R=i-Bu 29 
6 PhCH=CH2 C 14b, R=(E)-styryl 53 
7 CH2=CHCO2Me C 14f, R=(E)-acrylate 57b 
8 PhC≡CH D 14g, R=C≡CPh 89 
9 Al(Me)3 E 14h, R=Me 87 
10 BnMgCl E 14i, R=Bn 45 
11 Ph(CH2)2ZnX F 14c, R=(CH2)2Ph 77 
12 EtZnX F 14d, R=Et 76 
13 i-BuZnX F 14e, R=i-Bu 85 
14 i-PrZnX F 14j, R=i-Pr 86c 
15 Br(CH2)3CO2Et G 14k, R=(CH2)3CO2Et 32b 
a Conditions A: Ar or vinylB(OH)2 (1.5 equiv.), Cs2CO3 (2 equiv.), 
Pd(PPh3)4 (0.1 equiv.), dioxane/H2O (2/1), Ar, 90 ˚C, 6-16 h; 
Conditions B: AlkylB(OH)2 (1.1-1.5 equiv.), K2CO3 (3 equiv.), 
Pd(PPh3)4 (0.1 equiv.), dry dioxane, Ar, 90 ˚C, 72 h; Conditions C: 
styrene or methyl acrylate (5 equiv.), Et3N (7 equiv.), PPh3 (0.5 
equiv.), Pd(OAc)2 (0.1 equiv.), dry CH3CN, Ar, 90 ˚C, 36 h; 
Conditions D: phenylacetylene (1.5 equiv.), Pd(PPh3)2Cl2 (0.1 
equiv.), CuI (0.1 equiv.), dry DMF/Et3N (2/1), Ar, 80 ˚C, 24 h; 
Conditions E: Al(Me)3 or BnMgCl solution (3-3.3 equiv.), 
Pd(PPh3)4 (0.1 equiv.), dry THF, Ar, 75 ˚C, 4 h; Conditions F: 
ZnCl2 (0.5 M in THF, 5.7 equiv.), AlkylMgX solution (X = Br or 
Cl, 8.6 eq.), Ar, rt, 1 h, then 13 (1 equiv.), PddppfCl2 (0.1 eq.), Ar, 
rt, 21-29 h; Conditions G: Br(CH2)3CO2Et (1.1 equiv.), Zn (2 
equiv.), 4,4’-dimethoxy-2,2’-bipyridine (0.1 equiv.), NiI2 (0.13 
equiv.), pyridine (0.1 equiv.), NaI (0.25 equiv.), dry DMA, Ar, rt, 
5 min., then 60 ̊ C, 20 h; b Yield isolated after treatment of the crude 
mixture with NIS and separation of 13-I (for details, see 
Experimental Section); c Contains ~20% of n-propyl impurity. 
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Clearly, the fully protected nucleobase 13 allows the use of a broad scope of coupling 
conditions with the formation of not only saturated and unsaturated C-C bonds, but also 
the introduction of functional groups, to access the C3-modified 3-deazaadenine 
derivatives. These results pinpoint appropriateness of the PMB as a protecting group with 
suitable electronic and chemical properties that allowed to achieve the desired reactivity of 
13 among the other tested 3-deaza-3-haloadenine substrates.  
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We further aimed to elaborate the products to the protected phosphoramidites to verify their 
compatibility with producing building blocks for solid phase DNA synthesis. The route to 
phosphoramidites is exemplified by the synthesis of compound 20i (Scheme 3). We 
successfully optimized the procedure for complete deprotection of benzyl derivative 14i 
affording modified purine 15i.52 The known problem of selectivity for purine 
glycosylations prompted us to use the tetramethylsuccinimide directing/protecting group, 
developed by the McLaughlin group53 in order to increase the selectivity towards the 
desired N9 β-glycosylation. The crude salt 15i was converted accordingly to the 
corresponding imide 16i through the reported two-step procedure using 
tetramethylsuccinic anhydride (Me4SA).53 The imide 16i was subjected to glycosylation 
with 1-(α)-chloro-3,5-di-O-(p-toluoyl)-2-deoxy-D-ribose affording the desired N9 β-
nucleoside 17i in 39% yield. The configuration of nucleoside 17i was unambigously 
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confirmed by the NOESY experiment (Figure S1, Supporting Information). It was then 
elaborated to the corresponding phosphoramidite 20i through standard methods (Scheme 
3). Analogously, two other phosphoramidites 20d and 20e were were prepared from 14d 
and 14e, ethyl and isobutyl analogs, respectively. All three phosphoramidites were 
successfully used in solid-phase DNA synthesis and further studies are in progress. 
Interestingly, the preparation of the corresponding phosphoramidite 20a from phenyl 
derivative 14a could not be achieved due to the destabilizing effect of the Ph group on the 
glycosidic bond (see Experimental Section). We have also considered the possibility of the 
direct functionalization of nucleosides by an attempt to prepare a bromo analog of 17i 
through the halogenation of the reported non-modified 3-deazaadenine phosphoramidite.13 
However, the reactions with NBS in CH2Cl2 or DMF were unsuccessful, likely due to the 
electronegative effect of the tetramethylsuccinimide group. 
Additionally, the modified 3-deazaadenines could be readily converted to the 
corresponding 3-deazahypoxanthines, purine analogues of interest for medicinal 
chemistry,36,54 upon treatment with NaNO2 as exemplified by the reaction of crude salt 15c 
to produce 21c in 57% yield based on 14c (Scheme 4).55,56 This transformation further 
demonstrates the potential of our synthetic approach towards C3-modified purine scaffold. 









21c (57% from 14c)15c
aq. NaNO2, acetic acid




This study illustrates the merit of a new fully protected 3-bromo-3-deazadenine derivative 
developed by us as a building block for the deliberate synthesis of 3-substituted 3-
deazaadenine and adenosine derivatives through metal-catalyzed cross-coupling reactions 
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and selective N9 β-glycosylations. It should be expected that both modified purines and 
their nucleosides will be of interest for applications related to chemical biology, DNA 
studies and medicinal chemistry. 
5.4 Experimental Section 
General methods: All reagents were used as received unless otherwise stated from Sigma-
Aldrich, TCI America, Alfa Aesar, AK Scientific or Chem-Impex International. 4-Chloro-
1H-imidazo[4,5c]pyridine was obtained from MolBridge. Bis(4-methoxybenzyl)amine 
and TPPTS were obtained from Ark Pharm. 1-(α)-Chloro-3,5-di-O-(p-toluoyl)-2-deoxy-D-
ribose was purchased from Berry & Associates. Anhydrous methanol, pyridine, and N,N-
dimethylacetamide (DMA) were obtained from Sigma-Aldrich. N,N-dimethylformamide 
(DMF) and 1,4-dioxane were dried and stored over CaH2 before use. Dry acetonitrile, 
dichloromethane, and tetrahydrofuran were dispensed from an automated Innovative 
Technology Pure-Solv 400 Solvent Purification System. Analytical TLC was carried out 
on commercial SiliCycle SiliaPlate® 0.2 mm F254 plates. Preparative silica 
chromatography was performed using SiliCycle SiliaFlash® F60 40-63 µm (230-400 
mesh). 1H, 13C and 31P NMR spectra were recorded at room temperature with a Varian 
Unity Inova 400 MHz spectrometer. CDCl3, DMSO-d6, CD3OD, acetone-d6 and D2O were 
used as solvents and referenced to the corresponding residual solvent peaks (7.26 and 77.16 
ppm for CDCl3, respectively; 2.50 and 39.52 ppm for DMSO-d6, respectively; 3.31 and 
49.0 ppm for CD3OD, respectively; 2.05 and 29.84 ppm for acetone-d6, respectively; 4.79 
ppm for D2O).57 The following abbreviations are used to indicate the multiplicity: s - 
singlet; d - doublet; t - triplet; q - quartet; m - multiplet; b - broad signal; app - approximate. 
The coupling constants are expressed in Hertz (Hz). The multiplicity of carbon atoms was 
determined by DEPT-135 experiment; Cq - quaternary carbon. MS data (ESI) were 
obtained using a Thermo Finnigan LCQ Advantage Ion-Trap Mass Spectrometer. The high-
resolution (HR) MS data (ESI) were obtained using a Thermo Fisher Orbitrap Elite™ 
Hybrid Ion Trap-Orbitrap Mass Spectrometer at Chemical Advanced Resolution Methods 
(ChARM) Laboratory at Michigan Technological University.  
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Synthesis and characterization data. 
Compounds 1,15 4,15,22 and 5b34 were prepared according to the reported procedures.  
7-Iodo-1H-imidazo[4,5c]pyridin-4-amine (2): To a suspension of amine 1 (536 mg, ca. 
4 mmol) in dry DMF (8 ml), N-iodosuccinimide (NIS) (1.125 g, 5 mmol) was added in one 
portion. Slightly exothermic reaction occurred, and the resulting dark solution was stirred 
at room temperature for 24 h. After 24 h, the solution was added dropwise to EtOAc (100 
ml) with vigorous stirring, and the resulting solid was filtered and washed with EtOAc. 
The solid was then suspended in chloroform (50 ml) and vigorously stirred under reflux 
condenser at 70 ˚C overnight. After filtration and drying on air, 2 was obtained as a dark 
brown solid in 27% yield (0.27 g). HRMS (ESI): m/z [M+H]+ calc’d for C6H4N4I: 
260.96373; found: 260.96323. MS (ESI): m/z, 261.2 for [M+H]+. 1H NMR (400 MHz, 
DMSO-d6): δ, 8.49 (s, 1H), 8.44 (bs, 2H), 7.97 (s, 1H) ppm. We were not able to obtain 
satisfactory 13C NMR data in DMSO-d6.  
7-Phenyl-1H-imidazo[4,5c]pyridin-4-amine (3a): This compound was synthesized 
according to the reported general procedures.4,26 To a vial equipped with septa a mixture of 
deionized water/acetonitrile (2/1, 9 ml) was added and bubbled with argon for 10 min. 2 
(150 mg, 0.58 mmol), phenylboronic acid (88 mg, 0.72 mmol), palladium(II) acetate (7 
mg, 0.029 mmol), TPPTS (41 mg; 0.072 mmol) and anhydrous sodium carbonate (183 mg; 
1.7 mmol) were added, and the headspace of the vial was flushed with argon for 1 minute. 
The mixture was vigorously stirred at 100 ˚C for 7 h. The mixture was then cooled and 
diluted with ethyl acetate (50 ml) and brine (10 ml). The phases were separated, and the 
aqueous phase was extracted with additional ethyl acetate (3 x 30 ml). Combined organic 
extracts were dried with MgSO4. After filtration and concentration, the residue was purified 
by column chromatography on silica gel, eluting with 0-10% MeOH in CH2Cl2 to obtain 
3a as a yellow solid in 65% yield (79 mg). HRMS (ESI): m/z [M+H]+ calc’d for C12H11N4: 
211.09838; found: 211.09680. MS (ESI): m/z, 211.3 for [M+H]+. 1H NMR (400 MHz, 
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DMSO-d6): δ, 8.20 (s, 1H), 7.85 (s, 2H), 7.73 (b, 2H), 7.48-7.44 (m, 2H), 7.34-7.30 (m, 
1H), 6.46 (b, 2H) ppm. 13C NMR (100 MHz, DMSO-d6): δ, 141.3, 137.5, 136.1, 128.7, 
127.3, 126.5 ppm. 
(E)-7-Styryl-1H-imidazo[4,5-c]pyridin-4-amine (3b): This compound was synthesized 
in similar fashion as 3a. To a vial equipped with septa a mixture of deionized 
water/acetonitrile (2/1, 6 ml) was added and bubbled with argon for 10 min. 2 (100 mg, 
0.38 mmol), trans-2-phenylvinylboronic acid (71 mg, 0.48 mmol), palladium(II) acetate (5 
mg, 0.019 mmol), TPPTS (28 mg; 0.048 mmol) and anhydrous sodium carbonate (122 mg; 
1.2 mmol) were added, and the headspace of the vial was flushed with argon for 1 minute. 
The mixture was vigorously stirred at 100 ˚C for 16 h. The mixture was then cooled and 
diluted with ethyl acetate (40 ml) and brine (10 ml). The phases were separated, and the 
aqueous phase was extracted with additional ethyl acetate (3 x 20 ml). Combined organic 
extracts were dried with MgSO4. After filtration and concentration, the residue was purified 
by column chromatography on silica gel, eluting with 0-10% MeOH in CH2Cl2 to obtain 
3b as a cream solid in 58% yield (52 mg). HRMS (ESI): m/z [M+H]+ calc’d for C14H13N4: 
237.11403; found: 211.11269. 1H NMR (400 MHz, DMSO-d6): δ, 8.28 (s, 1H), 7.89 (s, 
1H), 7.58-7.56 (m, 2H), 7-38-7.31 (m, 4H), 7.23-7.20 (m, 1H), 6.52 (b, 2H) ppm. 13C NMR 
(100 MHz, DMSO-d6): δ, 141.1, 139.7, 138.2, 128.6, 126.8, 125.8, 124.0 ppm. 
Synthesis of 13. 
Compounds 8 and 9 were prepared by modification of the reported procedures.43 
5-Bromo-3-nitropyridine-2,3-diol (8): To the suspension of 3-nitropyridine-2,4-diol 7 (10 
g, 64.1 mmol) in glacial acetic acid (100 ml), bromine (4.6 ml, 90 mmol) was added in one 
portion, and the mixture was stirred at 70 ˚C for 2.5 h. Reaction mixture was then cooled 
and poured onto 300 ml of crushed ice, stirred vigorously for 30 min., and chilled in the 
freezer for 1 h. The precipitated solids were filtered on paper, washed with small volume 
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of ice-cold water several times, then ethanol (3 x 15 ml), and dried on air. 8 was obtained 
as a yellow solid in 74% yield (11.2 g). 1H NMR (400 MHz, DMSO-d6): δ, 7.86 (s, 1H) 
ppm. 13C NMR (100 MHz, DMSO-d6): δ, 159.1, 155.6, 138.6, 128.2, 94.0 ppm.  
5-Bromo-2,4-dichloro-3-nitropyridine (9): A suspension of 8 (11.1 g, 47.4 mmol) in 
POCl3 (100 ml) was stirred at 90 ̊ C for 24 h under argon, an excess pressure being released 
several times within first few hours. Then POCl3 was carefully distilled off under vacuum. 
The oily residue was diluted with Et2O (100 ml), cooled on an ice bath and crushed ice 
(200 ml) was carefully added (exothermic reaction). The phases were separated, aqueous 
phase was additionally extracted with Et2O (2 x 50 ml), the combined organics were 
washed with brine, and dried with MgSO4. After filtration and concentration, the residue 
was purified by column chromatography on silica gel, eluting with 0-10% EtOAc in 
hexanes to obtain 9 as a yellow oil that slowly solidified (9.27 g, 72% yield). 1H NMR (400 
MHz, CDCl3): δ, 8.68 (s, 1H) ppm. 13C NMR (100 MHz, CDCl3): δ, 152.1, 141.5, 137.8, 
121.3 ppm. 
5-Bromo-2-chloro-N-(4-methoxybenzyl)-3-nitropyrid-in-4-amine (10): To the solution 
of 9 (9.25 g, 34.3 mmol) in dry DMF (50 ml) at 0 ˚C under argon, 4-methoxybenzylamine 
(4.7 ml, 36 mmol) was added in one portion, followed by dropwise addition of Et3N (5.5 
ml, 36 mmol) over 5 minutes. The mixture was allowed to warm up to room temperature 
and stirred for 24 h. The mixture was then diluted with EtOAc (300 ml), washed with brine 
(4 x 100 ml), and dried with MgSO4. After filtration, the solution was concentrated in vacuo 
to give yellow solid that was triturated with hexanes to give 10 as a dark orange solid (12.1 
g, 95% yield). HRMS (ESI): m/z [M+H]+ calc’d for C13H1279Br35ClN3O3: 371.97507; 
found: 371.97488. 1H NMR (400 MHz, CDCl3): δ, 8.23 (s, 1H), 7.24-7.22 (d, J = 8.4, 2H), 
6.93-6.91 (d, J = 8.4, 2H), 5.24 (bs, 1H), 4.22-4.21 (d, J = 4.8, 2H), 3.82 (s, 3H) ppm. 13C 
NMR (100 MHz, CDCl3): δ, 160.1 (Cq), 149.3, 143.4 (Cq), 143.3 (Cq), 129.7, 127.9 (Cq), 
114.8, 109.4 (Cq), 55.5, 47.0 (CH2) ppm.  
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5-Bromo-N2,N2,N4-tris(4-methoxybenzyl)-3-nitropyridine-2,4-diamine (11): A 250 ml 
Schlenk tube was charged with 10 (12.1 g, 32.6 mmol), bis(4-methoxybenzyl)amine (10.9 
g, 42.4 mmol), n-butanol (100 ml) and Et3N (6 ml, 43.1 mmol). The mixture was heated at 
130 ˚C for 24 h. It was cooled, diluted with EtOAc (400 ml), washed with brine (200 ml), 
and dried with MgSO4. After filtration, the solution was concentrated to give a dark residue 
that was purified by column chromatography on silica gel, eluting with 0-15% EtOAc in 
hexanes to obtain 11 as a red foam (17.6 g, 92% yield). HRMS (ESI): m/z [M+H]+ calc’d 
for C29H3079BrN4O5: 593.13999; found: 593.13894. 1H NMR (400 MHz, CDCl3): δ, 8.09 
(s, 1H), 7.21-7.18 (d, J = 8.8, 2H), 7.08-7.05 (d, J = 8.8, 4H), 6.88-6.86 (d, J = 8.8, 2H), 
6.82-6.80 (d, J  = 8.8, 4H), 6.14-6.12 (t, J = 4.8, 1H), 4.46-4.45 (d, J = 4.8, 2H), 4.29 (s, 
4H), 3.782 (s, 3H), 3.778 (s, 6H) ppm. 13C NMR (100 MHz, CDCl3): δ, 159.6 (Cq), 159.0 
(Cq), 155.5 (Cq), 151.1, 146.5 (Cq), 129.7, 129.5 (Cq), 129.4, 129.2 (Cq), 126.0 (Cq), 
114.5, 113.9, 99.6 (Cq), 55.4, 55.3, 53.7 (CH2), 49.2 (CH2) ppm.  
5-Bromo-N2,N2,N4-tris(4-methoxybenzyl)pyridine-2,3,4-triamine (12): A 1 L round 
bottom flask was charged with 11 (16.7 g, 28.2 mmol), ethanol (600 ml) and deionized 
water (300 ml), followed by Na2S2O4 (9.81 g, 56.4 mmol, 2 equiv.). The mixture was heated 
at 85 ˚C under reflux condenser. Additional sodium hydrosulfite was added at 30 min. 
intervals (overall, 4 x 2 equiv.) over 2.5 h. The mixture was then concentrated in vacuo to 
remove most of ethanol, and diluted with EtOAc (200 ml). It was carefully neutralized with 
solid NaHCO3 (effervescence!) with vigorous stirring. The organic layer was separated, the 
aqueous phase was additionally extracted with EtOAc (2 x 150 ml) and the combined 
organics were washed with brine (100 ml), and dried with MgSO4. After filtration and 
concentration, the residue was purified by column chromatography on silica gel, eluting 
with 0-60% EtOAc in hexanes, and the product was additionally triturated with hexanes 
containing some EtOAc to obtain 12 as a cream solid in 59% yield (9.4 g). This compound 
is somewhat unstable and should be used within few days. HRMS (ESI): m/z [M+H]+ 
calc’d for C29H3279BrN4O3: 563.1658; found: 563.16396. 1H NMR (400 MHz, CDCl3): δ, 
7.77 (s, 1H), 7.22-7.20 (d, J = 8.8, 2H), 7.10-7.08 (d, J = 8.8, 4H), 6.84-6.82 (d, J = 8.8, 
2H), 6.81-6.79 (d, J = 8.8, 4H), 4.25-4.24 (d, J = 6.8, 2H), 4.14 (s, 4H), 4.00 (bs, 2H), 3.78 
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(s, 9H) ppm. 13C NMR (100 MHz, CDCl3): δ, 159.1 (Cq), 158.8 (Cq), 150.2 (Cq), 139.8 
(Cq), 138.3, 131.6 (Cq), 130.7 (Cq), 130.1, 129.9 (Cq), 129.2, 114.1, 113.7, 110.8 (Cq), 
55.36, 55.34, 53.5 (CH2), 48.7 (CH2) ppm.  
7-Bromo-N,N,1-tris(4-methoxybenzyl)-1H-imidazo-[4,5-c]pyridin-4-amine (13): A 
250 ml Schlenk tube was charged with 12 (9.4 g, 16.7 mmol) and trimethyl orthoformate 
(150 ml). The mixture was heated at 110 ˚C for 24 h, and concentrated in vacuo.  The 
remaining residue was dissolved in the smallest possible volume of EtOAc and hexane was 
carefully added dropwise with stirring to cause slight turbidity. The mixture was chilled in 
the freezer at -20 ˚C overnight and the resulting precipitate was filtered, washed with 
hexanes and dried on air to give 13 as an off-white to cream solid in 94% yield (8.96 g). 
HRMS (ESI): m/z [M+H]+ calc’d for C30H3081BrN4O3: 575.1481; found: 575.14530. 1H 
NMR (399.8 MHz, CDCl3): δ, 7.97 (s, 1H), 7.62 (s, 1H), 7.22-7.20 (d, J = 8.8, 4H), 7.13-
7.10 (d, J = 8.8, 2H), 6.90-6.87 (d, J = 8.8, 2H), 6.84-6.82 (d, J = 8.8, 4H), 5.65 (s, 2H), 
5.13 (s, 4H), 3.80 (s, 3H), 3.78 (s, 6H) ppm. 13C NMR (100 MHz, CDCl3): δ, 159.6 (Cq), 
158.7 (Cq), 151.6 (Cq), 143.1, 141.0, 136.6 (Cq), 131.2 (Cq), 129.5 (Cq), 129.2, 128.5, 
128.4 (Cq), 114.5, 113.9, 89.0 (Cq), 55.44, 55.38, 49.8 (CH2), 49.0 (CH2) ppm. 
Cross-coupling reactions of 13. 
General conditions A:43 a solution of 13 (0.25-3.5 mmol, 1 equiv.) in 2/1 dioxane/deionized 
water mixture (ca. 12 ml per mmol) was placed in a Schlenk tube or a vial equipped with 
septa. The mixture was bubbled with argon for ca. 1 minute/ml. An aryl or vinylboronic 
acid (1.5 equiv.), tetrakis(triphenylphosphine)palladium (0) (0.1 equiv.) and anhydrous 
cesium carbonate (2 equiv.) were added, the mixture was bubbled with argon for few more 
minutes and heated at 90 ˚C for 6-16 h with vigorous stirring. It was cooled and diluted 
with equal volumes of CH2Cl2 and 1/1 water/brine, the phases were separated and the 
aqueous phase extracted twice with CH2Cl2. The combined organic extracts were dried 
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with MgSO4. After filtration and concentration, the products were purified by column 
chromatography on silica gel eluting with 0-20% EtOAc in hexanes. 
General conditions B:44 to a flame-dried vial equipped with septa dry dioxane (ca. 7 ml per 
mmol) was added and bubbled with argon for ca. 1 minute/ml. Compound 13 (0.25-3.5 
mmol, 1 equiv.), alkylboronic acid (1.1–1.5 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (0.1 equiv.), and anhydrous potassium carbonate 
(3 equiv.) were added. The mixture was bubbled with argon for few more minutes and 
heated at 90 ˚C for 72 h with vigorous stirring. It was cooled and filtered through Celite®, 
washing with CH2Cl2. After concentration, the products were purified by column 
chromatography on silica gel eluting with 0-20% EtOAc in hexanes. 
General conditions C:45 to a flame dried vial equipped with septa dry acetonitrile (3.5 ml) 
was added and bubbled with argon for ca. 1 minute/ml. Compound 13 (0.25 mmol, 1 
equiv.), triphenylphosphine (0.5 equiv.) and palladium(II) acetate (0.1 equiv.) were added, 
followed by an olefin (5 equiv.) and triethylamine (7 equiv.) and the mixture was bubbled 
with argon for few more minutes and heated at 90 ˚C for 36 h with vigorous stirring. It was 
cooled, diluted with CH2Cl2 (50 ml), washed with aqueous NH4Cl (2 x 25 ml), and dried 
with MgSO4. After filtration and concentration, the products were purified by column 
chromatography on silica gel eluting with 0-40% EtOAc in hexanes. The procedure for 
separation of dehalogenated byproduct: the crude mixture obtained after the extractive 
workup was redissolved in CH2Cl2 (10 ml) and NIS (ca. 0.6 equiv.) was added. After 
stirring at room temperature for 2 h, the mixture was diluted with CH2Cl2 (50 ml), washed 
with brine containing sodium thiosulfate (25 ml), and dried with MgSO4. After filtration 
and concentration, the products were purified by column chromatography on silica gel 
eluting with 0-40% EtOAc in hexanes. 13-I eluted first. 
General conditions D:23 to a flame dried vial equipped with septa dry DMF (5 ml) and 
triethylamine (2.5 ml) were added and bubbled with argon for ca. 1 minute/ml. Compound 
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13 (0.25 mmol, 1 equiv.), CuI (0.1 equiv.) and bis(triphenylphosphine)palladium(II) 
dichloride (0.1 equiv.) were added, followed by phenylacetylene (1.5 equiv.). The mixture 
was bubbled with argon for few more minutes and heated at 80 ˚C for 24 h with vigorous 
stirring. It was cooled, quenched with saturated aqueous NH4Cl (10 ml), diluted with 
EtOAc (10 ml), washed with brine (3 x 10 ml), and dried with MgSO4. After filtration and 
concentration, the products were purified by column chromatography on silica gel eluting 
with 0-20% EtOAc in hexanes. 
General conditions E:46 to a flame dried vial equipped with septa dry THF (6 ml) was added 
and bubbled with argon for ca. 1 minute/ml. Compound 13 (0.25 mmol, 1 equiv.) and 
tetrakis(triphenylphosphine)palladium(0) (0.1 equiv.) were added, followed by 
trimethylaluminum or benzylmagnesium chloride solutions (3-3.3 equiv.) and the mixture 
was stirred at room temperature for 15 minutes and then heated at 80 ˚C for 4 h with 
vigorous stirring. It was cooled, carefully quenched with Et20 (30 ml), washed with 
saturated aqueous NH4Cl (30 ml), and dried with MgSO4. After filtration and 
concentration, the products were purified by column chromatography on silica gel eluting 
with 0-40% EtOAc in hexanes. 
General conditions F:58 to a flame dried vial equipped with septa was added a solution of 
ZnCl2 (0.5 M in THF, 5.7 eq.), followed by dropwise addition of Grignard reagent solution 
(8.6 eq.) and the mixture was allowed to stir under argon for 1 h. Then, compound 13 
(0.175-0.7 mmol, 1 eq.) and [1,1′-bis(diphenylphosphino)ferrocene]-dichloropalladium(II) 
(0.1 equiv.) were added, and the mixture was stirred at room temperature under argon for 
overall 21-29 h. It was carefully quenched with Et20 (30-50 ml), washed with equal volume 
of saturated aqueous NH4Cl, and dried with MgSO4. After filtration and concentration, the 
products were purified by column chromatography on silica gel eluting with 0-20% EtOAc 
in hexanes. 
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General conditions G:48 to a flame dried vial equipped with septa were added sequentially: 
NiI2 (0.065 mmol, 0.13 equiv.), 4,4’-dimethoxy-2,2’-bipyridine (0.05 mmol, 0.1 equiv.), 
NaI (0.125 mmol, 0.25 equiv.), 13 (0.5 mmol, 1 equiv.), dry DMA (2 ml), pyridine (5 μl), 
ethyl 4-bromobutyrate (0.55 mmol, 1.1 equiv.), and Zn powder (1 mmol, 2 equiv.). The 
headspace of the vial was flushed with argon for 1 minute. The reaction mixture was stirred 
at room temperature for 5 minutes and then heated at 60 ˚C for 20 h with vigorous stirring. 
It was cooled, diluted with EtOAc (50 ml), washed with brine (3 x 25 ml), and dried with 
MgSO4. The crude mixtures were subjected to the same procedure of dehalogenated by-
product separation as described under general conditions C. The products were purified by 
column chromatography on silica gel eluting with 0-40% EtOAc in hexanes. 13-I eluted 
first. 
Characterization data for compounds from Table 1. 
N,N,1-Tris(4-methoxybenzyl)-7-phenyl-1H-imidazo[4,5-c]pyridin-4-amine (14a): 
General conditions A, 6 h, 335 mg, 91%. Yellowish syrup. HRMS (ESI): m/z [M+H]+ 
calc’d for C36H35N4O3: 571.27093; found: 571.26842. 1H NMR (400 MHz, CDCl3): δ, 7.78 
(s, 1H), 7.68 (s, 1H), 7.36-7.34 (m, 3H), 7.29-7.27 (d, J = 8.8, 4H), 7.27-7.25 (m, 2H), 
6.87-6.85 (d, J = 8.8, 2H), 6.71-6.69 (d, J = 8.8, 2H), 6.56-6.54 (d, J = 8.8, 2H), 5.23 (s, 
4H), 4.94 (s, 2H), 3.80 (s, 6H), 3.76 (s, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ, 159.6 
(Cq), 158.7 (Cq), 151.6 (Cq), 141.8, 141.0, 137.7 (Cq), 136.7 (Cq), 131.6 (Cq), 130.4, 
129.3, 128.2, 128.10, 128.06 (Cq), 128.0 (Cq), 127.4, 114.1, 113.9, 113.8 (Cq), 55.40, 
55.38, 49.64 (CH2), 49.55 (CH2) ppm. 
(E)-N,N,1-Tris(4-methoxybenzyl)-7-styryl-1H-imid-azo[4,5-c]pyridin-4-amine (14b): 
General conditions A, 16 h, 123 mg, 79%. General conditions C, 36 h, 83 mg, 53%. Tan 
solid. HRMS (ESI): m/z [M+H]+ calc’d for C38H37N4O3: 597.28658; found: 597.28453. 1H 
NMR (400 MHz, CDCl3): δ, 8.10 (s, 1H). 7.69 (s, 1H), 7.32-7.23 (m, 8H), 7.20-7.16 (d, J 
= 15.6, 1H), 7.06-7.04 (d, J = 8.8, 2H), 6.92-6.89 (d, J = 8.8, 2H), 6.86-6.82 (m, 5H), 5.46 
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(s, 2H), 5.22 (s, 4H), 3.804 (s, 3H), 3.796 (s, 6H) ppm. 13C NMR (100 MHz, CDCl3): δ, 
159.6 (Cq), 158.7 (Cq), 151.7 (Cq), 141.0, 139.6, 138.1 (Cq), 137.8 (Cq), 131.5 (Cq), 
129.3, 129.0, 128.8, 128.6 (Cq), 127.8 (Cq), 127.6, 127.4, 126.4, 122.2, 114.7, 113.9, 110.8 
(Cq), 55.5, 55.4, 49.8 (CH2), 49.7 (CH2) ppm. 
N,N,1-Tris(4-methoxybenzyl)-7-phenethyl-1H-imid-azo[4,5-c]pyridin-4-amine (14c): 
General conditions B, 72 h, 55 mg, 35%. General conditions F, 29 h, 327 mg, 77%. 
Colorless syrup. HRMS (ESI): m/z [M+H]+ calc’d for C38H39N4O3: 599.30224; found: 
599.29971.  1H NMR (400 MHz, CDCl3): δ, 7.76 (s, 1H), 7.63 (s, 1H), 7.31 -7.20 (m, 3H), 
7.26-7.24 (d, J = 8.8, 4H), 7.10-7.08 (d, J = 8.8, 4H), 6.94-6.92 (d, J = 8.8, 2H), 6.87-6.84 
(m, 2H), 6.86-6.83 (d, J = 8.8, 2H), 5.34 (s, 2H), 5.18 (s, 4H), 3.80 (s, 6H), 3.79 (s, 3H), 
3.02-2.88 (m, 4H) ppm. 13C NMR (100 MHz, CDCl3): δ, 159.6 (Cq), 158.6 (Cq), 151.4 
(Cq), 141.4, 141.3 (Cq), 141.0, 138.8 (Cq), 131.7 (Cq), 129.3, 128.59, 128.56 (Cq), 128.48, 
127.6, 126.3, 114.7, 113.8, 110.9 (Cq), 55.44, 55.36, 49.7 (CH2), 49.4 (CH2), 38.5 (CH2), 
30.7 (CH2) ppm. For other conditions tested, see Supporting Information. 
N,N,1-Tris(4-methoxybenzyl)-1H-imidazo[4,5-c]pyrid-in-4-amine (13-H): General 
conditions B, 72 h, 34 mg, 30%. Yellowish syrup. HRMS (ESI): m/z [M+H]+ calc’d for 
C30H31N4O3: 495.23964; found: 495.23722. 1H NMR (400 MHz, CDCl3): δ, 7.96-7.94 (d, 
J = 5.6, 1H), 7.70 (s, 1H), 7.25-7.23 (d, J = 8.8, 4H), 7.16-7.14 (d, J = 8.8, 2H), 6.90-6.87 
(d, J = 8.8, 2H), 6.84-6.82 (d, J = 8.8, 4H), 6.64-6.62 (d, J = 5.6, 1H), 5.21 (s, 2H), 5.17 (s, 
4H), 3.80 (s, 3H), 3.78 (s, 6H) ppm. 13C NMR (100 MHz, CDCl3): δ, 159.8 (Cq), 158.6 
(Cq), 152.3 (Cq), 141.1, 140.5 (Cq), 139.2, 131.5 (Cq), 129.2, 129.0, 127.9 (Cq), 127.3 
(Cq), 114.6, 113.9, 96.2, 55.45, 55.36, 49.4 (CH2), 48.6 (CH2) ppm. 
7-Iodo-N,N,1-tris(4-methoxybenzyl)-1H-imidazo[4,5-c]pyridin-4-amine (13-I): 
General conditions C, 36 h, 50 mg, 31%. General conditions G, 20 h, 110 mg, 36%. 
Yellowish foam. HRMS (ESI): m/z [M+H]+ calc’d for C30H30IN4O3: 621.13629; found: 
621.13419. 1H NMR (400 MHz, CDCl3): δ, 8.17 (s, 1H), 7.62 (s, 1H), 7.23-7.20 (d, J = 
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8.8, 4H), 7.08-7.06 (d, J = 8.8, 2H), 6.90-6.88 (d, J = 8.8, 2H), 6.84-6.82 (d, J = 8.8, 4H), 
5.67 (s, 2H), 5.15 (s, 4H), 3.80 (s, 3H), 3.79 (s, 6H) ppm. 13C NMR (100 MHz, CDCl3): δ, 
159.6 (Cq), 158.7 (Cq), 152.3 (Cq), 149.2, 141.4, 138.5 (Cq), 131.2 (Cq), 129.8 (Cq), 
129.2, 128.5, 128.4 (Cq), 114.5, 113.9, 56.0 (Cq), 55.44, 55.38, 49.8 (CH2), 48.5 (CH2) 
ppm.  
7-Ethyl-N,N,1-tris(4-methoxybenzyl)-1H-imidazo[4,5-c]pyridin-4-amine (14d): 
General conditions B, 72 h, 284 mg, 31%. General conditions F, 25 h, 69 mg, 76%. 
Colorless syrup. HRMS (ESI): m/z [M+H]+ calc’d for C32H35N4O3: 523.27093; found: 
523.26894.  1H NMR (400 MHz, CDCl3): δ, 7.73 (s, 1H), 7.64 (s, 1H), 7.24-7.21 (d, J = 
8.8, 4H), 6.99-6.97 (d, J = 8.8, 2H), 6.88-6.86 (d, J = 8.8, 2H), 6.83-6.81 (d, J = 8.8, 4H), 
5.44 (s, 2H), 5.15 (s, 4H), 3.79 (s, 3H), 3.78 (s, 6H), 2.77-2.71 (q, J = 7.6, 2H), 1.25-1.21 
(t, J=7.6, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ, 159.6 (Cq), 158.6 (Cq), 151.3 (Cq), 
141.0, 140.5, 138.8 (Cq), 131.8 (Cq), 129.3, 128.8 (Cq), 128.6 (Cq), 127.6, 114.6, 113.8, 
113.2 (Cq), 55.5, 55.4, 49.7 (CH2), 49.6 (CH2), 22.0 (CH2), 16.2 ppm. 
7-Isobutyl-N,N,1-tris(4-methoxybenzyl)-1H-imid-azo[4,5-c]pyridin-4-amine (14e): 
General conditions B, 72 h, 658 mg, 29%. General conditions F, 21 h, 327 mg, 85%. 
Yellowish syrup. HRMS (ESI): m/z [M+H]+ calc’d for C34H39N4O3: 551.30224; found: 
551.29987.  1H NMR (400 MHz, CDCl3): δ, 7.67 (s, 1H), 7.63 (s, 1H), 7.24-7.21 (d, J = 
8.8, 4H), 6.98-6.95 (d, J = 8.8, 2H), 6.88-6.86 (d, J = 8.8, 2H), 6.84-6.82 (d, J = 8.8, 4H), 
5.40 (s, 2H), 5.15 (s, 4H), 3.79 (s, 3H), 3.78 (s, 6H), 2.51-2.49 (d, J = 7.2, 2H), 1.84-1.74 
(septet, J = 6.4, 1H), 0.95-0.94 (d, J = 6.4, 6H) ppm. 13C NMR (100 MHz, CDCl3): δ, 159.6 
(Cq), 158.6 (Cq), 151.4 (Cq), 142.3, 140.9, 139.0 (Cq), 131.8 (Cq), 129.3, 128.8 (Cq), 
128.7 (Cq), 127.6, 114.7, 113.8, 110.6 (Cq), 55.5, 55.4, 49.6 (CH2), 49.5 (CH2), 38.2 (CH2), 
30.7, 22.4 ppm. 
Methyl (E)-3-(4-(bis(4-methoxybenzyl)amino)-1-(4-methoxybenzyl)-1H-imidazo[4,5-
c]pyridin-7-yl)acryl-ate (14f): General conditions C, 36 h, 86 mg, 57%. Yellowish syrup. 
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HRMS (ESI): m/z [M+H]+ calc’d for C34H35N4O5: 579.26077; found: 579.25862. 1H NMR 
(400 MHz, CDCl3): δ, 8.23 (s, 1H), 8.05-8.01 (d, J = 15.6, 1H), 7.69 (s, 1H), 7.24-7.22 (d, 
J = 8.8, 4H), 7.12-7.09 (d, J = 8.8, 2H), 6.90-6.88 (d, J = 8.8, 2H), 6.85-6.83 (d, J = 8.8, 
4H), 6.26-6.22 (d, J = 15.6, 1H), 5.44 (s, 2H), 5.23 (s, 4H), 3.79-3.78 (overlapped s, 12H) 
ppm. 13C NMR (100 MHz, CDCl3): δ, 167.8 (Cq), 159.8 (Cq), 158.8 (Cq), 152.8 (Cq), 
141.3, 138.8, 138.0 (Cq), 130.9 (Cq), 129.4, 129.2, 128.2 (Cq), 127.6 (Cq), 127.3 (Cq), 
114.6, 114.5, 114.0, 107.6 (Cq), 55.41, 55.36, 51.6, 50.4 (CH2), 49.7 (CH2) ppm. 
N,N,1-Tris(4-methoxybenzyl)-7-(phenylethynyl)-1H-imidazo[4,5-c]pyridin-4-amine 
(14g): General conditions D, 20 h, 138 mg, 89%. Brown syrup. HRMS (ESI): m/z [M+H]+ 
calc’d for C38H35N4O3: 595.27093; found: 595.26894. 1H NMR (400 MHz, CDCl3): δ, 8.22 
(s, 1H), 7.67 (s, 1H), 7.39-7.37 (m, 2H), 7.33-7.30 (m, 3H), 7.26-7.24 (d, J = 8.4, 2H), 
7.25-7.23 (d, J = 8.4, 4H), 6.89-6.87 (d, J = 8.4, 2H), 6.86-6.84 (d, J = 8.4, 4H), 5.75 (s, 
2H), 5.21 (s, 4H), 3.80 (s, 9H) ppm. 13C NMR (100 MHz, CDCl3): δ, 159.6 (Cq), 158.8 
(Cq), 151.9 (Cq), 146.7, 140.3, 138.3 (Cq), 131.1, 129.3, 128.9, 128.8 (Cq), 128.5, 128.0, 
127.0 (Cq), 123.7 (Cq), 114.5, 113.9, 93.6 (Cq), 85.1 (Cq), 55.44, 55.38, 49.6 (CH2), 48.5 
(CH2) ppm. 
N,N,1-Tris(4-methoxybenzyl)-7-methyl-1H-imid-azo[4,5-c]pyridin-4-amine (14h): 
General conditions E, 4 h, 115 mg, 87%. Yellow syrup. HRMS (ESI): m/z [M+H]+ calc’d 
for C31H33N4O3: 509.25528; found: 509.25341. 1H NMR (400 MHz, CDCl3): δ, 7.66 (s, 
1H), 7.65 (s, 1H), 7.24-7.21 (d, J = 8.4, 4H), 7.00-6.97 (d, J = 8.4, 2H), 6.88-6.86 (d, J = 
8.4, 2H), 6.83-6.81 (d, J = 8.4, 2H), 5.45 (s, 2H), 5.15 (s, 4H), 3.79 (s, 3H), 3.78 (s, 6H), 
2.35 (s, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ, 159.5 (Cq), 158.6 (Cq), 151.4 (Cq), 
141.5, 140.8, 139.5 (Cq), 131.8 (Cq), 129.3, 129.0, 128.5 (Cq), 127.5, 114.6, 113.8, 106.6 
(Cq), 55.44, 55.36, 49.7 (CH2), 49.3 (CH2), 15.1 ppm. 
7-Benzyl-N,N,1-tris(4-methoxybenzyl)-1H-imid-azo[4,5-c]pyridin-4-amine (14i): 
General conditions E, 4 h, 69 mg, 45%. Brown syrup. HRMS (ESI): m/z [M+H]+ calc’d 
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for C37H37N4O3: 585.286588; found: 585.28433. 1H NMR (400 MHz, CDCl3): δ, 7.76 (s, 
1H), 7.59 (s, 1H), 7.32-7.23 (m, 7H), 7.09–7.08 (d, J = 8.8, 2H), 6.87–6.82 (m, 8H), 5.22 
(s, 4H), 5.05 (s, 2H), 4.00 (s, 2H), 3.80 (s, 9H) ppm. 13C NMR (100 MHz, CDCl3): δ, 159.5 
(Cq), 158.6 (Cq), 151.8 (Cq), 142.9, 141.4 (Cq), 140.9, 139.2 (Cq), 131.6 (Cq), 129.3, 
129.0 (Cq), 128.9 (Cq), 128.8, 128.0, 127.2, 126.5, 114.6, 113.8, 108.5 (Cq), 55.42, 55.35, 
49.7 (CH2), 49.0 (CH2), 35.0 (CH2) ppm. 
7-Isopropyl-N,N,1-tris(4-methoxybenzyl)-1H-imid-azo[4,5-c]pyridin-4-amine (14j): 
General conditions F, 27 h, 80 mg, 86%. Contains ~20% of n-propyl impurity. Colorless 
syrup. HRMS (ESI): m/z [M+H]+ calc’d for C33H37N4O3: 537.28658; found: 537.28573.  
1H NMR (400 MHz, CDCl3): δ, 7.89 (s, 1H), 7.63 (s, 1H), 7.25-7.22 (d, J = 8.8, 4H), 6.98-
6.96 (d, J = 8.8, 2H), 6.88-6.86 (d, J = 8.8, 2H), 6.84-6.82 (d, J = 8.8, 4H), 5.44 (s, 2H), 
5.16 (s, 4H), 3.79 (s, 3H), 3.78 (s, 6H), 3.30-3.20 (septet, J = 6.8, 1H), 1.25-1.24 (d, J = 
6.4, 6H) ppm. 13C NMR (100 MHz, CDCl3): δ, 159.6 (Cq), 158.6 (Cq), 151.0 (Cq), 141.4, 
138.1 (Cq), 138.0, 131.8 (Cq), 129.3, 128.7 (Cq), 128.6 (Cq), 127.6, 118.3 (Cq), 114.6, 
113.8, 55.45, 55.36, 50.0 (CH2), 49.7 (CH2), 26.3, 24.3 ppm. 
Ethyl 4-(4-(bis(4-methoxybenzyl)amino)-1-(4-methoxybenzyl)-1H-imidazo[4,5-
c]pyridin-7-yl)butanoate (14k): General conditions G, 20 h, 100 mg, 32%. Colorless 
syrup. HRMS (ESI): m/z [M+H]+ calc’d for C36H41N4O5: 609.30773; found: 609.30580. 
1H NMR (400 MHz, CDCl3): δ, 7.69 (s, 1H), 7.65 (s, 1H), 7.24-7.22 (d, J = 8.8, 4H), 6.98-
6.96 (d, J = 8.8, 2H), 6.87-6.85 (d, J = 8.8, 2H), 6.84-6.82 (d, J = 8.8, 4H), 5.47 (s, 2H), 
5.16 (s, 4H), 4.14-4.08 (q, J = 7.2, 2H), 3.78 (overlapped s, 9H), 2.71-2.68 (m, 2H), 2.37-
2.33 (t, J = 7.2, 2H), 1.91-1.86 (m, 2H), 1.26-1.22 (t, J = 7.2, 3H) ppm. 13C NMR (100 
MHz, CDCl3): δ, 173.5 (Cq), 159.5 (Cq), 158.6 (Cq), 151.4 (Cq), 141.6, 141.1, 138.7 (Cq), 
131.7 (Cq), 129.3, 128.8 (Cq), 128.7 (Cq), 127.5, 114.6, 113.8, 110.6 (Cq), 60.5 (CH2), 
55.42, 55.36, 49.6 (CH2), 49.4 (CH2), 33.7 (CH2), 28.4 (CH2), 27.4 (CH2), 14.4 ppm.  
Synthesis of phosphoramidites 20i, 20d, 20e and attempted synthesis of 20a. 
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7-Benzyl-1H-imidazo[4,5c]pyridin-4-amine, trifluoro-acetic acid salt (15i): This 
compound was synthesized according to the modified general procedure.52 A solution of 
14i (589 mg, 1 mmol) in TFA (6 ml) was placed in a 100 ml pressure tube, anisole (0.65 
ml, 6 equiv.) was added, and the mixture was heated at 70 ̊ C for 24 h with vigorous stirring. 
It was cooled and concentrated under reduced pressure. The residue was coevaporated with 
toluene (3 x 25 ml) to obtain 15i (ca. 0.34 g, quantitative) as an oil that was taken into next 
step without further purification.  
1-(7-Benzyl-1H-imidazo[4,5-c]pyridin-4-yl)-3,3,4,4-tetramethylpyrrolidine-2,5-dione 
(16i): This compound was synthesized according to the reported general procedure.53 A 
solution of 15i (0.34 g, 1 mmol) in pyridine (10 ml) was placed in a 100 ml Schlenk flask. 
Tetramethylsuccinic anhydride (M4SA)59 (0.312 g, 2 mmol) and DBU (0.6 ml, 4 mmol) 
were added, and the mixture was heated at 120 ˚C under argon for 20 h with vigorous 
stirring. It was cooled and concentrated under reduced pressure. The residue was 
coevaporated with toluene (3 x 25 ml). The product was purified by column 
chromatography on silica gel eluting with 0-5% MeOH in CH2Cl2 to give a cream foam. It 
was taken in SOCl2 (10 ml), heated at 80 ̊ C for 2 h, cooled and concentrated under reduced 
pressure. The residue was coevaporated with EtOAc (3 x 25 ml). The product was purified 
by column chromatography on silica gel eluting with 0-5% MeOH in CH2Cl2 to give 16i 
as a cream foam in 57% yield (0.208 g). HRMS (ESI): m/z [M+H]+ calc’d for C21H23N4O2: 
363.18212; found: 363.18045. 1H NMR (400 MHz, CD3OD): δ, 8.36 (s, 1H), 8.12 (s, 1H), 
7.29-7.20 (m, 5H), 4.35 (s, 2H), 1.37 (bs, 12H) ppm. 13C NMR (100 MHz, CD3OD): δ, 
183.4, 146.2, 141.8, 139.7, 137.5, 129.8, 127.7, 124.7, 118.3, 35.5, 21.8 ppm. 
(2R,3S,5R)-5-(7-Benzyl-4-(3,3,4,4-tetramethyl-2,5-dioxopyrrolidin-1-yl)-1H-
imidazo[4,5-c]pyridin-1-yl)-2-(((4-methylbenzoyl)oxy)methyl)tetrahydrofuran-3-yl 4-
methylbenzoate (17i): This compound was synthesized according to the reported general 
procedure.53 To a solution of 16i (0.19 g, 0.52 mmol) in dry CH3CN (25 ml) in a 100 ml 
round bottom flask, 60% NaH in oil (42 mg, 1.05 mmol) was added, and the mixture was 
vigorously stirred at room temperature under argon for 45 min. 1-(α)-Chloro-3,5-di-O-(p-
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toluoyl)-2-deoxy-D-ribose (0.368 g, 0.94 mmol) was subsequently added in one portion, 
and the stirring was continued at room temperature for 4.5 h. The mixture was filtered 
through Celite® and concentrated. The product was purified by column chromatography 
on silica gel eluting with 50% EtOAc in hexanes. 17i was obtained as a yellowish syrup in 
39% yield (0.145 g). HRMS (ESI): m/z [M+H]+ calc’d for C42H43N4O7: 715.31322; found: 
715.31184. 1H NMR (400 MHz, CDCl3): δ, 8.32 (s, 1H), 8.19 (s, 1H), 7.92-7.90 (d, J = 
8.4, 2H), 7.87-7.85 (d, J = 8.4, 2H), 7.34-7.32 (d, J = 8.4, 2H), 7.92-7.90 (d, J = 8.4, 2H), 
7.14-7.11 (m, 3H), 7.06-7.04 (m, 2H), 6.20-6.17 (dd, J1 = 5.2, J2 = 9.2, 1H), 5.54-5.53 (m, 
1H), 4.60-4.49 (m, 4H), 4.38-4.34 (AB/2, J=16.8, 1H), 2.49 (s, 3H), 2.46-2.42 (m, 1H), 
2.40 (s, 3H), 2.06-2.01 (m, 1H), 1.39 (bs, 1H) ppm. 13C NMR (100 MHz, CDCl3): δ, 181.6 
(Cq), 166.2 (Cq), 165.8 (Cq), 144.8 (Cq), 144.6, 144.4 (Cq), 142.3, 139.6 (Cq), 138.7 (Cq), 
138.6 (Cq), 137.5 (Cq), 130.0, 129.8, 129.54, 129.47, 129.2, 128.1, 127.1, 126.6 (Cq), 
126.5 (Cq), 120.0 (Cq), 85.8, 82.7, 74.8, 64.3 (CH2), 48.1 (Cq), 39.4 (CH2), 35.8 (CH2), 
21.9, 21.8, 21.7, 21.5 ppm. For the critical NOESY correlations, see Figure S1 and copies 
of spectra (Supporting Information). 
1-(7-Benzyl-1-((2R,4S,5R)-4-hydroxy-5-(hydroxylmethyl)tetrahydrofuran-2-yl)-1H-
imidazo[4,5-c]pyridin-4-yl)-3,3,4,4-tetramethylpyrrolidine-2,5-dione (18i): This 
compound was synthesized according to the general procedure.53 To a solution of 17i (0.14 
g, 0.20 mmol) in dry MeOH (4 ml) in a 25 ml round bottom flask, NaOMe (32 mg, 0.60 
mmol) was added. The mixture was stirred at room temperature under argon for 2 h and 
concentrated in vacuo. The product was purified by column chromatography on silica gel 
eluting with 0-10% MeOH in dichloromethane to obtain 18i as an off-white solid in 66% 
yield (62 mg). HRMS (ESI): m/z [M+H]+ calc’d for C26H31N4O5: 479.22948; found: 
479.22931. 1H NMR (400 MHz, CD3OD): δ, 8.69 (s, 1H), 8.14 (s, 1H), 7.32-7.14 (m, 5H), 
6.35-6.32 (dd, J1 = 6.4, J2 = 12.8, 1H), 4.61-4.57 (AB/2, J = 16.8, 1H), 4.47-4.30 (AB/2, J 
= 16.8, 1H), 4.46-4.44 (m, 1H), 3.95-3.92 (app q, J = 3.6, 1H), 3.73-3.69 (app dd, J1 = 3.6, 
J2 = 12.0, 1H), 3.66-3.62 (app dd, J1 = 3.6, J2 = 12.0, 1H), 2.52-2.46 (ddd, J1 = J2 = 6.0, J3 
= 12.8, 1H), 2.14-2.08 (ddd, J1 = 4.4, J2 = 6.0, J3 = 10.4, 1H), 1.37 (bs, 12H) ppm. 13C NMR 
(100 MHz, CD3OD): δ, 183.4 (Cq), 145.9 (Cq), 144.3, 141.0 (Cq), 140.1 (Cq), 138.6 (Cq), 
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138.4 (Cq), 130.1, 129.5, 127.9, 123.5 (Cq), 89.2, 87.1, 71.7, 62.6 (CH2), 48.9 (Cq), 42.0 
(CH2), 35.9 (CH2), 21.88, 21.84 ppm. 
1-(7-Benzyl-1-((2R,4S,5R)-5-((bis(4-methoxyphenyl)-(phenyl)methoxy)methyl)-4-
hydroxytetrahydrofuran-2-yl)-1H-imidazo[4,5-c]pyridin-4-yl)-3,3,4,4-
tetramethylpyrrolidine-2,5-dione (19i): This compound was synthesized according to the 
reported general procedure.53 To a solution of 18i (56 mg, 0.12 mmol) in pyridine (2 ml), 
4,4’-dimethoxytrityl chloride (DMT-Cl) (155 mg, 0.457 mmol) was added in one portion 
and the mixture was stirred at room temperature under argon for 5 h (TLC showed complete 
conversion). MeOH (0.2 ml) was then added, and the mixture was concentrated in vacuo. 
The product was purified by column chromatography on silica gel (neutralized with 
triethylamine) eluting with 5-20% acetone in dichloromethane to obtain 19i as a colorless 
solid in 69% yield (63 mg). HRMS (ESI): m/z [M+H]+ calc’d for C47H49N4O7: 781.36017; 
found: 781.35738. 1H NMR (400 MHz, CDCl3): δ, 8.24 (s, 1H), 8.10 (s, 1H), 7.38-7.10 
(m, 14H), 6.82-6.80 (d, J = 8.4, 4H), 6.16-6.12 (dd, J1 = 6.4, J2 = 12.4, 1H), 4.50-4.46 
(AB/2, J = 16.8, 1H), 4.43-4.38 (m, 1H), 4.36-4.32 (AB/2, J = 16.8, 1H), 4.01-3.98 (app q, 
J = 4.4, 1H), 3.78 (s, 6H), 3.36-3.32 (app dd, J1 = 4.4, J2 = 10.4, 1H), 3.28-3.24 (app dd, J1 
= 4.8, J2 = 10.4, 1H), 2.6 (bs, 1H), 2.28-2.22 (ddd, J1 = J2 = 6.0, J3 = 13.2, 1H), 1.90-1.84 
(ddd, J1 = J2 = 5.6, J3 = 9.6, 1H), 1.39-1.38 (overlapped s, 12H) ppm. 13C NMR (100 MHz, 
CDCl3): δ, 181.7 (Cq), 158.7 (Cq), 144.5 (Cq), 144.1, 142.6, 139.4 (Cq), 138.8 (Cq), 138.2 
(Cq), 137.6 (Cq), 135.63 (Cq), 135.55 (Cq), 130.12, 130.09, 129.1, 128.6, 128.13, 128.10, 
127.11, 127.07, 120.6 (Cq), 113.4, 86.8 (Cq), 85.7, 85.2, 72.0, 63.7 (CH2), 55.3, 48.0 (Cq), 




diisopropylphosphoramidite (20i): This compound was synthesized according to the 
reported general procedure.60 To a solution of 19i (62 mg, 0.080 mmol) in dry CH2Cl2 (2 
ml) containing N,N-diisopropylethylamine (DIEA) (70 μl, 0.4 mmol), 2-cyanoethyl-N,N-
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diisopropyl chlorophosphoramidite (40 μl, 0.175 mmol) was added in one portion and the 
mixture was stirred at room temperature under argon for 3 h (TLC showed complete 
conversion). The mixture was concentrated in vacuo at rt and the product was purified by 
column chromatography on silica gel (neutralized with triethylamine) eluting with 50% 
EtOAc in hexanes containing 1% triethylamine, to obtain 20i as a mixture of diastereomers 
(colorless solid, Rf ~0.5 in 5% acetone/CH2Cl2, two close spots visible on TLC) in 49% 
yield (38 mg). HRMS (ESI): m/z [M+H]+ calc’d for C56H66N6O8P: 981.46801; found: 
981.46481. 1H NMR (400 MHz, acetone-d6): δ, 8.40, 8.39 (s, 1H), 8.21, 8.19 (s, 1H), 7.45-
7.18 (m, 14H), 6.84-6.80 (m, 4H), 6.40-6.35 (dd, J1 = 7.0, J2 = 12.8, 1H), 4.68-4.78 (m, 
2H), 4.56-4.52, 4.53-4.49 (AB/2, J = 16.4, 1H), 4.28-4.26, 4.24-4.21 (app q, J = 4.4, 1H), 
3.763, 3.757 (s, 6H), 3.67-3.58 (m, 2H), 3.36-3.32 (m, 2H), 2.91-2.78 (m, 3H), 2.76-2.73 
(t, J = 6.0, 1H), 2.68-2.65 (t, J = 6.0, 1H), 1.35, 1.31 (bs, 12H), 1.21-1.19 (m, 6H), 1.15-
1.14, 1.13-1.11 (d, J = 6.8, 6H) ppm. 13C NMR (100 MHz, acetone-d6): δ, 181.7, 159.6, 
145.9, 144.36, 144.27, 144.02, 143.97, 140.4, 140.08, 140.05, 139.2, 138.8, 136.64, 
136.58, 136.52, 130.96, 130.93, 129.7, 129.34, 129.31, 128.97, 128.91, 128.6, 127.6, 
127.50, 127.47, 122.3, 122.2, 119.0, 114.0, 87.22, 87.18, 86.6, 86.4, 86.3, 86.2, 74.4, 74.0, 
73.8, 64.3, 64.3, 59.7, 59.6, 59.4, 55.5, 55.0, 48.3, 44.06, 43.99, 43.94, 43.86, 40.4, 40.3, 
35.5, 24.94, 24.86, 24.82, 22.0, 21.7, 21.4, 20.8, 20.7 ppm. 31P NMR (162 MHz, acetone-
d6): δ, 149.8, 149.6 ppm. 
7-Ethyl-1H-imidazo[4,5c]pyridin-4-amine, trifluoro-acetic acid salt (15d): This 
compound was synthesized in similar fashion as 15i. A solution of 14d (750 mg, 1.4 mmol) 
in TFA (10 ml) was placed in a 100 ml pressure tube, anisole (ca. 1 ml, 6 equiv.) was added, 
and the mixture was heated at 70 ˚C for 24 h with vigorous stirring. It was cooled and 
concentrated under reduced pressure. The residue was coevaporated with toluene (3 x 20 
ml) to obtain 15d (ca. 0.4 g, quantitative) as an oil that was taken into next step without 
further purification. 
1-(7-Ethyl-1H-imidazo[4,5-c]pyridin-4-yl)-3,3,4,4-tetramethylpyrrolidine-2,5-dione 
(16d): This compound was synthesized in similar fashion as 16i. A solution of 15d (0.4 g, 
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1.4 mmol) in pyridine (15 ml) was placed in a 100 ml Schlenk flask. Tetramethylsuccinic 
anhydride (M4SA) (0.5 g, 3.2 mmol) and DBU (1 ml, 6.7 mmol) were added, and the 
mixture was heated at 120 ˚C under argon for 22 h with vigorous stirring. It was cooled 
and concentrated under reduced pressure. The residue was coevaporated with toluene (3 x 
20 ml). The product was purified by column chromatography on silica gel eluting with 0-
5% MeOH in CH2Cl2 to give a cream solid. It was taken in SOCl2 (12 ml), heated at 80 ˚C 
for 2 h, cooled and concentrated under reduced pressure. The residue was coevaporated 
with EtOAc (3 x 20 ml). The product was purified by column chromatography on silica gel 
eluting with 0-8% MeOH in CH2Cl2 to give 16d as a cream solid in 88% yield (0.37 g). 
HRMS (ESI): m/z [M+H]+ calc’d for C16H21N4O2: 301.16647; found: 301.16501. 1H NMR 
(400 MHz, CD3OD): δ, 8.52 (s, 1H), 8.24 (s, 1H), 3.07-3.01 (q, J = 7.2, 2H), 1.41-1.37 (t, 
J = 7.2, 3H), 1.37 (bs, 12H) ppm. 13C NMR (100 MHz, CD3OD): δ, 182.9, 146.9, 143.5, 
139.6, 135.4, 135.1, 128.7, 48.9, 23.2, 21.8, 14.5 ppm. 
(2R,3S,5R)-5-(7-Ethyl-4-(3,3,4,4-tetramethyl-2,5-dioxopyrrolidin-1-yl)-1H-imidazo[4,5-
c]pyridin-1-yl)-2-(((4-methylbenzoyl)oxy)methyl)tetrahydrofuran-3-yl 4-methylbenzoate 
(17d): This compound was synthesized in similar fashion as 17i. To a solution of 16i (0.35 
g, 1.17 mmol) in dry CH3CN (60 ml) in a 250 ml round bottom flask, 60% NaH in oil (100 
mg, 2.5 mmol) was added, and the mixture was vigorously stirred at room temperature 
under argon for 45 min. 1-(α)-Chloro-3,5-di-O-(p-toluoyl)-2-deoxy-D-ribose (0.817 g, 2.1 
mmol) was subsequently added portionwise over 1 h, and the stirring was continued at 
room temperature for overall 5 h. The mixture was filtered through Celite® and 
concentrated. The product was purified by column chromatography on silica gel eluting 
with 0-50% EtOAc in hexanes, and concentrated repeatedly with dichloromethane. 17d 
was obtained as a yellowish syrup in 65% yield (0.494 g). HRMS (ESI): m/z [M+H]+ calc’d 
for C37H41N4O7: 653.29757; found: 653.29654. 1H NMR (400 MHz, CDCl3): δ, 8.27 (s, 
1H), 8.25 (s, 1H), 7.92-7.90 (d, J = 8.0, 2H), 7.88-7.86 (d, J = 8.0, 2H), 7.30-7.28 (d, J = 
8.4, 2H), 7.24-7.22 (d, J = 8.4, 2H), 6.60-6.57 (dd, J1 = 6.4, J2 = 12.8, 1H), 5.72-5.68 (m, 
1H), 4.67-4.59 (m, 3H), 3.16-3.00 (m, 2H), 2.82-2.79 (dd, J1 = 4.4, J2 = 6.8, 2H), 2.44 (s, 
3H), 2.40 (s, 3H), 1.43-1.40 (t, J = 7.6, 3H), 1.37 (bs, 1H) ppm. 13C NMR (100 MHz, 
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CDCl3): δ, 181.7 (Cq), 166.3 (Cq), 165.9 (Cq), 144.9 (Cq), 144.4 (Cq), 142.6, 142.0, 138.9 
(Cq), 137.6 (Cq), 137.3 (Cq), 130.0, 129.9, 129.8, 129.5, 126.6 (Cq), 126.4 (Cq), 124.2 
(Cq), 85.5, 82.7, 74.6, 64.0 (CH2), 48.0 (Cq), 39.7 (CH2), 22.9 (CH2), 21.9, 21.8, 21.7, 
21.5, 15.4 ppm. For the critical NOESY correlations, see Figure S2 and copies of spectra 
(Supporting Information). 
1-(7-Ethyl-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-
imidazo[4,5-c]pyridin-4-yl)-3,3,4,4-tetramethylpyrrolidine-2,5-dione (18d): This 
compound was synthesized in similar fashion as 18i. To a solution of 17d (0.46 g, 0.7 
mmol) in dry MeOH (6 ml) in a 25 ml round bottom flask, NaOMe (114 mg, 2.11 mmol) 
was added. The mixture was stirred at room temperature under argon for 2 h and 
concentrated in vacuo. The product was purified by column chromatography on silica gel 
eluting with 0-10% MeOH in dichloromethane to obtain 18d as an off-white solid in 74% 
yield (218 mg). HRMS (ESI): m/z [M+H]+ calc’d for C21H29N4O5: 417.21383; found: 
417.21265. 1H NMR (400 MHz, CD3OD): δ, 8.74 (s, 1H), 8.20 (s, 1H), 6.63-6.60 (dd, J1 = 
6.4, J2 = 12.8, 1H), 4.58-4.55 (m, 1H), 4.06-4.03 (app q, J = 3.6, 1H), 3.78-3.65 (m, 2H), 
3.23-3.12 (app septet, J = 3.6, 2H), 2.78-2.72 (m, 1H), 2.60-2.54 (ddd, J1 = 3.6, J2 = 6.0, J3 
= 10.4, 1H), 1.44-1.40 (t, J = 7.6, 3H), 1.37 (bs, 12H) ppm. 13C NMR (100 MHz, CD3OD): 
δ, 183.4 (Cq), 145.8 (Cq), 142.4, 140.4 (Cq), 138.4 (Cq), 137.8 (Cq), 127.2 (Cq), 89.4, 
87.2, 72.1, 62.7 (CH2), 48.8 (Cq), 42.2 (CH2), 23.5 (CH2), 21.9, 21.8, 15.7 ppm. 
1-(1-((2R,4S,5R)-5-((Bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-
hydroxytetrahydrofuran-2-yl)-7-ethyl-1H-imidazo[4,5-c]pyridin-4-yl)-3,3,4,4-
tetramethylpyrrolidine-2,5-dione (19d): This compound was synthesized in similar fashion 
as 19i. To a solution of 18d (190 mg, 0.457 mmol) in pyridine (3 ml), 4,4’-dimethoxytrityl 
chloride (DMT-Cl) (217 mg, 0.639 mmol) was added in one portion and the mixture was 
stirred at room temperature under argon for 4 h. The mixture was concentrated in vacuo. 
The product was purified by column chromatography on silica gel (neutralized with 
triethylamine) eluting with 0-20% acetone in dichloromethane to obtain 19d as a colorless 
solid in 33% yield (110 mg). HRMS (ESI): m/z [M+H]+ calc’d for C42H47N4O7: 719.34452; 
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found: 719.34247. 1H NMR (400 MHz, CDCl3): δ, 8.21 (s, 1H), 8.16 (s, 1H), 7.40-7.38 (d, 
J = 7.2, 2H), 7.30-7.20 (m, 7H), 6.82-6.80 (d, J = 9.2, 4H), 6.42-6.39 (dd, J1 = 6.4, J2 = 
12.4, 1H), 4.54-4.48 (m, 1H), 4.11-4.08 (app q, J = 4.4, 1H), 3.77 (s, 6H), 3.38-3.34 (app 
dd, J1 = 4.4, J2 = 10.4, 1H), 3.32-3.29 (app dd, J1 = 4.8, J2 = 10.4, 1H), 3.17 (bs, 1H), 3.03-
3.00 (app dd, J1 = 3.2, J2 = 7.6, 1H), 2.99-2.96 (app dd, J1 = 3.2, J2 = 7.6, 1H), 2.46-2.44 
(app t, J = 6.0, 2H), 1.38-1.37 (overlapped s, 12H), 1.36-1.32 (t, J = 7.2, 3H) ppm. 13C 
NMR (100 MHz, CDCl3): δ, 181.8 (Cq), 158.7 (Cq), 144.5 (Cq), 142.6, 141.9, 138.9 (Cq), 
137.3 (Cq), 137.2 (Cq), 135.63 (Cq), 135.58 (Cq), 130.1, 128.13, 128.06, 127.1, 124.6 
(Cq), 113.4, 86.8 (Cq), 86.0, 85.2, 71.9, 63.7 (CH2), 55.3, 48.0 (Cq), 41.7 (CH2), 22.7 
(CH2), 21.8, 21.4, 15.3 ppm. 
(2R,3S,5R)-2-((Bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5-(7-ethyl-4-(3,3,4,4-
tetramethyl-2,5-dioxopyrrolidin-1-yl)-1H-imidazo[4,5-c]pyridin-1-yl)tetrahydrofuran-3-
yl (2-cyanoethyl) diisopropylphosphoramidite (20d): This compound was synthesized in 
similar fashion as 20i. To a solution of 19d (105 mg, 0.146 mmol) in dry CH2Cl2 (4 ml) 
containing N,N-diisopropylethylamine (DIEA) (127 μl, 0.731 mmol), 2-cyanoethyl-N,N-
diisopropyl chloro-phosphoramidite (40 μl, 0.175 mmol) was added in one portion and the 
mixture was stirred at room temperature under argon for 4 h (TLC showed complete 
conversion). The mixture was concentrated in vacuo at rt and the product was purified by 
column chromatography on silica gel (neutralized with triethylamine) eluting with 40-60% 
EtOAc in hexanes containing 1% triethylamine, to obtain 20d as a mixture of diastereomers 
(white foam, Rf ~0.5 in 5% acetone/CH2Cl2, two close spots visible on TLC) in 67% yield 
(90 mg). HRMS (ESI): m/z [M+H]+ calc’d for C51H64N6O8P: 919.45236; found: 
919.45047. 1H NMR (400 MHz, CDCl3): δ, 8.25 (s, 1H), 8.23, 8.19 (s, 1H), 7.40-7.38 (m, 
2H), 7.30-7.20 (m, 7H), 6.83-6.79 (m, 4H), 6.49-6.46 (dd, J1 = 6.8, J2 = 13.6, 1H), 4.70-
4.59 (m, 1H), 4.32-4.24 (m, 1H), 3.78, 3.77 (s, 6H), 3.70-3.53 (m, 3H), 3.32-3.31 (m, 1H), 
3.13-2.99 (m, 2H), 2.62-2.59 (t, J = 6.4, 1H), 2.57-2.55 (m, 1H), 2.44-2.41 (t, J = 6.4, 1H), 
1.38, 1.37 (bs, 12H), 1.20-1.17 (m, 9H), 1.13-1.12 (d, J = 6.8, 3H) ppm. 13C NMR (100 
MHz, CDCl3): δ, 181.7, 158.7, 144.5, 142.5, 142.4, 139.0, 137.4, 135.63, 135.56, 130.2, 
128.3, 128.2, 128.1, 127.1, 124.5, 124.4, 117.5, 113.4, 86.7, 85.8, 85.5, 85.4, 74.1, 73.9, 
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63.4, 63.2, 58.4, 58.2, 55.38, 55.36, 48.0, 43.61, 43.55, 43.4, 41.0, 24.7, 24.6, 22.9, 21.8, 
21.5, 15.6 ppm. 31P NMR (162 MHz, CDCl3): δ, 150.8, 150.2 ppm. 
7-Isobutyl-1H-imidazo[4,5c]pyridin-4-amine, trifluoroacetic acid salt (15e): This 
compound was synthesized in similar fashion as 15i. A solution of 14e (1.3 g, 2.4 mmol) 
in TFA (20 ml) was placed in a 100 ml pressure tube, anisole (1.6 ml, 6 equiv.) was added, 
and the mixture was heated at 70 ˚C for 24 h with vigorous stirring. It was cooled and 
concentrated under reduced pressure. The residue was coevaporated with toluene (3 x 20 
ml) to obtain 15e (ca. 0.8 g, quantitative) as an oil that was taken into next step without 
further purification. 
1-(7-Isobutyl-1H-imidazo[4,5-c]pyridin-4-yl)-3,3,4,4-tetramethylpyrrolidine-2,5-
dione (16e): This compound was synthesized in similar fashion as 16i. A solution of 15e 
(ca. 0.8 g, 2.4 mmol) in pyridine (20 ml) was placed in a 100 ml Schlenk flask. 
Tetramethylsuccinic anhydride (M4SA) (0.8 g, 5.1 mmol) and DBU (1.5 ml, 10.0 mmol) 
were added, and the mixture was heated at 120 ˚C under argon for 22 h with vigorous 
stirring. It was cooled and concentrated under reduced pressure. The residue was 
coevaporated with toluene (3 x 20 ml). The product was purified by column 
chromatography on silica gel eluting with 0-5% MeOH in CH2Cl2 to give a cream foam. It 
was taken in SOCl2 (20 ml), heated at 80 ̊ C for 2 h, cooled and concentrated under reduced 
pressure. The residue was coevaporated with EtOAc (3 x 20 ml). The product was purified 
by column chromatography on silica gel eluting with 0-8% MeOH in CH2Cl2 to give 16e 
as a cream foam in 79% yield (0.61 g). HRMS (ESI): m/z [M+H]+ calc’d for C18H25N4O2: 
329.19777; found: 329.19608. 1H NMR (400 MHz, CD3OD): δ, 8.43 (s, 1H), 8.16 (s, 1H), 
2.87-2.85 (d, J = 7.6, 2H), 2.11-2.05 (app septet, J = 6.8, 1H), 1.37 (bs, 12H), 0.99-0.97 (d, 
J = 6.4, 6H) ppm. 13C NMR (100 MHz, CD3OD): δ, 183.2, 146.4, 143.7, 141.6, 135.8, 




methylbenzoate (17e): This compound was synthesized in similar fashion as 17i. To a 
solution of 16e (0.585 g, 1.78 mmol) in dry CH3CN (60 ml) in a 250 ml round bottom flask, 
60% NaH in oil (143 mg, 3.57 mmol) was added, and the mixture was vigorously stirred 
at room temperature under argon for 35 min. 1-(α)-Chloro-3,5-di-O-(p-toluoyl)-2-deoxy-
D-ribose (1.25 g, 3.21 mmol) was subsequently added portionwise over 1 h, and the stirring 
was continued at room temperature for overall 4.5 h. The mixture was filtered through 
Celite® and concentrated. The product was purified by column chromatography on silica 
gel eluting with 0-50% EtOAc in hexanes, and concentrated repeatedly with 
dichloromethane. 17e was obtained as a yellowish solid in 38% yield (0.465 g). HRMS 
(ESI): m/z [M+H]+ calc’d for C39H45N4O7: 681.32887; found: 681.32697. 1H NMR (400 
MHz, CDCl3): δ, 8.27 (s, 1H), 8.20 (s, 1H), 7.97-7.95 (d, J = 8.0, 2H), 7.92-7.90 (d, J = 
8.0, 2H), 7.30-7.28 (d, J = 8.4, 2H), 7.27-7.25 (d, J = 8.4, 2H), 6.59-6.55 (dd, J1 = 5.2, J2 = 
8.8, 1H), 5.73-5.72 (m, 1H), 4.70-4.61 (m, 3H), 2.98-2.92 (dd, J1 = 7.2, J2 = 14.4, 1H), 
2.84-2.72 (m, 3H), 2.45 (s, 3H), 2.42 (s, 3H), 1.98-1.88 (app septet, J = 6.4, 1H), 1.38 (bs, 
1H), 1.05-1.03 (d, J = 6.8, 6H) ppm. 13C NMR (100 MHz, CDCl3): δ, 181.6 (Cq), 166.3 
(Cq), 165.9 (Cq), 144.9 (Cq), 144.4 (Cq), 144.1, 142.2, 139.2 (Cq), 137.7 (Cq), 137.4 (Cq), 
129.9, 129.8, 129.54, 129.47, 126.6 (Cq), 126.3 (Cq), 121.8 (Cq), 85.4, 82.9, 74.9, 64.2 
(CH2), 48.0 (Cq), 39.9 (CH2), 39.1 (CH2), 30.2, 22.5, 21.9, 21.8, 21.7, 21.5 ppm. For the 
critical NOESY correlations, see Figure S3 and copies of spectra (Supporting Information). 
1-(1-((2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7-isobutyl-1H-
imidazo[4,5-c]pyridin-4-yl)-3,3,4,4-tetramethylpyrrolidine-2,5-dione (18e): This 
compound was synthesized in similar fashion as 18i. To a solution of 17e (0.46 g, 0.68 
mmol) in dry MeOH (7 ml) in a 25 ml round bottom flask, NaOMe (110 mg, 2.03 mmol) 
was added. The mixture was stirred at room temperature under argon for 2 h and 
concentrated in vacuo. The product was purified by column chromatography on silica gel 
eluting with 0-10% MeOH in dichloromethane to obtain 18e as an off-white foam in 85% 
yield (256 mg). HRMS (ESI): m/z [M+H]+ calc’d for C23H33N4O5: 445.24512; found: 
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445.24381. 1H NMR (400 MHz, CD3OD): δ, 8.74 (s, 1H), 8.14 (s, 1H), 6.58-6.55 (dd, J1 = 
6.4, J2 = 12.8, 1H), 4.58-4.55 (dt, J1 = 3.2, J2 = 6.8, 1H), 4.06-4.04 (app q, J = 3.2, 1H), 
3.77-3.73 (app dd, J1 = 3.6, J2 = 12.0, 1H), 3.72-3.68 (app dd, J1 = 3.6, J2 = 12.0, 1H), 3.06-
3.01 (app dd, J1 = 6.8, J2 = 14.4, 1H), 2.92-2.86 (app dd, J1 = 7.2, J2 = 14.0, 1H), 2.76-2.69 
(ddd, J1 = 5.6, J2 = 6.8, J3 = 13.2, 1H), 2.56-2.51 (ddd, J1 = 3.6, J2 = 6.0, J3 = 9.6, 1H), 2.04-
1.94 (app septet, J = 6.8, 1H), 1.37 (bs, 12H), 1.05-1.03 (d, J = 6.8, 6H) ppm. 13C NMR 
(100 MHz, CD3OD): δ, 183.4 (Cq), 146.0 (Cq), 144.0, 140.7 (Cq), 138.5 (Cq), 137.9 (Cq), 
124.6 (Cq), 89.4, 87.0, 72.3, 62.8 (CH2), 48.9 (Cq), 42.3 (CH2), 39.4 (CH2), 31.1, 22.6, 
22.5, 21.9, 21.8 ppm. 
1-(1-((2R,4S,5R)-5-((Bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-
hydroxytetrahydrofuran-2-yl)-7-isobutyl-1H-imidazo[4,5-c]pyridin-4-yl)-3,3,4,4-
tetramethylpyrrolidine-2,5-dione (19e): This compound was synthesized in similar fashion 
as 19i. To a solution of 18e (225 mg, 0.507 mmol) in dry pyridine (4 ml), 4,4’-
dimethoxytrityl chloride (DMT-Cl) (240 mg, 0.709 mmol) was added in one portion and 
the mixture was stirred at room temperature under argon for 4 h. TLC analysis indicated 
that a lot of starting material remained and then additional DMT-Cl (0.120 g, 0.355 mmol) 
and cat. DMAP (10 mg) were added.  After 14 h more DMT-Cl (0.120 g, 0.350 mmol), 
triethylamine (85 μl, 0.608 mmol), and cat. DMAP (10 mg) were added. After 8 h, another 
portion as above was added, and after 16 h TLC showed no further conversion (overall 42 
h). The mixture was quenched with 200 μl of MeOH, concentrated in vacuo, the residue 
was taken in AcOEt and filtered, and the filtrate was concentrated in vacuo. The product 
was purified by column chromatography on silica gel (neutralized with triethylamine) 
eluting with 0-25% acetone in dichloromethane to obtain 19e as a colorless foam in 46% 
yield (175 mg). Further elution with 10% MeOH in dichloromethane yielded the recovered 
starting material 18e as a colorless syrup in 45% yield (102 mg). HRMS (ESI): m/z [M+H]+ 
calc’d for C44H51N4O7: 747.37582; found: 747.37412. 1H NMR (400 MHz, CDCl3): δ, 8.17 
(s, 1H), 8.14 (s, 1H), 7.40-7.38 (d, J = 8.8, 2H), 7.30-7.20 (m, 7H), 6.82-6.80 (d, J = 8.8, 
4H), 6.42-6.38 (dd, J1 = 6.4, J2 = 12.8, 1H), 4.52-4.51 (m, 1H), 4.10-4.07 (app q, J = 4.4, 
1H), 3.77 (s, 6H), 3.38-3.35 (app dd, J1 = 4.4, J2 = 10.4, 1H), 3.33-3.29 (app dd, J1 = 4.8, 
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J2 = 10.4, 1H), 2.88-2.83 (app dd, J1 = 7.2, J2 = 14.4, 1H), 2.75-2.70 (app dd, J1 = 6.4, J2 = 
14.0, 1H), 2.46-2.41 (m, 2H), 1.90-1.84 (app quintet, J = 6.4 , 1H), 1.37-1.36 (overlapped 
s, 12H), 1.01-0.99 (dd, J1 = 2.4, J2 = 6.4, 6H) ppm. 13C NMR (100 MHz, CDCl3): δ, 181.7 
(Cq), 158.7 (Cq), 144.5 (Cq), 143.6, 142.7, 139.2 (Cq), 137.5 (Cq), 137.4 (Cq), 135.63 
(Cq), 135.58 (Cq), 130.1, 128.2, 128.1, 127.1, 122.2 (Cq), 113.4, 86.8 (Cq), 86.0, 85.0, 
72.0, 63.7 (CH2), 55.3, 48.0 (Cq), 41.8 (CH2), 38.8 (CH2), 30.1, 22.5, 22.4, 21.8, 21.4 ppm. 
(2R,3S,5R)-2-((Bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5-(7-isobutyl-4-(3,3,4,4-
tetramethyl-2,5-dioxopyrrolidin-1-yl)-1H-imidazo[4,5-c]pyridin-1-yl)tetrahydrofuran-3-
yl (2-cyanoethyl) diisopropylphosphoramidite (20e): This compound was synthesized in 
similar fashion as 20i. To a solution of 19e (105 mg, 0.146 mmol) in dry CH2Cl2 (5 ml) 
containing N,N-diisopropylethylamine (DIEA) (185 μl, 1.07 mmol), 2-cyanoethyl-N,N-
diisopropyl chloro-phosphoramidite (105 μl, 0.472 mmol) was added in one portion and 
the mixture was stirred at room temperature under argon for 4 h (TLC showed complete 
conversion). The mixture was concentrated in vacuo at rt and the product was purified by 
column chromatography on silica gel (neutralized with triethylamine) eluting with 40-60% 
EtOAc in hexanes containing 1% triethylamine, to obtain 20e as a mixture of diastereomers 
(white foam, Rf ~0.5 in 50% EtOAc in hexanes, two close spots visible on TLC) in 59% 
yield (120 mg). HRMS (ESI): m/z [M+H]+ calc’d for C53H68N6O8P: 947.48366; found: 
947.48314. 1H NMR (400 MHz, acetone-d6): δ, 8.43, 8.41 (s, 1H), 8.15 (s, 1H), 7.46-7.41 
(m, 2H), 7.33-7.19 (m, 7H), 6.85-6.81 (m, 4H), 6.62-6.58 (dd, J1 = 6.4, J2 = 13.2, 1H), 4.86-
4.81 (m, 1H), 4.37-4.29 (m, 1H), 3.96-3.82 (m, 1H), 3.77, 3.76 (s, 6H), 3.74-3.66 (m, 2H), 
3.39-3.34 (m, 2H), 3.13-3.09 (m, 1H), 3.03-2.96 (m, 1H), 2.94-2.87 (m, 1H), 2.81 (m, 3H), 
2.79-2.76 (t, J = 6.4, 1H), 2.68-2.64 (t, J = 6.0, 1H), 1.36, 1.35, 1.30 (bs, 12H), 1.23-1.21, 
1.22-1.20, 1.17-1.16 (d, J = 6.8, 12H), 1.08-1.06 (d, J = 6.8, 3H), 1.05-1.03 (dd, J1 = 1.6, 
J2 = 6.4, 3H) ppm. 13C NMR (100 MHz, acetone-d6): δ, 181.8, 159.6, 145.9, 144.1, 144.0, 
139.9, 138.7, 136.6, 136.5, 131.0, 130.9, 129.0, 128.9, 128.6, 127.6, 123.32, 123.28, 119.0, 
114.0, 87.2, 86.7, 86.1, 86.0, 75.0, 74.9, 74.5, 74.3, 64.5, 59.6, 59.4, 55.5, 48.4, 44.1, 44.0, 
40.4, 39.0, 25.0, 24.9, 24.8, 22.9, 22.5, 22.0, 21.7, 21.4, 20.8 ppm. 31P NMR (162 MHz, 
acetone-d6): δ, 149.9, 149.7 ppm. 
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7-Phenyl-1H-imidazo[4,5c]pyridin-4-amine, trifluoroacetic acid salt (15a, 3a*TFA): 
This compound was synthesized in similar fashion as 15i. A solution of 14a (2.09 g, 3.65 
mmol) in TFA (20 ml) was placed in a 100 ml pressure tube, anisole (2.4 ml, 6 equiv.) was 
added, and the mixture was heated at 70 ˚C for 24 h with vigorous stirring. It was cooled 
and concentrated under reduced pressure. The residue was coevaporated with toluene (3 x 
25 ml) to obtain grey-brown powder. It was taken in toluene (10 ml) and filtered, washing 
with toluene (2 x 5 ml), then hexane (2 x 5 ml) and dried on air to obtain 15a as a free 
flowing, light gray powder, 1.13 g (quantitative). MS (ESI): m/z, 211.3 for [M + H]+. 1H 
NMR (400 MHz, DMSO-d6): δ, 8.60 (bs, 2H), 8.52 (s, 1H), 7.82 (s, 1H), 7.70-7.69 (m, 
2H), 7.56-7.53 (m, 2H), 7.49-7.46 (m, 1H) ppm. 13C NMR (100 MHz, DMSO-d6): δ, 159.4, 
159.0, 158.7, 158.3, 147.5, 144.3, 132.7, 129.1, 128.5, 128.0, 126.7, 115.2 ppm.   
3,3,4,4-Tetramethyl-1-(7-phenyl-1H-imidazo[4,5-c]pyridin-4-yl)pyrrolidine-2,5-
dione (16a): This compound was synthesized in similar fashion as 16i. A solution of 15a 
(0.34 g, 1 mmol) in pyridine (10 ml) was placed in a 100 ml Schlenk flask. 
Tetramethylsuccinic anhydride (M4SA) (0.546 g, 3.5 mmol) and DBU (1.05 ml, 7 mmol) 
were added, and the mixture was heated at 120 ˚C under argon for 20 h with vigorous 
stirring. It was cooled and concentrated under reduced pressure. The residue was 
coevaporated with toluene (3 x 25 ml). The product was purified by column 
chromatography on silica gel eluting with 0-5% MeOH in CH2Cl2 to give a colorless syrup. 
It was taken in SOCl2 (12 ml), heated at 80 ˚C for 2 h, cooled and concentrated under 
reduced pressure. The residue was coevaporated with EtOAc (3 x 25 ml). The product was 
purified by column chromatography on silica gel eluting with 0-5% MeOH in CH2Cl2 to 
give 16a as a light brown foam in 92% yield (0.56 g). HRMS (ESI): m/z [M+H]+ calc’d 
for C20H21N4O2: 349.16647; found: 349.16505. 1H NMR (400 MHz, CD3OD): δ, 8.75 (s, 
1H), 8.52 (s, 1H), 7.76-7.75 (m, 2H), 7.61-7.51 (m, 3H), 1.40 (bs, 12H) ppm. 13C NMR 
(100 MHz, CD3OD): δ, 182.5, 147.9, 142.4, 139.6, 135.4, 134.4, 134.3, 130.5, 129.8, 




methylbenzoate (17a): This compound was synthesized in similar fashion as 17i. To a 
solution of 16a (0.51 g, 1.46 mmol) in dry CH3CN (60 ml) in a 100 ml round bottom flask, 
60% NaH in oil (117 mg, 2.93 mmol) was added, and the mixture was vigorously stirred 
at room temperature under argon for 45 min. 1-(α)-Chloro-3,5-di-O-(p-toluoyl)-2-deoxy-
D-ribose (0.368 g, 0.94 mmol) was subsequently added portionwise over 1 h, and the 
stirring was continued at room temperature for overall 5 h. The mixture was filtered 
through Celite® and concentrated. The product was purified by column chromatography 
on silica gel eluting with 0-50% EtOAc in hexanes. 17a was obtained as a yellowish syrup 
in 64% yield (0.64 g). HRMS (ESI): m/z [M+H]+ calc’d for C41H40N4O7: 701.29757; 
found: 701.29626. 1H NMR (400 MHz, CDCl3): δ, 8.33 (s, 1H), 8.31 (s, 1H), 7.86-7.84 (d, 
J = 8.0, 2H), 7.75-7.73 (d, J = 8.0, 2H), 7.46 (bs, 4H), 7.32-7.28 (m, 1H), 7.31-7.29 (d, J = 
8.0, 2H), 7.24-7.22 (d, J =  8.0, 2H), 5.96-5.93 (dd, J1 = 5.2, J2 = 8.8, 1H), 5.46-5.44 (m, 
1H), 4.62-4.53 (m, 2H), 4.38-4.36 (m, 1H), 2.48 (s, 3H), 2.40 (s, 3H), 2.30-2.16 (m, 2H), 
1.40 (bs, 12H) ppm. 13C NMR (100 MHz, CDCl3): δ, 181.7 (Cq), 166.2 (Cq), 165.6 (Cq), 
144.7 (Cq), 144.5 (Cq), 142.9, 142.7, 138.4 (Cq), 138.0 (Cq), 137.4 (Cq), 134.8 (Cq), 
130.0, 129.7, 129.6, 129.3, 129.0, 128.8, 126.6 (Cq), 126.4 (Cq), 123.5 (Cq), 85.9, 82.8, 
74.9, 64.2 (CH2), 48.1 (Cq), 40.1 (CH2), 21.9, 21.8, 21.6 ppm. For the critical NOESY 
correlations, see Figure S4 and copies of spectra (Supporting Information). 
1-(1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7-phenyl-1H-
imidazo[4,5-c]pyridin-4-yl)-3,3,4,4-tetramethylpyrrolidine-2,5-dione (18a): This 
compound was synthesized in similar fashion as 18i. To a solution of 17a (0.44 g, 0.63 
mmol) in dry MeOH (6 ml) in a 25 ml round bottom flask, NaOMe (102 mg, 1.89 mmol) 
was added, and the mixture was stirred at room temperature under argon for 2 h. It was 
concentrated in vacuo, and the product was purified by column chromatography on silica 
gel eluting with 0-10% MeOH in CH2Cl2 to obtain 18a as a white foam in 58% yield (0.17 
g). HRMS (ESI): m/z [M+H]+ calc’d for C25H29N4O5: 465.21383; found: 465.21228. 1H 
NMR (400 MHz, CD3OD): δ, 8.85 (s, 1H), 8.19 (s, 1H), 7.56 (m, 5H), 5.97-5.94 (t, J=6.0, 
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1H), 4.37-4.33 (m, 1H), 3.78-3.65 (m, 3H), 2.35-2.28 (m, 1H), 1.96-1.90 (ddd, J1 = 4.4, J2 
= 6.0, J3 = 10.8, 1H), 1.39 (bs, 12H) ppm. 13C NMR (100 MHz, CD3OD): δ, 183.4 (Cq), 
146.5 (Cq), 143.1, 139.4 (Cq), 138.7 (Cq), 138.6 (Cq), 135.6 (Cq), 130.9, 130.2, 129.9, 
126.0 (Cq), 88.9, 87.1, 71.2, 62.3 (CH2), 49.0 (Cq), 42.9 (CH2), 21.9, 21.8 ppm. 
The attempted tritylation of 18a was carried forward in similar fashion as for 18i. To a 
solution of 18a (0.15 g, 0.323 mmol) in pyridine (3 ml) under Ar, 4,4’-dimethoxytrityl 
chloride (DMT-Cl) (0.153 g, 0.453 mmol) was added in one portion, and the mixture was 
stirred at room temperature for 4.5 h. TLC analysis indicated that some starting material 
remained, and then additional DMT-Cl was added (0.076 g, 0.225 mmol). After 3.5 h, the 
starting material still remained, and then triethylamine (45 μl, 0.323 mmol), cat. DMAP 
(10 mg) and additional DMT-Cl (44 mg, 0.129 mmol) were added. After 8 h, most of the 
starting material was consumed, and the mixture was concentrated in vacuo, the residue 
was coevaporated with toluene (3 x 10 ml) to remove residual pyridine. A TLC analysis 
indicated that an extensive deglycosylation occurred, indicating the instability of the 
compound which may be ascribed to the electronic character of phenyl group at the position 
3 as suggested by other reports.15 Deglycosylation was also observed to occur upon mild 
heating of the TLC plate in order to remove pyridine before analysis. 
Synthesis of 3-deazahypoxanthine 21c. 
7-Phenethyl-1H-imidazo[4,5-c]pyridin-4-amine, tri-fluoroacetic acid salt (15c): This 
compound was synthesized in similar fashion as 15i. A solution of 14c (0.327 g, 0.55 mmol) 
in TFA (8 ml) was placed in a 100 ml pressure tube, anisole (0.36 ml, 6 equiv.) was added, 
and the mixture was heated at 70 ˚C for 21 h with vigorous stirring. It was cooled and 
concentrated under reduced pressure. The residue was coevaporated with toluene (3 x 15 
ml) to obtain 15c (ca. 0.2 g, quantitative) as a syrup that was taken into next step without 
further purification. 
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7-Phenethyl-1,5-dihydro-4H-imidazo[4,5-c]pyridin-4-one (21c): This compound was 
synthesized according to the general procedure.56 A solution of crude 15c (ca. 0.2 g, 0.55 
mmol) in acetone/H2O/AcOH (4/2/2 ml) was stirred at room temperature for 5 h in a closed 
vessel. The pressure was carefully released and the mixture was carefully neutralized with 
aq. NaHCO3 and diluted with Et20 (50 ml). The phases were shaken, and the precipitated 
solid was filtered, washing with water and Et20, and dried on air to obtain 21c as a light 
yellow solid (75 mg, 57% based on 14c). HRMS (ESI): m/z [M+H]+ calc’d for C14H14N3O: 
240.11369; found: 240.11281. MS (ESI): m/z, 240.3 for [M+H]+, 262.2 for for [M+Na]+, 
501.2 for for [2M+Na]+; 238.3 for [M-H]-. 1H NMR (400 MHz, DMSO-d6): δ, 10.9 (bs, 
1H), 8.09 (s, 1H), 7.26-7.16 (m, 5H), 6.79 (s, 1H), 2.93-2.89 (m, 4H) ppm. 13C NMR (100 
MHz, DMSO-d6): δ, 156.1, 141.6, 141.2, 128.4, 128.2, 125.8, 124.9, 110.7, 35.1, 29.7 ppm. 
Purification of salts 15: TFA salts 15 were used for synthetic purposes typically without 
further purification. Pure amines could be also isolated as water soluble HCl salts as 
exemplified below. Free amines could be obtained by neutralization of their aqueous 
solutions with Na2CO3 followed by extraction with AcOEt. 
7-Phenethyl-1H-imidazo[4,5-c]pyridin-4-amine, hydrochloric acid salt (15c*HCl): A 
solution of 14c (0.173 g, 0.29 mmol) in EtOH/H2O/HCl conc. (8/8/4 ml) was heated under 
reflux condenser at 100 ˚C for 23 h. It was cooled and EtOH was removed under reduced 
pressure. It was diluted with aq. HCl and washed with Et2O (40 ml, discarded) to remove 
a precipitated oil. The residue was concentrated and dried under vacuum to obtain 15c*HCl 
(ca. 0.08 g, quantitative) as an off-white solid. HRMS (ESI): m/z [M+H]+ calc’d for 
C14H15N4: 239.12968; found: 239.12930. MS (ESI): m/z, 239.3 for [M+H]+; 237.3 for [M-
H]-, 273.0 for [M+Cl]-. 1H NMR (400 MHz, D2O): δ, 8.35 (s, 1H), 7.28-7.19 (m, 4H), 7.11-
7.09 (m, 2H), 3.09-3.05 (m, 2H), 2.99-2.96 (m, 2H) ppm. 13C NMR (100 MHz, D2O): δ, 
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Appendix A Supporting Info for Chapter 2 
 
Multicolor GLUT5-Permeable Fluorescent Probes for Fructose Transport Analysis 
 
 
A.1 Supplementary Tables and Figures 
 
Table A1. Spectroscopic properties of ManCous. 
ManCou Absorbance,
a  
 λmax, nm 
Fluorescence, a  
λmax, nm 




Yield,b ΦF  
1 366 452 86 0.26 
2 360 461 101 0.30 
3 387 508 121 0.1 
4 376 506 130 0.44 
5 398 558 160 0.09 
6 371 538 167 0.21 
7 365 460 95 0.37 
8 384 459 75 0.08 
9 430 481 51 0.27 
10 382 564 182 0.06 
11 385 549 164 0.22 
12 383 554 171 0.12 
13 (2-furyl) 368 531 163 0.29 
14 (2-pyridyl) 374 535 161 0.21  
aAll data measured in water/ethanol (70:30 v/v) mixture. bAbsolute quantum yield was derived 








Table A2. Comparative analysis of UV λmax and HOMO/LUMO contribution 








1 366 -445/-186 259 1 352 -459/-190 269 
2 360 -440/-177 263 2 347 -453/-180 273 
3 387 -468/-232 236 3 372 -486/-253 233 
4 376 -441/-193 248 4 358 -453/-196 257 
5 398 -467/-217 250 5 377 -482/-223 259 
13 374 -438/-209 219 13 366 -449/-213 236 
aData provided for probes showing the uptake through GLUT5; bHOMO/LUMO orbital 
energies were calculated with Spartan ’14 V1.1.2 (Wavefunction Inc.) using Density 







Figure A1. ManCous uptake analysis. a) Concentration-dependent uptake of ManCous at 37 °C; 
b) Comparative uptake of ManCous vs. corresponding coumarins (Cou) at 20 µM concentration 
(37 °C); c) Z-stack imaged of MCF7 cells treated with 7-aminocoumarin (Cou1) at 37 °C; d) 
Comparative analysis of ManCou1 vs. Cou1 uptake at varied concentrations (37 °C); e) 
Comparative analysis of ManCou1 uptake at 37 °C vs. 4 °C. All uptake data are measured in 
triplicates in 96-well plate after 10 min incubation of cells, removal of the probe and repeated cell 
wash. Data represents the Gained Fluorescence (exc. 385 nm) measured for 20 µM solutions of 
probes. Confocal images obtained with 60X objective using exc/em 405 nm/461 nm. 
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Curve fit - ligand binding one site
f = Bmax*abs(x)/(Kd + abs(x))
Rsqr = 0.9964





Figure A2. Analysis of ManCou uptake in the presence of fructose (a and b); glucose (c); 
glucosamine (d); cytochalasin B (e); and culture media (f). All data obtained in triplicates. Data 
collected for 20 µM ManCou probe. Plots represents average data, error bars represent standart 
deviation. Data are collected after 10 min incubation of cells with ManCou in 96-well plates, removal 
of the probe, and cell wash (exc. 360 nm, em. 430 nm for ManCous 1 and 2, and em. 500 nm for 














Figure A3. Blight-field and fluorescence overlay images of ManCou-treated cells: A) Images of 
HepG2 and MCF7 cells treated with 20 µm ManCou1 (40X objective); B) Z-stack images of HepG2 
cells treated with ManCou1 and ManCou3 (20X objective). Images taken with EVOS optical 





Figure A4. Fluorescence confocal Z-stack images of MCF7 cells treated with ManCous and 
established stains. a) ManCou1 with DID membrane staining; b) ManCou3 with RedDot nuclear 
staining; c) ManCou4 with RedDot nuclear staining. ManCous imaged under exc/em 405 nm/425-


















Curve fit - ligand binding one site
A
      
Concentration, uM















Curve fit - ligand binding one site
Rsqr = 0.9723
KD = 64.97 ± 15.67 uM





















Curve fit - ligand binding one side
Kd = 74.84 ± 14.8 uM
Rsqr = 0.9818
f = Bmax*abs(x)/(Kd + abs(x))
C
    
Concentration, uM















Curve fit - ligand binding one site
Rsqr = 0.9905







Figure A5. GLUT5-ManCou uptake analysis. A-D) Binding affinity. Data derived after fitting the 
concentration-dependent change in fluorescence into the ligand binding (one site) curve 












Figure S6. ManCous as competitors for NBDM and NBDG uptake in MCF7 cells 
(Confocal, Z-stack images). a) equimolar NBDM and ManCou3; b) equimolar NBDM and 
ManCou1; c) Equimolar ManCou1 and NBDG; d) Equimolar ManCou3 and NBDG; e) 
NBDM; f) NBDG. Z-stack images taken after 10 min treatment and cell wash. Cells 
imaged with 60X objective using exc/em. 405 nm/425-525 nm for ManCous, and exc/em 
450 nm/565 nm for NBDM and NBDG (eGFP, green fluorescence). All images obtained 
at the same laser intensity and exposure time. 
 
A.2 Materials and Methods 
 
All reagents were used as received unless otherwise stated from Sigma-Aldrich, 
TCI America, Alfa Aesar, Ark Pharm, AK Scientific, Combi-Blocks or Chem-Impex 
International. Commercially available coumarins were purchased from: 7-amino-4-
methylcoumarin (Cou2), Sigma-Aldrich; 7-amino-4-(trifluoromethyl)coumarin 
(Cou3), Alfa Aesar; 2-(7-amino-2-oxo-2H-chromen-4-yl)acetic acid (Cou7), Ark 
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Pharm; 6-amino-2H-chromen-2-one (Cou8), Enamine; 7-(diethylamino)-2-oxo-
2H-chromene-3-carboxylic acid (Cou9), Combi-Blocks. N,N-Dimethylformamide 
(DMF) was dried and stored over CaH2 before use. Dry tetrahydrofuran was 
dispensed from an automated Innovative Technology Pure-Solv 400 Solvent 
Purification System. Analytical TLC was carried out on commercial SiliCycle 
SiliaPlate® 0.2 mm F254 plates. Preparative silica chromatography was performed 
using SiliCycle SiliaFlash® F60 40-63 μm (230-400 mesh). Final purification of 
compounds was achieved with Agilent-1200 HPLC (high-pressure liquid 
chromatography) using reversed phase semi-preparative column (Phenomenex® 
Luna® 10 µm C18(2) 100 Å, LC Column 100 x 10 mm, Ea). 1H and 13C NMR 
spectra were recorded at room temperature with a Varian Unity Inova 400 MHz 
spectrometer. CD3OD, DMSO-d6, and D2O were used as solvents and referenced 
to the corresponding residual solvent peaks (3.31 and 49.0 ppm for CD3OD, 
respectively; 2.50 and 39.52 ppm for DMSO-d6, respectively; 4.79 ppm for D2O).1 
The following abbreviations are used to indicate the multiplicity: s - singlet; d - 
doublet; t - triplet; q - quartet; m - multiplet; b - broad signal; app - approximate. 
The coupling constants are expressed in Hertz (Hz). The high-resolution (HR) MS 
data (ESI) were obtained using a Thermo Fisher Orbitrap Elite™ Hybrid Ion Trap-
Orbitrap Mass Spectrometer at Chemical Advanced Resolution Methods (ChARM) 
Laboratory at Michigan Technological University. UV-vis spectra were recorded on 
a Cary 100 Bio-spectrophotometer from Agilent Technologies. Fluorescence 
spectra were obtained with FluoroMax-4 spectrophotometer. 96-well plate analysis 
of cell fluorescence was carried out with Victor3 fluorescence plate reader 
(excitation at 385 nm). Confocal images were taken with Olympus FluoViewTM 
FV1000 using the FluoView software. Fluorescence imaging was done with EVOS 
FLAuto inverted microscope. 
RPMI-1640, Penicillin/Streptomycin, FBS (Fetal Bovine Serum), 25% Trypsin-
EDTA (1X), and PBS (phosphate buffered saline solution) were purchased from 
Life Technologies, USA. MEM Non-Essential Amino Acids 100X were purchased 
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from Quality Biological, USA. Sterile DMSO (25-950-CQC, 250mL) was purchased 
from Sigma. MCF7 and Hep G2 cells were purchased from ATCC, USA and 
cultured according to the suggested growth methods. 
 










Scheme A1: Synthesis of 2,5-anhydro-2-carbaldehyde-D-mannitol 2. 
 
(2S,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carbaldehyde (2):2 D-
Glucosamine hydrochloride 1 (4.00 g, 18.5 mmol) was dissolved in water (100 ml) and stirred at 
room temperature for 5 h. Sodium nitrite (3.19 g, 45.3 mmol) was then added, followed by cautious 
addition of Amberlite 120 H+ resin (90 g) by portion, maintaining the temperature of ice bath for 4 
h. After the reaction, the resin was removed by filtration and the solution was then neutralized by 
adding sodium carbonate. The remaining solution was vacuum dried and then methanol was added 
to the residue to precipitate the inorganic salts. After removing the salts by filtration, the solution 
was vacuum dried to get the compound 2 as a yellow sticky solid (2.49 g, 70%) that was used 















ManCou1-7, 10-14Cou1: R = H
Cou2: R = CH3
Cou3: R = CF3
Cou4: R = Ph
Cou5: R = CO2Et
Cou6: R = CO2H
NaBH3CN
MeOH/AcOH
Cou7: R = CH2CO2H
Cou10: R = C(O)NH2
Cou11: R = C(O)NHMe
Cou12: R = C(O)NHPh
Cou13: R = 2-furyl








































Scheme A2: Synthesis of ManCous1-14. 
General procedure for the synthesis of ManCous1-8, 10-14:3 Typically, (2S,3S,4S,5R)-3,4-
dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carbaldehyde2 (up to 1 mmol) and the 
corresponding coumarin (0.8 equiv.) were dissolved in methanol (10 ml). AcOH (1 ml) was used to 
adjust the pH to <6, followed by portionwise addition of NaBH3CN to the reaction mixture (3 X 0.8 
equiv, every 20-30 minutes). Water could also be added to improve solubility of some coumarin 
substrates (up to 20% v/v). The solutions were stirred at room temperature for up to 24 h. The 
mixtures were then concentrated to dryness under reduced pressure and purified by column 
chromatography on silica gel using CH2Cl2 : MeOH (up to 90 : 10), EtOAc : MeOH (up to 80 : 20) 
or water : isopropanol : EtOAc (1 : 2 : 7 up to 2 : 4 : 4) mixtures. The final purification was achieved 
by semi-preparative HPLC using water-acetonitrile gradient starting with 2-20% acetonitrile to 
obtain the final products as yellow solids or semi-solids, 10-30 mg samples. No attempts were 
made to optimize the yields of the products, which could be estimated as 30-40% average. The 
composition and purity of the final products was confirmed by HRMS, 1H NMR, and 13C NMR. 
7-((((2R,3S,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)methyl)amino)-
2H-chromen-2-one (ManCou1): 1H NMR (400 MHz, CD3OD): δ, 7.76-7.36 (d, J = 9.2, 1H), 7.32-
7.30 (d, J = 8.4, 1H), 6.68-6.65 (dd, J1 = 2.4, J2 = 8.4, 1H), 6.53 (d, J = 2.4, 1H), 6.01-5.99 (d, J = 
9.2, 1H), 4.02-3.98 (m, 2H), 3.95-3.92 (m, 1H), 3.88-3.85 (m, 1H), 3.73-3.69 (app dd, J1 = 3.2, J2 = 
12.0, 1H), 3.66-3.61 (app dd, J1 = 5.6, J2 = 12.0, 1H), 3.48-3.44 (app dd, J1 = 3.6, J2 = 13.6, 1H), 
3.38-3.32 (app dd, J1 = 6.8, J2 = 13.6, 1H) ppm. 13C NMR (100 MHz, CD3OD): δ, 164.7, 158.1, 
154.5, 146.5, 130.2, 112.3, 110.6, 109.1, 98.0, 85.3, 83.2, 80.3, 78.9, 63.3, 46.2 ppm. HRMS (ESI): 
m/z [M + Na]+ calcd for C15H17NNaO6: 330.09539; found 330.09434. 
7-((((2R,3S,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)methyl)amino)-
4-methyl-2H-chromen-2-one (ManCou2): 1H NMR (400 MHz, CD3OD): δ, 7.48-7.45 (dd, J1 = 3.2, 
J2 = 8.8, 1H), 6.71-6.67 (dt, J1 = 2.4, J2 = 8.8, 1H), 6.52-6.51 (t, J = 2.4, 1H), 5.93 (m, 1H), 4.02-
3.98 (m, 2H), 3.96-3.93 (m, 1H), 3.88-3.85 (m, 1H), 3.73-3.69 (app dd, J1 = 3.6, J2 = 11.6, 1H), 
3.66-3.61 (app dd, J1 = 5.6, J2 = 12.0, 1H), 3.48-3.43 (app dd, J1 = 3.6, J2 = 13.6, 1H), 3.37-3.32 
(app dd, J1 = 6.8, J2 = 13.6, 1H), 2.38 (d, J = 0.8, 3H)  ppm. 13C NMR (100 MHz, CD3OD): δ, 164.7, 
164 
157.3, 156.5, 154.4, 126.9, 112.1, 111.1, 108.6, 98.2, 85.3, 83.2, 80.3, 78.9, 63.3, 46.2, 18.5 ppm. 
HRMS (ESI): m/z [M + Na]+ calcd for C16H19NNaO6: 344.11104; found 344.11043. 
7-((((2R,3S,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)methyl)amino)-
4-(trifluoromethyl)-2H-chromen-2-one (ManCou3): 1H NMR (400 MHz, CD3OD): δ, 7.44-7.41 
(dd, J1 = 2.0, J2 = 9.2, 1H), 6.74-6.71 (dt, J1 = 2.4, J2 = 9.2, 1H), 6.60-6.59 (d, J = 2.4, 1H), 6.37 (s, 
1H), 4.02-3.98 (m, 2H), 3.95-3.92 (m, 1H), 3.89-3.85 (m, 1H), 3.73-3.69 (app dd, J1 = 3.6, J2 = 11.6, 
1H), 3.66-3.61 (app dd, J1 = 5.6, J2 = 12.0, 1H), 3.50-3.46 (app dd, J1 = 3.6, J2 = 14.0, 1H), 3.40-
3.35 (app dd, J1 = 6.4, J2 = 13.6, 1H) ppm. 13C NMR (100 MHz, CD3OD): δ, 162.2, 158.6, 155.0, 
143.3, 143.0, 124.8, 122.1, 112.8, 108.3, 104.1, 98.5, 85.4, 83.2, 80.2, 78.8, 63.3, 46.1 ppm. HRMS 
(ESI): m/z [M + H]+ calcd for C16H17F3NO6: 376.10082; found 376.09955.  
7-((((2R,3S,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)methyl)amino)-
4-phenyl-2H-chromen-2-one (ManCou4): 1H NMR (400 MHz, CD3OD): δ, 7.50-7.48 (m, 3H), 
7.42-7.39 (m, 2H), 7.15-7.13 (d, J = 8.8, 1H), 6.59-6.56 (m, 2H), 5.90 (s, 1H), 4.03-3.99 (m, 2H), 
3.97-3.94 (m, 1H), 3.90-3.86 (m, 1H), 3.74-3.70 (app dd, J1 = 3.6, J2 = 11.6, 1H), 3.66-3.61 (app 
dd, J1 = 5.6, J2 = 12.0, 1H), 3.47-3.43 (app dd, J1 = 3.6, J2 = 14.0, 1H), 3.37-3.32 (app dd, J1 = 6.8, 
J2 = 13.6, 1H) ppm. 13C NMR (100 MHz, CD3OD): δ, 164.2, 158.7, 157.9, 154.2, 137.2, 130.4, 
129.7, 129.3, 128.8, 112.0, 109.6, 108.2, 98.4, 85.2, 83.1, 80.2, 78.8, 63.2, 46.2 ppm. HRMS (ESI): 
m/z [M + Na]+ calcd for C21H21NNaO6: 406.12669; found 406.12520.  
Ethyl 7-((((2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-
yl)methyl)amino)-2-oxo-2H-chromene-4-carboxylate (ManCou5): 1H NMR (400 MHz, CD3OD): 
δ, 7.84-7.82 (d, J = 8.8, 1H), 6.64-6.61 (dd, J1 = 2.4, J2 = 8.8, 1H), 6.49-6.48 (d, J = 2.4, 1H), 6.36 
(s, 1H), 4.43-4.38 (q, J = 7.2, 2H), 4.03-3.99 (m, 2H), 3.96-3.94 (m, 1H), 3.90-3.86 (m, 1H), 3.74-
3.70 (app dd, J1 = 3.6, J2 = 11.6, 1H), 3.66-3.62 (app dd, J1 = 5.6, J2 = 12.0, 1H), 3.47-3.43 (app 
dd, J1 = 3.6, J2 = 14.0, 1H), 3.38-3.32 (app dd, J1 = 6.8, J2 = 14.0, 1H), 1.42-1.38 (t, J = 7.2, 2H) 
ppm. 13C NMR (100 MHz, CD3OD): δ, 165.8, 163.6, 158.3, 154.5, 145.3, 128.6, 112.5, 111.0, 106.9, 
98.2, 85.3, 83.1, 80.3, 78.8, 63.30, 63.25, 46.1, 14.4 ppm. HRMS (ESI): m/z [M + H]+ calcd for 
C18H22NO8: 380.13458; found 380.13345.  
7-((((2R,3S,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)methyl)amino)-
2-oxo-2H-chromene-4-carboxylic acid (ManCou6): 1H NMR (400 MHz, D2O): δ, 7.47-7.45 (d, J 
= 8.8, 1H), 6.73-6.70 (d, J = 8.8, 1H), 6.53 (s, 1H), 6.07 (m, 1H), 4.07 (bs, 3H), 3.96-3.93 (m, 1H), 
3.80-3.76 (app dd, J1 = 3.2, J2 = 12.4, 1H), 3.73-3.68 (app dd, J1 = 6.0, J2 = 12.0, 1H), 3.48-3.36 
(m, 2H) ppm. 13C NMR (100 MHz, D2O): δ, 172.6, 165.9, 156.4, 155.4, 152.8, 127.7, 112.1, 106.7, 
165 
103.4, 97.7, 82.7, 81.0, 78.4, 76.8, 61.4, 44.6 ppm. HRMS (ESI): m/z [M + H]+ calcd for C16H18NO8: 
352.10328; found 352.10300. 
2-(7-((((2R,3S,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-
yl)methyl)amino)-2-oxo-2H-chromen-4-yl)acetic acid (ManCou7): 1H NMR (400 MHz, D2O): δ, 
7.48-7.45 (d, J = 8.8, 1H), 6.77-6.74 (dd, J1 = 2.4, J2 = 8.8, 1H), 6.59 (d, J = 2.4, 1H), 6.06 (s, 1H), 
4.10 (bs, 2H), 3.98-3.94 (m, 1H), 3.81-3.65 (m, 5H), 3.54-3.46 (m, 2H) ppm. We were not able to 
obtain satisfactory 13C NMR data in D2O. HRMS (ESI): m/z [M + H]+ calcd for C17H20NO8: 
366.11893; found 366.11771. 
6-((((2R,3S,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)methyl)amino)-
2H-chromen-2-one (ManCou8): 1H NMR (400 MHz, CD3OD): δ, 7.84-7.82 (d, J = 9.2, 1H), 7.13-
7.11 (d, J = 8.8, 1H), 6.99-6.96 (dd, J1 = 2.4, J2 = 9.2, 1H), 6.80-6.79 (d, J = 2.4, 1H), 6.36-6.33 (d, 
J = 9.2, 1H), 4.03-3.96 (m, 3H), 3.89-3.85 (m, 1H), 3.74-3.70 (app dd, J1 = 3.6, J2 = 12.0, 1H), 3.66-
3.62 (app dd, J1 = 5.6, J2 = 11.6, 1H), 3.42-3.38 (app dd, J1 = 3.6, J2 = 13.6, 1H), 3.30-3.32 (app 
dd, J1 = 6.4, J2 = 13.6, 1H) ppm. 13C NMR (100 MHz, CD3OD): δ, 163.7, 147.59, 147.56, 146.1, 
120.8, 119.9, 118.0, 116.7, 109.4, 85.2, 83.2, 80.4, 78.9, 63.3, 47.3 ppm. HRMS (ESI): m/z [M + 
H]+ calcd for C15H18NO6: 308.11344; found 308.11234. 
7-(Diethylamino)-N-(((2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-
yl)methyl)-2-oxo-2H-chromene-3-carboxamide (ManCou9): This compound was synthesized 
according to the reported general procedure.4 To a solution of 1-amino-2,5-anhydro-D-mannitol2 
(100 mg, 0.61 mmol), 7-(diethylamino)-2-oxo-2H-chromene-3-carboxylic acid (120 mg, 0.46 mmol), 
1-hydroxybenzotriazole monohydrate (HOBt; 93 mg, 0.69 mmol) and diisopropylethylamine (DIEA; 
0.24 ml, 1.4 mmol) in dry DMF (4 ml), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDCI; 132 mg, 0.69 mmol) was added and the mixture was stirred at room 
temperature for 12 h. It was diluted with EtOAc (100 ml), washed with brine (3 X 20 ml), and dried 
with MgSO4. After filtration and concentration, the residue was purified by column chromatography 
on silica gel, eluting with 0-100% EtOAc in hexanes, followed by 20% MeOH in EtOAc. The final 
purification was achieved by semi-preparative HPLC using water-acetonitrile gradient starting with 
50% acetonitrile. A sample of compound was obtained as a yellow semi-solid (~20 mg). 1H NMR 
(400 MHz, CD3OD): δ, 8.60 (s, 1H), 7.53-7.51 (d, J = 9.2, 1H), 6.81-6.78 (dd, J1 = 2.4, J2 = 9.2, 
1H), 6.54-6.53 (d, J = 2.4, 1H), 4.04-3.86 (m, 4H), 3.75-3.62 (m, 4H), 3.54-3.49 (q, J = 7.2, 4H), 
1.25-1.21 (t, J = 7.2, 6H) ppm. 13C NMR (100 MHz, CD3OD): δ, 165.4, 163.8, 159.0, 154.4, 149.2, 
132.5, 111.6, 109.9, 109.4, 97.2, 85.0, 82.7, 79.8, 78.4, 63.2, 46.0, 42.3, 12.8 ppm. HRMS (ESI): 
m/z [M + H]+ calcd for C20H27N2O7: 407.18187; found 407.18109. 
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7-((((2R,3S,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)methyl)amino)-
2-oxo-2H-chromene-4-carboxamide (ManCou10): 1H NMR (400 MHz, CD3OD): δ, 7.52-7.50 (d, 
J = 8.8, 1H), 6.70-6.68 (dd, J1 = 2.4, J2 = 8.8, 1H), 6.57-6.56 (d, J = 2.4, 1H), 6.08 (s, 1H), 4.02-
3.98 (m, 2H), 3.95-3.92 (m, 1H), 3.88-3.84 (m, 1H), 3.73-3.69 (app dd, J1 = 3.6, J2 = 12.0, 1H), 
3.65-3.61 (app dd, J1 = 5.6, J2 = 12.0, 1H), 3.49-3.45 (app dd, J1 = 4.0, J2 = 13.6, 1H), 3.39-3.34 
(app dd, J1 = 6.4, J2 = 13.6, 1H) ppm. 13C NMR (100 MHz, CD3OD): δ, 170.0, 163.8, 158.3, 154.7, 
151.7, 128.2, 112.4, 106.9, 98.2, 85.3, 83.1, 80.2, 78.8, 63.2, 46.2 ppm. HRMS (ESI): m/z [M + H]+ 
calcd for C16H19N2O7: 351.11927; found 351.11826. 
7-((((2R,3S,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)methyl)amino)-
N-methyl-2-oxo-2H-chromene-4-carboxamide (ManCou11): 1H NMR (400 MHz, CD3OD): δ, 
7.46-7.44 (d, J = 8.8, 1H), 6.69-6.66 (dd, J1 = 2.4, J2 = 8.8, 1H), 6.56 (d, J = 2.4, 1H), 6.04 (s, 1H), 
4.02-3.92 (m, 3H), 3.88-3.84 (m, 1H), 3.73-3.69 (app dd, J1 = 3.6, J2 = 11.6, 1H), 3.65-3.61 (app 
dd, J1 = 5.6, J2 = 11.6, 1H), 3.49-3.45 (app dd, J1 = 3.6, J2 = 13.6, 1H), 3.39-3.33 (app dd, J1 = 6.4, 
J2 = 13.6, 1H), 2.92 (s, 3H) ppm. 13C NMR (100 MHz, CD3OD): δ, 168.4, 163.9, 158.4, 154.8, 151.9, 
128.3, 112.4, 107.1, 98.3, 85.3, 83.2, 80.3, 78.8, 63.3, 46.2, 26.5 ppm. HRMS (ESI): m/z [M + H]+ 
calcd for C17H21N2O7: 365.13492; found 365.13368. 
7-((((2R,3S,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)methyl)amino)-
2-oxo-N-phenyl-2H-chromene-4-carboxamide (ManCou12): 1H NMR (400 MHz, CD3OD): δ, 
7.70-7.67 (m, 2H), 7.50-7.47 (d, J = 9.2, 1H), 7.40-7.35 (m, 2H), 7.21-7.16 (m, 1H), 6.71-6.68 (dd, 
J1 = 2.4, J2 = 8.8, 1H), 6.59-6.58 (d, J = 2.4, 1H), 6.18 (s, 1H), 4.02-3.98 (m, 2H), 3.95-3.93 (app 
dd, J1 = 5.2, J2 = 6.0, 1H), 3.88-3.85 (m, 1H), 3.73-3.69 (app dd, J1 = 3.6, J2 = 12.0, 1H), 3.65-3.61 
(app dd, J1 = 5.6, J2 = 12.0, 1H), 3.50-3.45 (app dd, J1 = 3.6, J2 = 14.0, 1H), 3.40-3.34 (app dd, J1 
= 6.8, J2 = 14.0, 1H) ppm. 13C NMR (100 MHz, CD3OD): δ, 165.7, 163.7, 158.3, 154.7, 151.7, 139.0, 
129.9, 128.0, 126.0, 121.6, 112.4, 107.01, 106.95, 98.3, 85.3, 83.1, 80.2, 78.8, 63.2, 46.2 ppm. 
HRMS (ESI): m/z [M + H]+ calcd for C23H23N2O7: 427.15057; found 427.15000. 
7-((((2R,3S,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)methyl)amino)-
4-(furan-2-yl)-2H-chromen-2-one (ManCou13): 1H NMR (400 MHz, CD3OD): δ, 7.92-7.90 (d, J = 
8.8, 1H), 7.81-7.80 (dd, J1 = 0.4, J2 = 1.6, 1H), 7.17-7.16 (dd, J1 = 0.4, J2 = 3.6, 1H), 6.70-6.67 (m, 
2H), 6.54-6.53 (d, J = 2.4, 1H), 6.24 (s, 1H), 4.04-4.00 (m, 2H), 3.97-3.44 (app dd, J1 = 5.2, J2 = 
6.0, 1H), 3.90-3.87 (m, 1H), 3.74-3.70 (app dd, J1 = 3.6, J2 = 12.0, 1H), 3.67-3.62 (app dd, J1 = 5.6, 
J2 = 12.0, 1H), 3.49-3.44 (app dd, J1 = 3.6, J2 = 14.0, 1H), 3.39-3.34 (app dd, J1 = 6.8, J2 = 14.0, 
1H) ppm. 13C NMR (100 MHz, CD3OD): δ, 164.5, 158.1, 154.1, 150.2, 146.5, 144.6, 128.4, 115.5, 
113.3, 112.3, 107.0, 104.3, 98.5, 85.3, 83.1, 80.2, 78.8, 63.3, 46.2 ppm. HRMS (ESI): m/z [M + H]+ 
calcd for C19H20NO7: 374.12401; found 374.12338. 
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7-((((2R,3S,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)methyl)amino)-
4-(pyridin-2-yl)-2H-chromen-2-one (ManCou14): 1H NMR (400 MHz, CD3OD): δ, 8.71-8.69 (ddd, 
J1 = 1.2, J2 = 1.6, J2 = 5.2, 1H), 8.02-7.98 (dt, J1 = 1.6, J2 = 8.0, 1H), 7.66-7.64 (d, J = 8.0, 1H), 
7.56-7.53 (ddd, J1 = 0.8, J2 = 5.2, J2 = 8.0, 1H), 7.30-7.28 (d, J = 8.8, 1H), 6.63-6.60 (app dd, J1 = 
2.4, J2 = 8.8, 1H), 6.59 (d, J = 2.4, 1H), 6.09 (s, 1H), 4.02-3.99 (m, 2H), 3.96-3.93 (m, 1H), 3.89-
3.85 (m, 1H), 3.73-3.69 (app dd, J1 = 3.6, J2 = 12.0, 1H), 3.66-3.61 (app dd, J1 = 5.6, J2 = 12.0, 
1H), 3.48-3.44 (app dd, J1 = 3.6, J2 = 14.0, 1H), 3.38-3.33 (app dd, J1 = 6.8, J2 = 14.0, 1H) ppm. 
13C NMR (100 MHz, CD3OD): δ, 164.0, 158.2, 155.7, 155.6, 154.3, 150.3, 139.0, 128.8, 125.6, 
125.5, 112.2, 109.0, 108.8, 98.3, 85.2, 83.1, 80.2, 78.8, 63.2, 46.2 ppm. HRMS (ESI): m/z [M + H]+ 
calcd for C20H21N2O6: 385.14000; found 385.13907. 
 
A.4 Synthesis of Coumarins 
 



















4 5 6 Cou4: Ar = Ph
Cou13: Ar = 2-furyl




Scheme A3: Synthesis of C4-aryl coumarins Cou4 and Cous13-14. 
(3-Hydroxyphenyl)carbamic acid ethyl ester (6):6 This compound was synthesized 
according to the reported procedure.6 3-Aminophenol 4 (10.0 g, 91.6 mmol) and ethyl acetate (350 
ml) were refluxed for 1 hour with vigorous stirring.  Ethyl chloroformate 5 (11.92 g, 109.9 mmol) 
was then added via addition funnel over a 30 minute period.  The reaction mixture was refluxed for 
an additional hour and then allowed to cool to room temperature. Upon cooling a grey/white 
precipitate formed within the flask. The precipitate was removed via filtration, and washed with ethyl 
acetate (3 x 150 ml). The combined filtrates were concentrated to afford 6 as a grey solid (9.46 g, 
57%) that was used without further purification. 1H NMR (400 MHz, DMSO-d6): δ, 9.45 (s, 1H), 9.29 
(bs, 1H), 7.04-7.00 (m, 2H), 6.86-6.84 (m, 1H), 6.39-6.36 (ddd, J1 = 1.2, J2 = 2.4, J3 = 8.0, 1H), 
4.12-4.07 (q, J = 7.2, 2H), 1.24-1.21 (t, J = 7.2, 3H) ppm.  
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7-Amino-4-phenyl-2H-chromen-2-one (Cou4):7 This compound was synthesized according 
to the reported procedure.7 6 (1.00 g, 5.52 mmol) and ethyl benzoylacetate (1.27g, 6.62 mmol) 
were added to a 100 ml round-bottom flask equipped with a stir bar. 70% H2SO4 (30 ml) was added 
and the mixture was stirred at room temperature. More 70% H2SO4 was added until the reaction 
mixture turned from yellow/cloudy to amber/clear and then stirring was maintained overnight at 
room temperature. The reaction mixture was then poured over 100 ml of crushed ice to give a bright 
yellow precipitate. The solid was filtered and recrystallized from hot methanol to afford clear large 
crystals of Cou4-precursor (0.717g, 42%). 1H NMR (400 MHz, DMSO-d6): δ, 10.14 (s, 1H), 7.62-
7.61 (d, J = 2.4, 1H), 7.54-7.48 (m, 5H), 7.36-7.30 (m, 2H), 6.20 (s, 1H), 4.18-4.13 (q, J = 7.2, 2H), 
1.27-1.24 (t, J = 7.2, 3H) ppm.  
Cou4-precursor (0.408 g, 1.32 mmol) was added to a 50 ml round-bottom flask, followed by 
H2SO4 conc. (5 ml) and glacial AcOH (5 ml). The reaction mixture was heated to 125 ˚C for 2 hours 
under reflux condenser, after which it was cooled to room temperature and poured over 50 ml of 
crushed ice. The resulting suspension was neutralized till weakly basic using 4M NaOH, affording 
a yellow precipitate.  The precipitate was filtered and recrystallized from hot methanol to give Cou4 
as a fine yellow powder (0.175 g, 56%). 1H NMR (400 MHz, DMSO-d6): δ, 7.54-7.46 (m, 5H), 7.09-
7.07 (d, J = 8.8, 1H), 6.54-6.51 (app dd, J1 = 2.0, J2 = 8.8, 1H), 6.50 (d, J = 2.0, 1H), 6.24 (bs, 2H), 
5.90 (s, 1H) ppm. 13C NMR (100 MHz, DMSO-d6): δ, 160.3, 156.0, 155.6, 153.1, 135.5, 129.2, 
128.6, 128.1, 127.6, 111.3, 107.2, 107.0, 98.8 ppm. HRMS (ESI): m/z [M + H]+ calcd for C15H12NO2: 
238.08681; found 238.08597. 
7-Amino-4-(furan-2-yl)-2H-chromen-2-one (Cou13): This compound was synthesized 
according to the reported general procedure.8 6 (1.00g, 5.52 mmol) and 3-furan-2-yl-3-oxo-
propionic acid ethyl ester (1.27 g, 6.62 mmol) were added to a 50 ml round-bottom flask equipped 
with a stir bar. Methanesulfonic acid (10 ml) was added and the mixture was stirred at room 
temperature for overnight while the colour turned from clear/amber to black. The reaction mixture 
was then poured over 50 ml of ice water. It was then extracted with ethyl acetate (3 x 75 ml), and 
the combined organics were washed with brine (2 x 50 ml) and dried over Na2SO4. After filtration 
and concentration, a brown solid was obtained which was then recrystallized from hot methanol to 
afford Cou13-precursor as grey-black crystals (0.446 g, 27 %). 1H NMR (400 MHz, DMSO-d6): δ, 
10.18 (s, 1H), 8.16-8.14 (d, J = 8.8, 1H), 8.05-8.04 (d, J = 1.6, 1H), 7.59 (d, J = 2.0, 1H), 7.47-7.46 
(d, J = 3.6, 1H), 7.44-7.42 (dd, J1 = 2.0, J2 = 8.8, 1H), 6.80-6.78 (dd, J1 = 1.6, J2 = 3.6, 1H), 6.53 (s, 
1H), 4.20-4.14 (q, J = 7.2, 2H), 1.28-1.25 (t, J = 7.2, 3H) ppm. 13C NMR (100 MHz, DMSO-d6): δ, 
159.8, 154.6, 153.1, 147.6, 146.2, 142.8, 140.9, 127.0, 115.3, 114.3, 112.7, 110.0, 107.6, 104.7, 
60.7, 14.4 ppm. 
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Cou13-precursor (1.00 g, 3.34 mmol) was added to a 50 ml round-bottom flask, followed by 
H2SO4 conc. (5 ml) and glacial AcOH (5 ml). The reaction mixture was heated to 125 ˚C for 2 hours 
under reflux condenser, after which it was cooled to room temperature and poured over 50 ml of 
crushed ice. The resulting suspension was neutralized till weakly basic using 4M NaOH, extracted 
with ethyl acetate (3 x 75 ml) and dried over Na2SO4. After filtration and concentration, the residue 
was purified by column chromatography on silica gel (dry loading), eluting with 40-100% EtOAc in 
hexanes, followed by 5% MeOH in EtOAc. The residue was triturated with hexanes containing little 
CH2Cl2. The product was filtered, washed with hexanes and dried in air to obtain Cou13 as a yellow-
brown powder (0.11 g, 14%). 1H NMR (400 MHz, DMSO-d6): δ, 8.02 (s, 1H), 7.92-7.90 (d, J = 8.4, 
1H), 7.36 (s, 1H), 6.76 (s, 1H), 6.63-6.61 (d, J = 8.4, 1H), 6.48 (s, 1H), 6.26 (bs, 2H), 6.24 (s, 1H) 
ppm. 13C NMR (100 MHz, DMSO-d6): δ, 160.7, 156.4, 153.2, 148.6, 145.9, 142.0, 127.5, 114.7, 
112.6, 111.6, 104.6, 103.3, 99.1 ppm. HRMS (ESI): m/z [M + H]+ calcd for C13H10NO3: 228.06608; 
found 228.06500. 
7-Amino-4-(pyridin-2-yl)-2H-chromen-2-one (Cou14): This compound was synthesized 
according to the reported general procedure.8 6 (2.00 g, 11.03 mmol) and ethyl 3-oxo-3-(pyridin-2-
yl)propanoate (2.56 g, 13.24 mmol) were added to a 50 ml round-bottom flask with a stir bar. 
Methanesulfonic acid (10 ml) was added and the mixture was stirred at room temperature for 
overnight while the colour turned from clear/amber to black. The reaction mixture was then poured 
over 50 ml of ice water. It was then extracted with ethyl acetate (3 x 75 ml), and the combined 
organics were washed with brine (2 x 50 ml) and dried over Na2SO4. After filtration and 
concentration, a grey solid was obtained which was then recrystallized from hot methanol to afford 
Cou14-precursor as fine white crystals of 1 : 1 MeOH solvate (1.403 g, 41 %). 1H NMR (400 MHz, 
DMSO-d6): δ, 10.17 (s, 1H), 8.78-8.76 (ddd, J1 = 1.2, J2 = 2.0, J2 = 8.8, 1H), 8.03-8.00 (dt, J1 = 2.0, 
J2 = 8.0, 1H), 7.77-7.75 (m, 1H), 7.70-7.68 (d, J = 8.8, 1H), 7.64-7.63 (d, J = 2.0, 1H), 7.58-7.54 
(m, 1H), 7.36-7.34 (dd, J1 = 2.0, J2 = 8.8, 1H), 4.19-4.14 (q, J = 7.2, 2H), 4.11-4.07 (q, J = 5.2, 1H), 
3.18-3.16 (d, J = 5.2, 3H), 1.28-1.24 (t, J = 7.2, 3H) ppm. 13C NMR (100 MHz, DMSO-d6): δ, 159.8, 
154.6, 153.3, 153.1, 152.2, 149.3, 142.8, 137.5, 127.8, 124.4, 124.2, 114.1, 112.7, 112.0, 104.6, 
60.7, 48.6, 14.4 ppm. 
Cou14-precursor (0.50 g, 1.61 mmol) was added to a 50 ml round-bottom flask, followed by 
H2SO4 conc. (5 ml) and glacial AcOH (5 ml). The reaction mixture was heated to 125 ˚C for 2 hours 
under reflux condenser, after which it was cooled to room temperature and poured over 50 ml of 
crushed ice. The resulting suspension was neutralized till weakly basic using 4M NaOH, affording 
a beige precipitate. The precipitate was filtered and recrystallized from hot methanol to give Cou14 
as fine yellow crystals (0.162 g, 68%). 1H NMR (400 MHz, CD3OD): δ, 8.72-8.70 (ddd, J1 = 1.2, J2 
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= 1.6, J2 = 4.8, 1H), 8.04-8.00 (dt, J1 = 2.0, J2 = 8.0, 1H), 7.69-7.66 (dt, J1 = 1.2, J2 = 8.0, 1H), 7.58-
7.54 (ddd, J1 = 0.8, J2 = 4.8, J2 = 8.0, 1H), 7.29-7.26 (app dd, J1 = 3.2, J2 = 6.4, 1H), 6.60-6.57 (m, 
2H), 6.11 (s, 1H) ppm. 13C NMR (100 MHz, CD3OD): δ, 164.1, 158.2, 156.0, 155.8, 155.0, 150.5, 
139.2, 129.2, 125.7, 125.6, 113.2, 109.2, 109.1, 100.7 ppm. HRMS (ESI): m/z [M + H]+ calcd for 
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Scheme A4: Synthesis of Cou5. 
Ethyl 7-amino-2-oxo-2H-chromene-4-carboxylate (Cou5):9 3-Aminophenol (4) (5.00 g, 45.8 
mmol), diethyl oxaloacetate sodium salt (8) (14.4 g, 68.7 mmol) and EtOH (20 ml) were heated at 
reflux overnight. The mixture was cooled and concentrated to dryness and the residue was purified 
by silica gel chromatography (50% EtOAc in hexanes). Cou5 was obtained as an yellow-orange 
solid (4.17 g, 39%). 1H NMR (400 MHz, DMSO-d6): δ, 7.69-7.66 (d, J = 8.8, 1H), 6.60-6.57 (dd, J1 
= 2.4, J2 = 8.8, 1H), 6.46-6.45 (d, J = 2.4, 1H), 6.37 (bs, 2H), 6.31 (s, 1H), 4.39-4.33 (q, J = 7.2, 
1H), 1.35-1.31 (t, J = 7.2, 1H) ppm. 13C NMR (100 MHz, DMSO-d6): δ, 164.3, 160.3, 156.5, 153.6, 
143.8, 127.4, 111.8, 109.2, 104.4, 98.8, 62.0, 13.9 ppm. HRMS (ESI): m/z [M + H]+ calcd for 
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Scheme A5: Synthesis of Cou6 and Cous10-12. 
7-Amino-2-oxo-2H-chromene-4-carboxylic acid (Cou6):9 Ethyl 7-amino-2-oxo-2H-
chromene-4-carboxylate (Cou5) (1.00 g, 4.30 mmol) and 2M KOH solution (25 ml) were added to 
the flask and refluxed for 4 h. After cooling, the reaction mixture was washed with AcOEt (25 ml, 
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discarded). AcOH was used to neutralize the solution that was concentrated to dryness. The 
residue was purified by column chromatography on silica gel, eluting with water : isopropanol : 
EtOAc mixtures (1 : 2 : 7 to 2 : 4 : 4). The residue was triturated with CH2Cl2 containing little EtOH, 
and then refluxed in CHCl3 overnight. The product was filtered, washed with CHCl3 and dried in air 
to obtain orange solid (0.38 g, 43%) in satisfying purity. 1H NMR (400 MHz, DMSO-d6): δ, 7.73-
7.70 (d, J = 8.8, 1H), 6.53-6.50 (dd, J1 = 2.0, J2 = 8.8, 1H), 6.40 (d, J = 2.0, 1H), 5.93 (s, 1H) ppm. 
13C NMR (100 MHz, DMSO-d6): δ, 167.1, 161.6, 156.3, 152.6, 128.6, 111.0, 106.2, 104.8, 98.4 
ppm. HRMS (ESI): m/z [M + H]+ calcd for C10H8NO4: 206.04535; found 206.04487. 
7-Amino-2-oxo-2H-chromene-4-carboxamide (Cou10): This compound was synthesized 
according to the modified general procedure.10 Cou5 (1.00 g, 4.30 mmol) was placed in the flame-
dried flask under the flow of Ar. Then 7N NH3 in absolute MeOH (20 ml) was added and the mixture 
was allowed to react at room temperature under Ar for 24 h. Then the mixture was concentrated to 
dryness. The residue was purified by column chromatography on silica gel, eluting with 100% 
CH2Cl2 to 100% EtOAc, followed by 10-40% MeOH in EtOAc. The residue was triturated with 
CH2Cl2, and filtered washing sequentially with CH2Cl2, water, ethanol, again CH2Cl2 and dried in 
air. The product was obtained as a yellow solid (0.12 g, 14%). 1H NMR (400 MHz, DMSO-d6): δ, 
8.16 (bs, 1H), 7.83 (bs, 1H), 7.43-7.41 (d, J = 8.8, 1H), 6.57-6.55 (dd, J1 = 2.0, J2 = 8.8, 1H), 6.44 
(d, J = 2.0, 1H), 6.27 (bs, 2H), 5.99 (s, 1H) ppm. 13C NMR (100 MHz, DMSO-d6): δ, 166.8, 160.8, 
156.4, 153.5, 150.2, 127.6, 111.6, 105.5, 105.0, 98.7 ppm. HRMS (ESI): m/z [M + H]+ calcd for 
C10H9N2O3: 205.06134; found 205.06064. 
7-Amino-N-methyl-2-oxo-2H-chromene-4-carboxamide (Cou11): This compound was 
synthesized according to the modified general procedure.10 Cou5 (1.00 g, 4.30 mmol) was placed 
in the flame-dried flask under the flow of Ar. 33 wt. % CH3NH2 in MeOH (20 ml) was added and the 
mixture was allowed to react at room temperature under Ar for 24 h. Then the mixture was 
concentrated to dryness. The residue was purified by column chromatography on silica gel, eluting 
with 50-100% EtOAc in hexanes, followed by 10% MeOH in EtOAc. The residue was stirred 
overnight in CH2Cl2/EtOAc, filtered, washed with CH2Cl2 and dried in air. The product was obtained 
as a yellow solid (0.08 g, 9%). 1H NMR (400 MHz, DMSO-d6): δ, 8.66 (d, J = 4.0, 1H), 7.38-7.36 
(d, J = 8.8, 1H), 6.56-6.54 (d, J = 8.8, 1H), 6.44 (s, 1H), 6.28 (bs, 2H), 5.98 (s, 1H), 2.77 (d, J = 4.0, 
3H) ppm. 13C NMR (100 MHz, DMSO-d6): δ, 165.0, 160.5, 156.2, 153.4, 150.0, 127.5, 111.5, 105.6, 
105.0, 98.6, 25.8 ppm. HRMS (ESI): m/z [M + H]+ calcd for C11H11N2O3: 219.07699; found 
219.07602. 
7-Amino-2-oxo-N-phenyl-2H-chromene-4-carboxamide (Cou12): This compound was 
synthesized according to the modified general procedure.11 A solution of aniline (0.729 ml, 8 mmol) 
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in dry THF (20 ml) was cooled to 0 ˚C under Ar and a commercial 2.0 M solution of 
trimethylaluminum in hexanes (10 ml, 20 mmol) was added dropwise over 10 minutes. Then, to the 
resulting mixture a solution of Cou5 (0.932 g, 4 mmol) in dry THF (40 ml) was added dropwise over 
20 minutes at 0 ˚C. The mixture was allowed to warm to rt and stirred for overall 22 h. It was diluted 
with EtOAc (100 ml) and carefully neutralized with aq. NH4Cl (100 ml) with vigorous stirring. The 
phases were separated, and the aqueous phase was additionally extracted with EtOAc (100 ml). 
The combined organic extracts were washed with brine (50 ml) and dried over MgSO4. After 
filtration and concentration, the residue was purified by column chromatography on silica gel, 
eluting with 0-80% EtOAc in hexanes. The product was further purified by recrystallization from 
EtOAc and filtered washing copiously with CH2Cl2 to obtain an orange solid (0.165 g, 14%). 1H 
NMR (400 MHz, DMSO-d6): δ, 10.7 (bs, 1H), 7.74-7.72 (d, J = 8.0, 2H), 7.39-7.36 (m, 3H), 7.16-
7.13 (t, J = 7.2, 1H), 6.60-6.58 (d, J = 8.0, 1H), 6.49 (s, 1H), 6.34 (bs, 2H), 6.20 (s, 1H) ppm. 13C 
NMR (100 MHz, DMSO-d6): δ, 163.2, 160.5, 156.2, 153.5, 149.6, 138.2, 128.7, 127.2, 124.2, 119.9, 
111.7, 105.8, 104.8, 98.6 ppm. HRMS (ESI): m/z [M + H]+ calcd for C16H13N2O3: 281.09264; found 
281.09189. 
A.5 Cell Imaging 
For confocal microscopy cells were plated (100,000/plate) in 35 mm glass-bottom confocal 
dishes (MatTek) and allowed to grow in their respective growth media for 24 hours. For optical 
microscope analysis cells were plated in a 6-well plates (3 x 105) and allowed to adhere and grow 
for 24 h. For treatment, cell media was removed and ManCou solution in PBS (1 ml) was added. 
Cells were incubated with ManCous at 37 Co for 10 min. After incubation, probe solution was 
removed, and cells were washed with warmed PBS (3 x 1 ml) and leaving 1 ml of PBS for imaging. 
Cell images were taken using Olympus FluoViewTM FV1000 using the FluoView software. 60X oil 
suspended lens was used to observe fluorescent activity with the following conditions: DAPI 
(ManCous) and eGFP (NBDM and NBDG) filters; lasers 405 nm (45% intensity), 450/490 nm (30% 
intensity); 10 µs/pixel. Z-stacking was done using FluoView software and depth command.  
A.6 Microplate uptake and inhibition assays 
For microplate assays, at ~80% confluence cells were collected and plated in 96-well flat 
bottom plates (20,000 cells/well) and allowed to grow for 24 hours. Cells were then washed with 
warmed (37 ˚C) PBS solution, treated with ManCou probes (concentration varies) in PBS and 
incubated at 37 ˚C and 5% CO2 for 10 min. After incubation, cells were carefully washed with 
warmed PBS (3 x 100 µl). Fluorescent data were immediately collected using Victor3 plate reader 
173 
and using WallacTM umbelliferone (excitation 355 nm, emission 460 nm, 1.0 s) protocol. All trials 
were done in triplicate on each plate. 
Uptake Inhibition studies were carried out in microplate format. Using 96-well plate method 
fluorescence of ManCou probes in cells was measured in the presence of varying concentrations 
of fructose, glucose, glucosamine, and cytochalasin B. For this part, PBS solution containing 20 
µM ManCou and the specific concentration of a sugar were prepare and introduced to cells. 
Separately, complete culture media were used to establish the impact of nutrients on ManCou 
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A.9 HRMS data for ManCou3. 
Figure A56. HRMS data for ManCou1. 
 
Figure A57. HRMS data for ManCou2. 
 
   
      
MCH_2 #1-50 RT: 0.01-0.77 AV: 50 NL: 1.11E6
T: FTMS + p ESI Full ms [200.00-400.00]



















































ManCouCh3_FT240K #8-48 RT: 0.16-1.03 AV: 41 NL: 7.60E4
T: FTMS + p ESI Full ms [200.00-500.00]




































Figure A58. HRMS data for ManCou3. 
Figure A59. HRMS data for ManCou4. 
 
 
MCPh #1-49 RT: 0.00-0.71 AV: 49 NL: 4.96E6
T: FTMS + p ESI Full ms [300.00-500.00]












































   
   
MC3_240K #1-49 RT: 0.01-0.70 AV: 49 NL: 2.35E6
T: FTMS + p ESI Full ms [200.00-600.00]



















































Figure A60. HRMS data for ManCou5.  
 
Figure A61. HRMS data for ManCou6.  
 
MCester #1-49 RT: 0.01-0.82 AV: 49 NL: 9.16E5
T: FTMS + p ESI Full ms [300.00-500.00]













































Sample2_FT240K #1-70 RT: 0.00-0.97 AV: 70 NL: 1.51E6
T: FTMS + p ESI Full ms [300.00-400.00]
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Figure A62. HRMS data for ManCou7. 
 
Figure A63. HRMS data for ManCou8.  
   
MEmethylcooh #1-49 RT: 0.01-0.87 AV: 49 NL: 3.88E5
T: FTMS + p ESI Full ms [300.00-500.00]


















































Sample13_FT240K #1 RT: 0.01 AV: 1 NL: 8.25E6
T: FTMS + p ESI Full ms [280.00-400.00]














































Figure A64. HRMS data for ManCou9.  
Figure A65. HRMS data for ManCou10. 
Sample14_FT240K #1 RT: 0.01 AV: 1 NL: 5.40E6
T: FTMS + p ESI Full ms [380.00-500.00]




















































Sample15_FT240K #1 RT: 0.00 AV: 1 NL: 3.48E6
T: FTMS + p ESI Full ms [320.00-420.00]









































Figure A66. HRMS data for ManCou11. 
 
Figure A67. HRMS data for ManCou12.  
   
Sample15_FT240K #1 RT: 0.00 AV: 1 NL: 3.48E6
T: FTMS + p ESI Full ms [320.00-420.00]








































Sample3_FT240K #2-70 RT: 0.02-0.96 AV: 69 NL: 1.21E6
T: FTMS + p ESI Full ms [350.00-500.00]












































Figure A68. HRMS data for ManCou13. 
Figure A69. HRMS data for ManCou14.  
 
Sample4_FT240K #2-69 RT: 0.02-1.05 AV: 68 NL: 8.05E5
T: FTMS + p ESI Full ms [300.00-450.00]












































Sample5_FT240K_2 #3-69 RT: 0.04-0.99 AV: 67 NL: 3.80E6
T: FTMS + p ESI Full ms [300.00-450.00]







































Appendix B Supporting Info for Chapter 5 
 
 Tuning Cross-Coupling Approaches to C3-Modification of 3-Deazapurines 
B.1 General Methods 
All reagents were used as received unless otherwise stated from Sigma-Aldrich, TCI 
America, Alfa Aesar, AK Scientific or Chem-Impex International. 4-Chloro-1H-
imidazo[4,5c]pyridine was obtained from MolBridge. Bis(4-methoxybenzyl)amine and 
TPPTS were obtained from Ark Pharm. 1-(α)-Chloro-3,5-di-O-(p-toluoyl)-2-deoxy-D-
ribose was purchased from Berry & Associates. Anhydrous methanol, pyridine, and N,N-
dimethylacetamide (DMA) were obtained from Sigma-Aldrich. N,N-dimethylformamide 
(DMF) and 1,4-dioxane were dried and stored over CaH2 before use. Dry acetonitrile, 
dichloromethane, and tetrahydrofuran were dispensed from an automated Innovative 
Technology Pure-Solv 400 Solvent Purification System. Analytical TLC was carried out 
on commercial SiliCycle SiliaPlate® 0.2 mm F254 plates. Preparative silica 
chromatography was performed using SiliCycle SiliaFlash® F60 40-63 µm (230-400 
mesh). 1H, 13C and 31P NMR spectra were recorded at room temperature with a Varian 
Unity Inova 400 MHz spectrometer. CDCl3, DMSO-d6, CD3OD, acetone-d6 and D2O were 
used as solvents and referenced to the corresponding residual solvent peaks (7.26 and 77.16 
ppm for CDCl3, respectively; 2.50 and 39.52 ppm for DMSO-d6, respectively; 3.31 and 
49.0 ppm for CD3OD, respectively; 2.05 and 29.84 ppm for acetone-d6, respectively; 4.79 
ppm for D2O).1 The following abbreviations are used to indicate the multiplicity: s - singlet; 
d - doublet; t - triplet; q - quartet; m - multiplet; b - broad signal; app - approximate. The 
coupling constants are expressed in Hertz (Hz). The multiplicity of carbon atoms was 
determined by DEPT-135 experiment; Cq - quaternary carbon. MS data (ESI) were 
obtained using a Thermo Finnigan LCQ Advantage Ion-Trap Mass Spectrometer. The 
high-resolution (HR) MS data (ESI) were obtained using a Thermo Fisher Orbitrap Elite™ 
Hybrid Ion Trap-Orbitrap Mass Spectrometer at Chemical Advanced Resolution Methods 
(ChARM) Laboratory at Michigan Technological University.   
231 
B.2 Synthesis and Characterization Data 
Compounds 1,2 4,1,3 and 5b4 were prepared according to the reported procedures. 
 
7-Iodo-1H-imidazo[4,5c]pyridin-4-amine (2) 
To a suspension of crude amine 1 (536 mg, ca. 4 mmol) in dry DMF (8 ml), 
N-iodosuccinimide (NIS) (1.125 g, 5 mmol) was added in one portion. 
Slightly exothermic reaction occurred, and the resulting dark solution was stirred at room 
temperature for 24 h. After 24 h, the solution was added dropwise to EtOAc (100 ml) with 
vigorous stirring, and the resulting solid was filtered and washed with EtOAc. The solid 
was then suspended in chloroform (50 ml) and vigorously stirred under reflux condenser 
at 70 ˚C overnight. After filtration and drying on air, 2 was obtained as a dark brown solid 
in 27% yield (0.27 g). HRMS (ESI): m/z [M+H]+ calc’d for C6H4N4I: 260.96373; found: 
260.96323. MS (ESI): m/z, 261.2 for [M+H]+. 1H NMR (400 MHz, DMSO-d6): δ, 8.49 (s, 
1H), 8.44 (bs, 2H), 7.97 (s, 1H) ppm. We were not able to obtain satisfactory 13C NMR 
data in DMSO-d6. 
7-Phenyl-1H-imidazo[4,5c]pyridin-4-amine (3a) 
This compound was synthesized according to the reported general 
procedures.5-7 To a vial equipped with septa a mixture of deionized 
water/acetonitrile (2/1, 9 ml) was added and bubbled with argon for 10 min. 
2 (150 mg, 0.58 mmol), phenylboronic acid (88 mg, 0.72 mmol), palladium(II) acetate (7 
mg, 0.029 mmol), TPPTS (41 mg; 0.072 mmol) and anhydrous sodium carbonate (183 mg; 
1.7 mmol) were added, and the headspace of the vial was flushed with argon for 1 minute. 
The mixture was vigorously stirred at 100 ˚C for 7 h. The mixture was then cooled and 
diluted with ethyl acetate (50 ml) and brine (10 ml). The phases were separated, and the 
aqueous phase was extracted with additional ethyl acetate (3 x 30 ml). Combined organic 
extracts were dried with MgSO4. After filtration and concentration, the residue was purified 












3a as a yellow solid in 65% yield (79 mg). HRMS (ESI): m/z [M+H]+ calc’d for C12H11N4: 
211.09838; found: 211.09680. MS (ESI): m/z, 211.3 for [M+H]+. 1H NMR (400 MHz, 
DMSO-d6): δ, 8.20 (s, 1H), 7.85 (s, 2H), 7.73 (b, 2H), 7.48-7.44 (m, 2H), 7.34-7.30 (m, 
1H), 6.46 (b, 2H) ppm. 13C NMR (100 MHz, DMSO-d6): δ, 141.3, 137.5, 136.1, 128.7, 
127.3, 126.5 ppm.  
 
(E)-7-Styryl-1H-imidazo[4,5-c]pyridin-4-amine (3b) 
This compound was synthesized in similar fashion as 3a. To a vial equipped 
with septa a mixture of deionized water/acetonitrile (2/1, 6 ml) was added 
and bubbled with argon for 10 min. 2 (100 mg, 0.38 mmol), trans-2-
phenylvinylboronic acid (71 mg, 0.48 mmol), palladium(II) acetate (5 mg, 
0.019 mmol), TPPTS (28 mg; 0.048 mmol) and anhydrous sodium carbonate (122 mg; 1.2 
mmol) were added, and the headspace of the vial was flushed with argon for 1 minute. The 
mixture was vigorously stirred at 100 ˚C for 16 h. The mixture was then cooled and diluted 
with ethyl acetate (40 ml) and brine (10 ml). The phases were separated, and the aqueous 
phase was extracted with additional ethyl acetate (3 x 20 ml). Combined organic extracts 
were dried with MgSO4. After filtration and concentration, the residue was purified by 
column chromatography on silica gel, eluting with 0-10% MeOH in CH2Cl2 to obtain 3b 
as a cream solid in 58% yield (52 mg). HRMS (ESI): m/z [M+H]+ calc’d for C14H13N4: 
237.11403; found: 211.11269. 1H NMR (400 MHz, DMSO-d6): δ, 8.28 (s, 1H), 7.89 (s, 
1H), 7.58-7.56 (m, 2H), 7-38-7.31 (m, 4H), 7.23-7.20 (m, 1H), 6.52 (b, 2H) ppm. 13C NMR 
(100 MHz, DMSO-d6): δ, 141.1, 139.7, 138.2, 128.6, 126.8, 125.8, 124.0 ppm. 
 









To the suspension of 3-nitropyridine-2,4-diol 7 (10 g, 64.1 mmol) in 
glacial acetic acid (100 ml), bromine (4.6 ml, 90 mmol) was added in 
one portion, and the mixture was stirred at 70 ˚C for 2.5 h. Reaction 
mixture was then cooled and poured onto 300 ml of crushed ice, stirred vigorously for 30 
min., and chilled in the freezer for 1 h. The precipitated solids were filtered on paper, 
washed with small volume of ice-cold water several times, then ethanol (3 x 15 ml), and 
dried on air. 8 was obtained as a yellow solid in 74% yield (11.2 g). 1H NMR (400 MHz, 
DMSO-d6): δ, 7.86 (s, 1H) ppm. 13C NMR (100 MHz, DMSO-d6): δ, 159.1, 155.6, 138.6, 
128.2, 94.0 ppm.  
5-Bromo-2,4-dichloro-3-nitropyridine (9) 
A suspension of 8 (11.1 g, 47.4 mmol) in POCl3 (100 ml) was stirred at 
90 ˚C for 24 h under argon, an excess pressure being released several 
times within first few hours. Then POCl3 was carefully distilled off 
under vacuum. The oily residue was diluted with Et2O (100 ml), cooled on an ice bath and 
crushed ice (200 ml) was carefully added (exothermic reaction). The phases were 
separated, aqueous phase was additionally extracted with Et2O (2 x 50 ml), the combined 
organics were washed with brine, and dried with MgSO4. After filtration and concentration, 
the residue was purified by column chromatography on silica gel, eluting with 0-10% 
EtOAc in hexanes to obtain 9 as a yellow oil that slowly solidified (9.27 g, 72% yield). 1H 
NMR (400 MHz, CDCl3): δ, 8.68 (s, 1H) ppm. 13C NMR (100 MHz, CDCl3): δ, 152.1, 
141.5, 137.8, 121.3 ppm. 
5-Bromo-2-chloro-N-(4-methoxybenzyl)-3-nitropyridin-4-amine (10) 
To the solution of 9 (9.25 g, 34.3 mmol) in dry DMF (50 ml) at 0 ˚C 
under argon, 4-methoxybenzylamine (4.7 ml, 36 mmol) was added in 
one portion, followed by dropwise addition of Et3N (5.5 ml, 36 mmol) 
over 5 minutes. The mixture was allowed to warm up to room temperature and stirred for 
24 h. The mixture was then diluted with EtOAc (300 ml), washed with brine (4 x 100 ml), 














yellow solid that was triturated with hexanes to give 10 as a dark orange solid (12.1 g, 95% 
yield). HRMS (ESI): m/z [M+H]+ calc’d for C13H1279Br35ClN3O3: 371.97507; found: 
371.97488. 1H NMR (400 MHz, CDCl3): δ, 8.23 (s, 1H), 7.24-7.22 (d, J = 8.4, 2H), 6.93-
6.91 (d, J = 8.4, 2H), 5.24 (bs, 1H), 4.22-4.21 (d, J = 4.8, 2H), 3.82 (s, 3H) ppm. 13C NMR 
(100 MHz, CDCl3): δ, 160.1 (Cq), 149.3, 143.4 (Cq), 143.3 (Cq), 129.7, 127.9 (Cq), 114.8, 
109.4 (Cq), 55.5, 47.0 (CH2) ppm.  
 
5-Bromo-N2,N2,N4-tris(4-methoxybenzyl)-3-nitropyridine-2,4-diamine (11) 
A 250 ml Schlenk tube was charged with 10 (12.1 g, 32.6 mmol), 
bis(4-methoxybenzyl)amine (10.9 g, 42.4 mmol), n-butanol (100 
ml) and Et3N (6 ml, 43.1 mmol). The mixture was heated at 130 ˚C 
for 24 h. It was cooled, diluted with EtOAc (400 ml), washed with brine (200 ml), and 
dried with MgSO4. After filtration, the solution was concentrated to give a dark residue 
that was purified by column chromatography on silica gel, eluting with 0-15% EtOAc in 
hexanes to obtain 11 as a red foam (17.6 g, 92% yield). HRMS (ESI): m/z [M+H]+ calc’d 
for C29H3079BrN4O5: 593.13999; found: 593.13894. 1H NMR (400 MHz, CDCl3): δ, 8.09 
(s, 1H), 7.21-7.18 (d, J = 8.8, 2H), 7.08-7.05 (d, J = 8.8, 4H), 6.88-6.86 (d, J = 8.8, 2H), 
6.82-6.80 (d, J  = 8.8, 4H), 6.14-6.12 (t, J = 4.8, 1H), 4.46-4.45 (d, J = 4.8, 2H), 4.29 (s, 
4H), 3.782 (s, 3H), 3.778 (s, 6H) ppm. 13C NMR (100 MHz, CDCl3): δ, 159.6 (Cq), 159.0 
(Cq), 155.5 (Cq), 151.1, 146.5 (Cq), 129.7, 129.5 (Cq), 129.4, 129.2 (Cq), 126.0 (Cq), 
114.5, 113.9, 99.6 (Cq), 55.4, 55.3, 53.7 (CH2), 49.2 (CH2) ppm.  
 
5-Bromo- N2,N2,N4-tris(4-methoxybenzyl)pyridine-2,3,4-triamine (12) 
A 1 L round bottom flask was charged with 11 (16.7 g, 28.2 mmol), 
ethanol (600 ml) and deionized water (300 ml), followed by 










85 ˚C under reflux condenser. Additional sodium hydrosulfite was added at 30 min. 
intervals (overall, 4 x 2 equiv.) over 2.5 h. The mixture was then concentrated in vacuo to 
remove most of ethanol, and diluted with EtOAc (200 ml). It was carefully neutralized with 
solid NaHCO3 (effervescence!) with vigorous stirring. The organic layer was separated, 
the aqueous phase was additionally extracted with EtOAc (2 x 150 ml) and the combined 
organics were washed with brine (100 ml), and dried with MgSO4. After filtration and 
concentration, the residue was purified by column chromatography on silica gel, eluting 
with 0-60% EtOAc in hexanes, and the product was additionally triturated with hexanes 
containing some EtOAc to obtain 12 as a cream solid in 59% yield (9.4 g). This compound 
is somewhat unstable and should be used within few days. HRMS (ESI): m/z [M+H]+ 
calc’d for C29H3279BrN4O3: 563.1658; found: 563.16396. 1H NMR (400 MHz, CDCl3): δ, 
7.77 (s, 1H), 7.22-7.20 (d, J = 8.8, 2H), 7.10-7.08 (d, J = 8.8, 4H), 6.84-6.82 (d, J = 8.8, 
2H), 6.81-6.79 (d, J = 8.8, 4H), 4.25-4.24 (d, J = 6.8, 2H), 4.14 (s, 4H), 4.00 (bs, 2H), 3.78 
(s, 9H) ppm. 13C NMR (100 MHz, CDCl3): δ, 159.1 (Cq), 158.8 (Cq), 150.2 (Cq), 139.8 
(Cq), 138.3, 131.6 (Cq), 130.7 (Cq), 130.1, 129.9 (Cq), 129.2, 114.1, 113.7, 110.8 (Cq), 
55.36, 55.34, 53.5 (CH2), 48.7 (CH2) ppm.  
 
7-Bromo-N,N,1-tris(4-methoxybenzyl)-1H-imidazo[4,5-c]pyridin-4-amine (13) 
A 250 ml Schlenk tube was charged with 12 (9.4 g, 16.7 mmol) and 
trimethyl orthoformate (150 ml). The mixture was heated at 110 ˚C 
for 24 h, and concentrated in vacuo.  The remaining residue was 
dissolved in the smallest possible volume of EtOAc and hexane was carefully added 
dropwise with stirring to cause slight turbidity. The mixture was chilled in the freezer at -
20 ˚C overnight and the resulting precipitate was filtered, washed with hexanes and dried 
on air to give 13 as an off-white to cream solid in 94% yield (8.96 g). HRMS (ESI): m/z 
[M+H]+ calc’d for C30H3081BrN4O3: 575.1481; found: 575.14530. 1H NMR (399.8 MHz, 
CDCl3): δ, 7.97 (s, 1H), 7.62 (s, 1H), 7.22-7.20 (d, J = 8.8, 4H), 7.13-7.10 (d, J = 8.8, 2H), 








3H), 3.78 (s, 6H) ppm. 13C NMR (100 MHz, CDCl3): δ, 159.6 (Cq), 158.7 (Cq), 151.6 
(Cq), 143.1, 141.0, 136.6 (Cq), 131.2 (Cq), 129.5 (Cq), 129.2, 128.5, 128.4 (Cq), 114.5, 












General conditions A:8 a solution of 13 (0.25-3.5 mmol, 1 equiv.) in 2/1 
dioxane/deionized water mixture (ca. 12 ml per mmol) was placed in a Schlenk tube or a 
vial equipped with septa. The mixture was bubbled with argon for ca. 1 minute/ml. An aryl 
or vinylboronic acid (1.5 equiv.), tetrakis(triphenylphosphine)palladium (0) (0.1 equiv.) 
and anhydrous cesium carbonate (2 equiv.) were added, the mixture was bubbled with 
argon for few more minutes and heated at 90 ˚C for 6-16 h with vigorous stirring. It was 
cooled and diluted with equal volumes of CH2Cl2 and 1/1 water/brine, the phases were 
separated and the aqueous phase extracted twice with CH2Cl2. The combined organic 
extracts were dried with MgSO4. After filtration and concentration, the products were 
purified by column chromatography on silica gel eluting with 0-20% EtOAc in hexanes. 
General conditions B:9 to a flame-dried vial equipped with septa dry dioxane (ca. 7 ml 
per mmol) was added and bubbled with argon for ca. 1 minute/ml. Compound 13 (0.25-3.5 
mmol, 1 equiv.), alkylboronic acid (1.1–1.5 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (0.1 equiv.), and anhydrous potassium carbonate 
(3 equiv.) were added. The mixture was bubbled with argon for few more minutes and 
heated at 90 ˚C for 72 h with vigorous stirring. It was cooled and filtered through Celite®, 
washing with CH2Cl2. After concentration, the products were purified by column 
chromatography on silica gel eluting with 0-20% EtOAc in hexanes. 
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General conditions C:10 to a flame dried vial equipped with septa dry acetonitrile (3.5 ml) 
was added and bubbled with argon for ca. 1 minute/ml. Compound 13 (0.25 mmol, 1 
equiv.), triphenylphosphine (0.5 equiv.) and palladium(II) acetate (0.1 equiv.) were added, 
followed by an olefin (5 equiv.) and triethylamine (7 equiv.) and the mixture was bubbled 
with argon for few more minutes and heated at 90 ˚C for 36 h with vigorous stirring. It was 
cooled, diluted with CH2Cl2 (50 ml), washed with aqueous NH4Cl (2 x 25 ml), and dried 
with MgSO4. After filtration and concentration, the products were purified by column 
chromatography on silica gel eluting with 0-40% EtOAc in hexanes. The procedure for 
separation of dehalogenated byproduct: the crude mixture obtained after the extractive 
workup was redissolved in CH2Cl2 (10 ml) and NIS (ca. 0.6 equiv.) was added. After 
stirring at room temperature for 2 h, the mixture was diluted with CH2Cl2 (50 ml), washed 
with brine containing sodium thiosulfate (25 ml), and dried with MgSO4. After filtration 
and concentration, the products were purified by column chromatography on silica gel 
eluting with 0-40% EtOAc in hexanes. 13-I eluted first. 
General conditions D:11 to a flame dried vial equipped with septa dry DMF (5 ml) and 
triethylamine (2.5 ml) were added and bubbled with argon for ca. 1 minute/ml. Compound 
13 (0.25 mmol, 1 equiv.), CuI (0.1 equiv.) and bis(triphenylphosphine)palladium(II) 
dichloride (0.1 equiv.) were added, followed by phenylacetylene (1.5 equiv.). The mixture 
was bubbled with argon for few more minutes and heated at 80 ˚C for 24 h with vigorous 
stirring. It was cooled, quenched with saturated aqueous NH4Cl (10 ml), diluted with 
EtOAc (10 ml), washed with brine (3 x 10 ml), and dried with MgSO4. After filtration and 
concentration, the products were purified by column chromatography on silica gel eluting 
with 0-20% EtOAc in hexanes.  
General conditions E:12 to a flame dried vial equipped with septa dry THF (6 ml) was 
added and bubbled with argon for ca. 1 minute/ml. Compound 13 (0.25 mmol, 1 equiv.) 
and tetrakis(triphenylphosphine)palladium(0) (0.1 equiv.) were added, followed by 
trimethylaluminum or benzylmagnesium chloride solutions (3-3.3 equiv.) and the mixture 
was stirred at room temperature for 15 minutes and then heated at 80 ˚C for 4 h with 
vigorous stirring. It was cooled, carefully quenched with Et20 (30 ml), washed with 
238 
saturated aqueous NH4Cl (30 ml), and dried with MgSO4. After filtration and 
concentration, the products were purified by column chromatography on silica gel eluting 
with 0-40% EtOAc in hexanes.  
General conditions F:13 to a flame dried vial equipped with septa was added a solution of 
ZnCl2 (0.5 M in THF, 5.7 eq.), followed by dropwise addition of Grignard reagent solution 
(8.6 eq.) and the mixture was allowed to stir under argon for 1 h. Then, compound 13 
(0.175-0.7 mmol, 1 eq.) and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) 
(0.1 equiv.) were added, and the mixture was stirred at room temperature under argon for 
overall 21-29 h. It was carefully quenched with Et20 (30-50 ml), washed with equal volume 
of saturated aqueous NH4Cl, and dried with MgSO4. After filtration and concentration, the 
products were purified by column chromatography on silica gel eluting with 0-20% EtOAc 
in hexanes.  
General conditions G:14 to a flame dried vial equipped with septa were added 
sequentially: NiI2 (0.065 mmol, 0.13 equiv.), 4,4’-dimethoxy-2,2’-bipyridine (0.05 mmol, 
0.1 equiv.), NaI (0.125 mmol, 0.25 equiv.), 13 (0.5 mmol, 1 equiv.), dry DMA (2 ml), 
pyridine (5 μl), ethyl 4-bromobutyrate (0.55 mmol, 1.1 equiv.), and Zn powder (1 mmol, 2 
equiv.). The headspace of the vial was flushed with argon for 1 minute. The reaction 
mixture was stirred at room temperature for 5 minutes and then heated at 60 ˚C for 20 h 
with vigorous stirring. It was cooled, diluted with EtOAc (50 ml), washed with brine (3 x 
25 ml), and dried with MgSO4. The crude mixtures were subjected to the same procedure 
of dehalogenated by-product separation as described under general conditions C. The 
products were purified by column chromatography on silica gel eluting with 0-40% EtOAc 
in hexanes. 13-I eluted first. 
N,N,1-Tris(4-methoxybenzyl)-7-phenyl-1H-imidazo[4,5-c]pyridin-4-amine (14a) 
General conditions A, 6 h, 335 mg, 91%. Yellowish syrup. HRMS 
(ESI): m/z [M+H]+ calc’d for C36H35N4O3: 571.27093; found: 
571.26842. 1H NMR (400 MHz, CDCl3): δ, 7.78 (s, 1H), 7.68 (s, 








8.8, 2H), 6.71-6.69 (d, J = 8.8, 2H), 6.56-6.54 (d, J = 8.8, 2H), 5.23 (s, 4H), 4.94 (s, 2H), 
3.80 (s, 6H), 3.76 (s, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ, 159.6 (Cq), 158.7 (Cq), 
151.6 (Cq), 141.8, 141.0, 137.7 (Cq), 136.7 (Cq), 131.6 (Cq), 130.4, 129.3, 128.2, 128.10, 




General conditions A, 16 h, 123 mg, 79%. General conditions C, 36 
h, 83 mg, 53%. Tan solid. HRMS (ESI): m/z [M+H]+ calc’d for 
C38H37N4O3: 597.28658; found: 597.28453. 1H NMR (400 MHz, 
CDCl3): δ, 8.10 (s, 1H). 7.69 (s, 1H), 7.32-7.23 (m, 8H), 7.20-7.16 
(d, J = 15.6, 1H), 7.06-7.04 (d, J = 8.8, 2H), 6.92-6.89 (d, J = 8.8, 
2H), 6.86-6.82 (m, 5H), 5.46 (s, 2H), 5.22 (s, 4H), 3.804 (s, 3H), 3.796 (s, 6H) ppm. 13C 
NMR (100 MHz, CDCl3): δ, 159.6 (Cq), 158.7 (Cq), 151.7 (Cq), 141.0, 139.6, 138.1 (Cq), 
137.8 (Cq), 131.5 (Cq), 129.3, 129.0, 128.8, 128.6 (Cq), 127.8 (Cq), 127.6, 127.4, 126.4, 
122.2, 114.7, 113.9, 110.8 (Cq), 55.5, 55.4, 49.8 (CH2), 49.7 (CH2) ppm. 
 
N,N,1-Tris(4-methoxybenzyl)-7-phenethyl-1H-imidazo[4,5-c]pyridin-4-amine (14c) 
General conditions B, 72 h, 55 mg, 35%. General conditions F, 29 h, 
327 mg, 77%. Colorless syrup. HRMS (ESI): m/z [M+H]+ calc’d for 
C38H39N4O3: 599.30224; found: 599.29971.  1H NMR (400 MHz, 
CDCl3): δ, 7.76 (s, 1H), 7.63 (s, 1H), 7.31 -7.20 (m, 3H), 7.26-7.24 
(d, J = 8.8, 4H), 7.10-7.08 (d, J = 8.8, 4H), 6.94-6.92 (d, J = 8.8, 2H), 6.87-6.84 (m, 2H), 
6.86-6.83 (d, J = 8.8, 2H), 5.34 (s, 2H), 5.18 (s, 4H), 3.80 (s, 6H), 3.79 (s, 3H), 3.02-2.88 
(m, 4H) ppm. 13C NMR (100 MHz, CDCl3): δ, 159.6 (Cq), 158.6 (Cq), 151.4 (Cq), 141.4, 














126.3, 114.7, 113.8, 110.9 (Cq), 55.44, 55.36, 49.7 (CH2), 49.4 (CH2), 38.5 (CH2), 30.7 
(CH2) ppm. 
Note: Extensive optimization studies were conducted to improve the synthesis of 14c 
through the Suzuki method. Among the most important variables tested were solvents and 
bases. The crude reaction mixtures were routinely analyzed by 1H NMR. The reaction 
performed best in dry dioxane with K2CO3 as a base at 90 ˚C for 72 h to give ~ 1:1 mixture 
of the cross-coupled and hydrodebrominated products 14c and 13-H, respectively, 
corresponding with up to 35% isolated yields of 14c. Similar results could be obtained 
using K3PO4 in dry dioxane. Other bases such as CaCO3, Na2CO3 or Et3N did not promote 
the reaction at all, while Cs2CO3 afforded 13-H as a major product. CsF was inferior. 
Dioxane performed best as a solvent, while THF, toluene or DMA were inferior. The 
addition of water led to complicated mixtures and the formation of styryl derivatives. 
Shortening the time or lowering the temperature of the reaction led to incomplete 
conversions. Additives such as Ag2O or 18-C-6 were detrimental. When 13-I was used as 
a substrate, 13-H was a major product. When phenethylboronic acid pinacol ester was used 
instead of the free boronic acid, an unreacted 13 was recovered with no trace of 14c 
formation. Also, the use of more soluble carbonates such as Cs2CO3 (or increasing the 
solubility of K2CO3 by addition of 18-C-6 or the use of DMA as a solvent) led 
predominantly to hydrodebromination and often the substantial amounts of recovered 13. 
Hence, we believe that the activation of boronic acid is occurring on the surface of 
potassium carbonate. However, increasing the amount of a solid base to 20-100 equiv. did 
not improve the isolated yields of 14c. 
N,N,1-Tris(4-methoxybenzyl)-1H-imidazo[4,5-c]pyridin-4-amine (13-H) 
General conditions B, 72 h, 34 mg, 30%. Yellowish syrup. HRMS 
(ESI): m/z [M+H]+ calc’d for C30H31N4O3: 495.23964; found: 
495.23722. 1H NMR (400 MHz, CDCl3): δ, 7.96-7.94 (d, J = 5.6, 1H), 
7.70 (s, 1H), 7.25-7.23 (d, J = 8.8, 4H), 7.16-7.14 (d, J = 8.8, 2H), 6.90-6.87 (d, J = 8.8, 







(s, 3H), 3.78 (s, 6H) ppm. 13C NMR (100 MHz, CDCl3): δ, 159.8 (Cq), 158.6 (Cq), 152.3 
(Cq), 141.1, 140.5 (Cq), 139.2, 131.5 (Cq), 129.2, 129.0, 127.9 (Cq), 127.3 (Cq), 114.6, 
113.9, 96.2, 55.45, 55.36, 49.4 (CH2), 48.6 (CH2) ppm. 
 
7-Iodo-N,N,1-tris(4-methoxybenzyl)-1H-imidazo[4,5-c]pyridin-4-amine (13-I) 
General conditions C, 36 h, 50 mg, 31%. General conditions G, 20 
h, 110 mg, 36%. Yellowish foam. HRMS (ESI): m/z [M+H]+ calc’d 
for C30H30IN4O3: 621.13629; found: 621.13419. 1H NMR (400 MHz, 
CDCl3): δ, 8.17 (s, 1H), 7.62 (s, 1H), 7.23-7.20 (d, J = 8.8, 4H), 7.08-7.06 (d, J = 8.8, 2H), 
6.90-6.88 (d, J = 8.8, 2H), 6.84-6.82 (d, J = 8.8, 4H), 5.67 (s, 2H), 5.15 (s, 4H), 3.80 (s, 
3H), 3.79 (s, 6H) ppm. 13C NMR (100 MHz, CDCl3): δ, 159.6 (Cq), 158.7 (Cq), 152.3 
(Cq), 149.2, 141.4, 138.5 (Cq), 131.2 (Cq), 129.8 (Cq), 129.2, 128.5, 128.4 (Cq), 114.5, 




General conditions B, 72 h, 284 mg, 31%. General conditions F, 25 h, 
69 mg, 76%. Colorless syrup. HRMS (ESI): m/z [M+H]+ calc’d for 
C32H35N4O3: 523.27093; found: 523.26894.  1H NMR (400 MHz, CDCl3): δ, 7.73 (s, 1H), 
7.64 (s, 1H), 7.24-7.21 (d, J = 8.8, 4H), 6.99-6.97 (d, J = 8.8, 2H), 6.88-6.86 (d, J = 8.8, 
2H), 6.83-6.81 (d, J = 8.8, 4H), 5.44 (s, 2H), 5.15 (s, 4H), 3.79 (s, 3H), 3.78 (s, 6H), 2.77-
2.71 (q, J = 7.6, 2H), 1.25-1.21 (t, J=7.6, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ, 159.6 
(Cq), 158.6 (Cq), 151.3 (Cq), 141.0, 140.5, 138.8 (Cq), 131.8 (Cq), 129.3, 128.8 (Cq), 
















General conditions B, 72 h, 658 mg, 29%. General conditions F, 21 h, 
327 mg, 85%. Yellowish syrup. HRMS (ESI): m/z [M+H]+ calc’d for 
C34H39N4O3: 551.30224; found: 551.29987.  1H NMR (400 MHz, 
CDCl3): δ, 7.67 (s, 1H), 7.63 (s, 1H), 7.24-7.21 (d, J = 8.8, 4H), 6.98-
6.95 (d, J = 8.8, 2H), 6.88-6.86 (d, J = 8.8, 2H), 6.84-6.82 (d, J = 8.8, 4H), 5.40 (s, 2H), 
5.15 (s, 4H), 3.79 (s, 3H), 3.78 (s, 6H), 2.51-2.49 (d, J = 7.2, 2H), 1.84-1.74 (septet, J = 
6.4, 1H), 0.95-0.94 (d, J = 6.4, 6H) ppm. 13C NMR (100 MHz, CDCl3): δ, 159.6 (Cq), 
158.6 (Cq), 151.4 (Cq), 142.3, 140.9, 139.0 (Cq), 131.8 (Cq), 129.3, 128.8 (Cq), 128.7 





General conditions C, 36 h, 86 mg, 57%. Yellowish syrup. HRMS 
(ESI): m/z [M+H]+ calc’d for C34H35N4O5: 579.26077; found: 
579.25862. 1H NMR (400 MHz, CDCl3): δ, 8.23 (s, 1H), 8.05-8.01 
(d, J = 15.6, 1H), 7.69 (s, 1H), 7.24-7.22 (d, J = 8.8, 4H), 7.12-7.09 
(d, J = 8.8, 2H), 6.90-6.88 (d, J = 8.8, 2H), 6.85-6.83 (d, J = 8.8, 4H), 6.26-6.22 (d, J = 
15.6, 1H), 5.44 (s, 2H), 5.23 (s, 4H), 3.79-3.78 (overlapped s, 12H) ppm. 13C NMR (100 
MHz, CDCl3): δ, 167.8 (Cq), 159.8 (Cq), 158.8 (Cq), 152.8 (Cq), 141.3, 138.8, 138.0 (Cq), 
130.9 (Cq), 129.4, 129.2, 128.2 (Cq), 127.6 (Cq), 127.3 (Cq), 114.6, 114.5, 114.0, 107.6 
















General conditions D, 20 h, 138 mg, 89%. Brown syrup. HRMS 
(ESI): m/z [M+H]+ calc’d for C38H35N4O3: 595.27093; found: 
595.26894. 1H NMR (400 MHz, CDCl3): δ, 8.22 (s, 1H), 7.67 (s, 1H), 
7.39-7.37 (m, 2H), 7.33-7.30 (m, 3H), 7.26-7.24 (d, J = 8.4, 2H), 7.25-7.23 (d, J = 8.4, 4H), 
6.89-6.87 (d, J = 8.4, 2H), 6.86-6.84 (d, J = 8.4, 4H), 5.75 (s, 2H), 5.21 (s, 4H), 3.80 (s, 
9H) ppm. 13C NMR (100 MHz, CDCl3): δ, 159.6 (Cq), 158.8 (Cq), 151.9 (Cq), 146.7, 
140.3, 138.3 (Cq), 131.1, 129.3, 128.9, 128.8 (Cq), 128.5, 128.0, 127.0 (Cq), 123.7 (Cq), 
114.5, 113.9, 93.6 (Cq), 85.1 (Cq), 55.44, 55.38, 49.6 (CH2), 48.5 (CH2) ppm. 
 
N,N,1-Tris(4-methoxybenzyl)-7-methyl-1H-imidazo[4,5-c]pyridin-4-amine (14h) 
General conditions E, 4 h, 115 mg, 87%. Yellow syrup. HRMS (ESI): 
m/z [M+H]+ calc’d for C31H33N4O3: 509.25528; found: 509.25341. 
1H NMR (400 MHz, CDCl3): δ, 7.66 (s, 1H), 7.65 (s, 1H), 7.24-7.21 
(d, J = 8.4, 4H), 7.00-6.97 (d, J = 8.4, 2H), 6.88-6.86 (d, J = 8.4, 2H), 6.83-6.81 (d, J = 8.4, 
2H), 5.45 (s, 2H), 5.15 (s, 4H), 3.79 (s, 3H), 3.78 (s, 6H), 2.35 (s, 3H) ppm. 13C NMR (100 
MHz, CDCl3): δ, 159.5 (Cq), 158.6 (Cq), 151.4 (Cq), 141.5, 140.8, 139.5 (Cq), 131.8 (Cq), 
129.3, 129.0, 128.5 (Cq), 127.5, 114.6, 113.8, 106.6 (Cq), 55.44, 55.36, 49.7 (CH2), 49.3 















General conditions E, 4 h, 69 mg, 45%. Brown syrup. HRMS (ESI): 
m/z [M+H]+ calc’d for C37H37N4O3: 585.286588; found: 585.28433. 
1H NMR (400 MHz, CDCl3): δ, 7.76 (s, 1H), 7.59 (s, 1H), 7.32-7.23 
(m, 7H), 7.09–7.08 (d, J = 8.8, 2H), 6.87–6.82 (m, 8H), 5.22 (s, 4H), 
5.05 (s, 2H), 4.00 (s, 2H), 3.80 (s, 9H) ppm. 13C NMR (100 MHz, CDCl3): δ, 159.5 (Cq), 
158.6 (Cq), 151.8 (Cq), 142.9, 141.4 (Cq), 140.9, 139.2 (Cq), 131.6 (Cq), 129.3, 129.0 
(Cq), 128.9 (Cq), 128.8, 128.0, 127.2, 126.5, 114.6, 113.8, 108.5 (Cq), 55.42, 55.35, 49.7 
(CH2), 49.0 (CH2), 35.0 (CH2) ppm. 
 
7-Isopropyl-N,N,1-tris(4-methoxybenzyl)-1H-imidazo[4,5-c]pyridin-4-amine (14j) 
General conditions F, 27 h, 80 mg, 86%. Contains ~20% of n-propyl 
impurity. Colorless syrup. HRMS (ESI): m/z [M+H]+ calc’d for 
C33H37N4O3: 537.28658; found: 537.28573.  1H NMR (400 MHz, 
CDCl3): δ, 7.89 (s, 1H), 7.63 (s, 1H), 7.25-7.22 (d, J = 8.8, 4H), 6.98-6.96 (d, J = 8.8, 2H), 
6.88-6.86 (d, J = 8.8, 2H), 6.84-6.82 (d, J = 8.8, 4H), 5.44 (s, 2H), 5.16 (s, 4H), 3.79 (s, 
3H), 3.78 (s, 6H), 3.30-3.20 (septet, J = 6.8, 1H), 1.25-1.24 (d, J = 6.4, 6H) ppm. 13C NMR 
(100 MHz, CDCl3): δ, 159.6 (Cq), 158.6 (Cq), 151.0 (Cq), 141.4, 138.1 (Cq), 138.0, 131.8 
(Cq), 129.3, 128.7 (Cq), 128.6 (Cq), 127.6, 118.3 (Cq), 114.6, 113.8, 55.45, 55.36, 50.0 




General conditions G, 20 h, 100 mg, 32%. Colorless syrup. HRMS 
(ESI): m/z [M+H]+ calc’d for C36H41N4O5: 609.30773; found: 
609.30580. 1H NMR (400 MHz, CDCl3): δ, 7.69 (s, 1H), 7.65 (s, 



















6.85 (d, J = 8.8, 2H), 6.84-6.82 (d, J = 8.8, 4H), 5.47 (s, 2H), 5.16 (s, 4H), 4.14-4.08 (q, J 
= 7.2, 2H), 3.78 (overlapped s, 9H), 2.71-2.68 (m, 2H), 2.37-2.33 (t, J = 7.2, 2H), 1.91-
1.86 (m, 2H), 1.26-1.22 (t, J = 7.2, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ, 173.5 (Cq), 
159.5 (Cq), 158.6 (Cq), 151.4 (Cq), 141.6, 141.1, 138.7 (Cq), 131.7 (Cq), 129.3, 128.8 
(Cq), 128.7 (Cq), 127.5, 114.6, 113.8, 110.6 (Cq), 60.5 (CH2), 55.42, 55.36, 49.6 (CH2), 
49.4 (CH2), 33.7 (CH2), 28.4 (CH2), 27.4 (CH2), 14.4 ppm. 
 
7-Benzyl-1H-imidazo[4,5c]pyridin-4-amine, trifluoroacetic acid salt (15i) 
This compound was synthesized according to the modified general 
procedure.15 A solution of 14i (589 mg, 1 mmol) in TFA (6 ml) was 
placed in a 100 ml pressure tube, anisole (0.65 ml, 6 equiv.) was added, 
and the mixture was heated at 70 ˚C for 24 h with vigorous stirring. It was cooled and 
concentrated under reduced pressure. The residue was coevaporated with toluene (3 x 25 





This compound was synthesized according to the reported general 
procedure.16 A solution of 15i (0.34 g, 1 mmol) in pyridine (10 ml) was 
placed in a 100 ml Schlenk flask. Tetramethylsuccinic anhydride 
(M4SA)17 (0.312 g, 2 mmol) and DBU (0.6 ml, 4 mmol) were added, and 
the mixture was heated at 120 ˚C under argon for 20 h with vigorous 
stirring. It was cooled and concentrated under reduced pressure. The residue was 
coevaporated with toluene (3 x 25 ml). The product was purified by column 













was taken in SOCl2 (10 ml), heated at 80 ̊ C for 2 h, cooled and concentrated under reduced 
pressure. The residue was coevaporated with EtOAc (3 x 25 ml). The product was purified 
by column chromatography on silica gel eluting with 0-5% MeOH in CH2Cl2 to give 16i 
as a cream foam in 57% yield (0.208 g). HRMS (ESI): m/z [M+H]+ calc’d for C21H23N4O2: 
363.18212; found: 363.18045. 1H NMR (400 MHz, CD3OD): δ, 8.36 (s, 1H), 8.12 (s, 1H), 
7.29-7.20 (m, 5H), 4.35 (s, 2H), 1.37 (bs, 12H) ppm. 13C NMR (100 MHz, CD3OD): δ, 





This compound was synthesized according to the reported 
general procedure.16 To a solution of 16i (0.19 g, 0.52 mmol) 
in dry CH3CN (25 ml) in a 100 ml round bottom flask, 60% 
NaH in oil (42 mg, 1.05 mmol) was added, and the mixture was 
vigorously stirred at room temperature under argon for 45 min. 
1-(α)-Chloro-3,5-di-O-(p-toluoyl)-2-deoxy-D-ribose (0.368 g, 
0.94 mmol) was subsequently added in one portion, and the stirring was continued at room 
temperature for 4.5 h. The mixture was filtered through Celite® and concentrated. The 
product was purified by column chromatography on silica gel eluting with 50% EtOAc in 
hexanes. 17i was obtained as a yellowish syrup in 39% yield (0.145 g). HRMS (ESI): m/z 
[M+H]+ calc’d for C42H43N4O7: 715.31322; found: 715.31184. 1H NMR (400 MHz, 
CDCl3): δ, 8.32 (s, 1H), 8.19 (s, 1H), 7.92-7.90 (d, J = 8.4, 2H), 7.87-7.85 (d, J = 8.4, 2H), 
7.34-7.32 (d, J = 8.4, 2H), 7.92-7.90 (d, J = 8.4, 2H), 7.14-7.11 (m, 3H), 7.06-7.04 (m, 2H), 
6.20-6.17 (dd, J1 = 5.2, J2 = 9.2, 1H), 5.54-5.53 (m, 1H), 4.60-4.49 (m, 4H), 4.38-4.34 
(AB/2, J=16.8, 1H), 2.49 (s, 3H), 2.46-2.42 (m, 1H), 2.40 (s, 3H), 2.06-2.01 (m, 1H), 1.39 
(bs, 1H) ppm. 13C NMR (100 MHz, CDCl3): δ, 181.6 (Cq), 166.2 (Cq), 165.8 (Cq), 144.8 








129.8, 129.54, 129.47, 129.2, 128.1, 127.1, 126.6 (Cq), 126.5 (Cq), 120.0 (Cq), 85.8, 82.7, 

























This compound was synthesized according to the general 
procedure.16 To a solution of 17i (0.14 g, 0.20 mmol) in dry 
MeOH (4 ml) in a 25 ml round bottom flask, NaOMe (32 mg, 
0.60 mmol) was added. The mixture was stirred at room 
temperature under argon for 2 h and concentrated in vacuo. The 
product was purified by column chromatography on silica gel 
eluting with 0-10% MeOH in dichloromethane to obtain 18i as 
an off-white solid in 66% yield (62 mg). HRMS (ESI): m/z [M+H]+ calc’d for C26H31N4O5: 
479.22948; found: 479.22931. 1H NMR (400 MHz, CD3OD): δ, 8.69 (s, 1H), 8.14 (s, 1H), 
7.32-7.14 (m, 5H), 6.35-6.32 (dd, J1 = 6.4, J2 = 12.8, 1H), 4.61-4.57 (AB/2, J = 16.8, 1H), 
4.47-4.30 (AB/2, J = 16.8, 1H), 4.46-4.44 (m, 1H), 3.95-3.92 (app q, J = 3.6, 1H), 3.73-
3.69 (app dd, J1 = 3.6, J2 = 12.0, 1H), 3.66-3.62 (app dd, J1 = 3.6, J2 = 12.0, 1H), 2.52-2.46 








(bs, 12H) ppm. 13C NMR (100 MHz, CD3OD): δ, 183.4 (Cq), 145.9 (Cq), 144.3, 141.0 
(Cq), 140.1 (Cq), 138.6 (Cq), 138.4 (Cq), 130.1, 129.5, 127.9, 123.5 (Cq), 89.2, 87.1, 71.7, 





This compound was synthesized according to the 
reported general procedure.16 To a solution of 18i 
(56 mg, 0.12 mmol) in pyridine (2 ml), 4,4’-
dimethoxytrityl chloride (DMT-Cl) (155 mg, 
0.457 mmol) was added in one portion and the 
mixture was stirred at room temperature under 
argon for 5 h (TLC showed complete conversion). 
MeOH (0.2 ml) was then added, and the mixture 
was concentrated in vacuo. The product was purified by column chromatography on silica 
gel (neutralized with triethylamine) eluting with 5-20% acetone in dichloromethane to 
obtain 19i as a colorless solid in 69% yield (63 mg). HRMS (ESI): m/z [M+H]+ calc’d for 
C47H49N4O7: 781.36017; found: 781.35738. 1H NMR (400 MHz, CDCl3): δ, 8.24 (s, 1H), 
8.10 (s, 1H), 7.38-7.10 (m, 14H), 6.82-6.80 (d, J = 8.4, 4H), 6.16-6.12 (dd, J1 = 6.4, J2 = 
12.4, 1H), 4.50-4.46 (AB/2, J = 16.8, 1H), 4.43-4.38 (m, 1H), 4.36-4.32 (AB/2, J = 16.8, 
1H), 4.01-3.98 (app q, J = 4.4, 1H), 3.78 (s, 6H), 3.36-3.32 (app dd, J1 = 4.4, J2 = 10.4, 1H), 
3.28-3.24 (app dd, J1 = 4.8, J2 = 10.4, 1H), 2.6 (bs, 1H), 2.28-2.22 (ddd, J1 = J2 = 6.0, J3 = 
13.2, 1H), 1.90-1.84 (ddd, J1 = J2 = 5.6, J3 = 9.6, 1H), 1.39-1.38 (overlapped s, 12H) ppm. 
13C NMR (100 MHz, CDCl3): δ, 181.7 (Cq), 158.7 (Cq), 144.5 (Cq), 144.1, 142.6, 139.4 
(Cq), 138.8 (Cq), 138.2 (Cq), 137.6 (Cq), 135.63 (Cq), 135.55 (Cq), 130.12, 130.09, 129.1, 
128.6, 128.13, 128.10, 127.11, 127.07, 120.6 (Cq), 113.4, 86.8 (Cq), 85.7, 85.2, 72.0, 63.7 















This compound was synthesized according to 
the reported general procedure.18 To a solution 
of 19i (62 mg, 0.080 mmol) in dry CH2Cl2 (2 
ml) containing N,N-diisopropylethylamine 
(DIEA) (70 μl, 0.4 mmol), 2-cyanoethyl-N,N-
diisopropyl chlorophosphoramidite (40 μl, 
0.175 mmol) was added in one portion and the 
mixture was stirred at room temperature under argon for 3 h (TLC showed complete 
conversion). The mixture was concentrated in vacuo at rt and the product was purified by 
column chromatography on silica gel (neutralized with triethylamine) eluting with 50% 
EtOAc in hexanes containing 1% triethylamine, to obtain 20i as a mixture of diastereomers 
(colorless solid, Rf ~0.5 in 5% acetone/CH2Cl2, two close spots visible on TLC) in 49% 
yield (38 mg). HRMS (ESI): m/z [M+H]+ calc’d for C56H66N6O8P: 981.46801; found: 
981.46481. 1H NMR (400 MHz, acetone-d6): δ, 8.40, 8.39 (s, 1H), 8.21, 8.19 (s, 1H), 7.45-
7.18 (m, 14H), 6.84-6.80 (m, 4H), 6.40-6.35 (dd, J1 = 7.0, J2 = 12.8, 1H), 4.68-4.78 (m, 
2H), 4.56-4.52, 4.53-4.49 (AB/2, J = 16.4, 1H), 4.28-4.26, 4.24-4.21 (app q, J = 4.4, 1H), 
3.763, 3.757 (s, 6H), 3.67-3.58 (m, 2H), 3.36-3.32 (m, 2H), 2.91-2.78 (m, 3H), 2.76-2.73 
(t, J = 6.0, 1H), 2.68-2.65 (t, J = 6.0, 1H), 1.35, 1.31 (bs, 12H), 1.21-1.19 (m, 6H), 1.15-
1.14, 1.13-1.11 (d, J = 6.8, 6H) ppm. 13C NMR (100 MHz, acetone-d6): δ, 181.7, 159.6, 
145.9, 144.36, 144.27, 144.02, 143.97, 140.4, 140.08, 140.05, 139.2, 138.8, 136.64, 
136.58, 136.52, 130.96, 130.93, 129.7, 129.34, 129.31, 128.97, 128.91, 128.6, 127.6, 
127.50, 127.47, 122.3, 122.2, 119.0, 114.0, 87.22, 87.18, 86.6, 86.4, 86.3, 86.2, 74.4, 74.0, 













35.5, 24.94, 24.86, 24.82, 22.0, 21.7, 21.4, 20.8, 20.7 ppm. 31P NMR (162 MHz, acetone-
d6): δ, 149.8, 149.6 ppm. 
 
7-Ethyl-1H-imidazo[4,5c]pyridin-4-amine, trifluoroacetic acid salt (15d) 
This compound was synthesized in similar fashion as 15i. A solution of 
14d (750 mg, 1.4 mmol) in TFA (10 ml) was placed in a 100 ml pressure 
tube, anisole (ca. 1 ml, 6 equiv.) was added, and the mixture was heated 
at 70 ˚C for 24 h with vigorous stirring. It was cooled and concentrated under reduced 
pressure. The residue was coevaporated with toluene (3 x 20 ml) to obtain 15d (ca. 0.4 g, 




This compound was synthesized in similar fashion as 16i. A solution of 15d 
(0.4 g, 1.4 mmol) in pyridine (15 ml) was placed in a 100 ml Schlenk flask. 
Tetramethylsuccinic anhydride (M4SA) (0.5 g, 3.2 mmol) and DBU (1 ml, 
6.7 mmol) were added, and the mixture was heated at 120 ˚C under argon 
for 22 h with vigorous stirring. It was cooled and concentrated under 
reduced pressure. The residue was coevaporated with toluene (3 x 20 ml). The product was 
purified by column chromatography on silica gel eluting with 0-5% MeOH in CH2Cl2 to 
give a cream solid. It was taken in SOCl2 (12 ml), heated at 80 ˚C for 2 h, cooled and 
concentrated under reduced pressure. The residue was coevaporated with EtOAc (3 x 20 
ml). The product was purified by column chromatography on silica gel eluting with 0-8% 
MeOH in CH2Cl2 to give 16d as a cream solid in 88% yield (0.37 g). HRMS (ESI): m/z 
[M+H]+ calc’d for C16H21N4O2: 301.16647; found: 301.16501. 1H NMR (400 MHz, 










1.37 (bs, 12H) ppm. 13C NMR (100 MHz, CD3OD): δ, 182.9, 146.9, 143.5, 139.6, 135.4, 





This compound was synthesized in similar fashion as 17i. To a 
solution of 16i (0.35 g, 1.17 mmol) in dry CH3CN (60 ml) in a 
250 ml round bottom flask, 60% NaH in oil (100 mg, 2.5 mmol) 
was added, and the mixture was vigorously stirred at room 
temperature under argon for 45 min. 1-(α)-Chloro-3,5-di-O-(p-
toluoyl)-2-deoxy-D-ribose (0.817 g, 2.1 mmol) was 
subsequently added portionwise over 1 h, and the stirring was continued at room 
temperature for overall 5 h. The mixture was filtered through Celite® and concentrated. 
The product was purified by column chromatography on silica gel eluting with 0-50% 
EtOAc in hexanes, and concentrated repeatedly with dichloromethane. 17d was obtained 
as a yellowish syrup in 65% yield (0.494 g). HRMS (ESI): m/z [M+H]+ calc’d for 
C37H41N4O7: 653.29757; found: 653.29654. 1H NMR (400 MHz, CDCl3): δ, 8.27 (s, 1H), 
8.25 (s, 1H), 7.92-7.90 (d, J = 8.0, 2H), 7.88-7.86 (d, J = 8.0, 2H), 7.30-7.28 (d, J = 8.4, 
2H), 7.24-7.22 (d, J = 8.4, 2H), 6.60-6.57 (dd, J1 = 6.4, J2 = 12.8, 1H), 5.72-5.68 (m, 1H), 
4.67-4.59 (m, 3H), 3.16-3.00 (m, 2H), 2.82-2.79 (dd, J1 = 4.4, J2 = 6.8, 2H), 2.44 (s, 3H), 
2.40 (s, 3H), 1.43-1.40 (t, J = 7.6, 3H), 1.37 (bs, 1H) ppm. 13C NMR (100 MHz, CDCl3): 
δ, 181.7 (Cq), 166.3 (Cq), 165.9 (Cq), 144.9 (Cq), 144.4 (Cq), 142.6, 142.0, 138.9 (Cq), 
137.6 (Cq), 137.3 (Cq), 130.0, 129.9, 129.8, 129.5, 126.6 (Cq), 126.4 (Cq), 124.2 (Cq), 
























This compound was synthesized in similar fashion as 18i. To a 
solution of 17d (0.46 g, 0.7 mmol) in dry MeOH (6 ml) in a 25 ml 
round bottom flask, NaOMe (114 mg, 2.11 mmol) was added. The 
mixture was stirred at room temperature under argon for 2 h and 
concentrated in vacuo. The product was purified by column 
chromatography on silica gel eluting with 0-10% MeOH in 
dichloromethane to obtain 18d as an off-white solid in 74% yield (218 mg). HRMS (ESI): 
m/z [M+H]+ calc’d for C21H29N4O5: 417.21383; found: 417.21265. 1H NMR (400 MHz, 
CD3OD): δ, 8.74 (s, 1H), 8.20 (s, 1H), 6.63-6.60 (dd, J1 = 6.4, J2 = 12.8, 1H), 4.58-4.55 (m, 
1H), 4.06-4.03 (app q, J = 3.6, 1H), 3.78-3.65 (m, 2H), 3.23-3.12 (app septet, J = 3.6, 2H), 
2.78-2.72 (m, 1H), 2.60-2.54 (ddd, J1 = 3.6, J2 = 6.0, J3 = 10.4, 1H), 1.44-1.40 (t, J = 7.6, 
3H), 1.37 (bs, 12H) ppm. 13C NMR (100 MHz, CD3OD): δ, 183.4 (Cq), 145.8 (Cq), 142.4, 
140.4 (Cq), 138.4 (Cq), 137.8 (Cq), 127.2 (Cq), 89.4, 87.2, 72.1, 62.7 (CH2), 48.8 (Cq), 












This compound was synthesized in similar fashion as 
19i. To a solution of 18d (190 mg, 0.457 mmol) in 
pyridine (3 ml), 4,4’-dimethoxytrityl chloride (DMT-
Cl) (217 mg, 0.639 mmol) was added in one portion 
and the mixture was stirred at room temperature 
under argon for 4 h. The mixture was concentrated in 
vacuo. The product was purified by column 
chromatography on silica gel (neutralized with triethylamine) eluting with 0-20% acetone 
in dichloromethane to obtain 19d as a colorless solid in 33% yield (110 mg). HRMS (ESI): 
m/z [M+H]+ calc’d for C42H47N4O7: 719.34452; found: 719.34247. 1H NMR (400 MHz, 
CDCl3): δ, 8.21 (s, 1H), 8.16 (s, 1H), 7.40-7.38 (d, J = 7.2, 2H), 7.30-7.20 (m, 7H), 6.82-
6.80 (d, J = 9.2, 4H), 6.42-6.39 (dd, J1 = 6.4, J2 = 12.4, 1H), 4.54-4.48 (m, 1H), 4.11-4.08 
(app q, J = 4.4, 1H), 3.77 (s, 6H), 3.38-3.34 (app dd, J1 = 4.4, J2 = 10.4, 1H), 3.32-3.29 (app 
dd, J1 = 4.8, J2 = 10.4, 1H), 3.17 (bs, 1H), 3.03-3.00 (app dd, J1 = 3.2, J2 = 7.6, 1H), 2.99-
2.96 (app dd, J1 = 3.2, J2 = 7.6, 1H), 2.46-2.44 (app t, J = 6.0, 2H), 1.38-1.37 (overlapped 
s, 12H), 1.36-1.32 (t, J = 7.2, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ, 181.8 (Cq), 158.7 
(Cq), 144.5 (Cq), 142.6, 141.9, 138.9 (Cq), 137.3 (Cq), 137.2 (Cq), 135.63 (Cq), 135.58 
(Cq), 130.1, 128.13, 128.06, 127.1, 124.6 (Cq), 113.4, 86.8 (Cq), 86.0, 85.2, 71.9, 63.7 














This compound was synthesized in similar 
fashion as 20i. To a solution of 19d (105 mg, 
0.146 mmol) in dry CH2Cl2 (4 ml) containing 
N,N-diisopropylethylamine (DIEA) (127 μl, 
0.731 mmol), 2-cyanoethyl-N,N-diisopropyl 
chloro-phosphoramidite (40 μl, 0.175 mmol) was 
added in one portion and the mixture was stirred 
at room temperature under argon for 4 h (TLC 
showed complete conversion). The mixture was concentrated in vacuo at rt and the product 
was purified by column chromatography on silica gel (neutralized with triethylamine) 
eluting with 40-60% EtOAc in hexanes containing 1% triethylamine, to obtain 20d as a 
mixture of diastereomers (white foam, Rf ~0.5 in 5% acetone/CH2Cl2, two close spots 
visible on TLC) in 67% yield (90 mg). HRMS (ESI): m/z [M+H]+ calc’d for C51H64N6O8P: 
919.45236; found: 919.45047. 1H NMR (400 MHz, CDCl3): δ, 8.25 (s, 1H), 8.23, 8.19 (s, 
1H), 7.40-7.38 (m, 2H), 7.30-7.20 (m, 7H), 6.83-6.79 (m, 4H), 6.49-6.46 (dd, J1 = 6.8, J2 = 
13.6, 1H), 4.70-4.59 (m, 1H), 4.32-4.24 (m, 1H), 3.78, 3.77 (s, 6H), 3.70-3.53 (m, 3H), 
3.32-3.31 (m, 1H), 3.13-2.99 (m, 2H), 2.62-2.59 (t, J = 6.4, 1H), 2.57-2.55 (m, 1H), 2.44-
2.41 (t, J = 6.4, 1H), 1.38, 1.37 (bs, 12H), 1.20-1.17 (m, 9H), 1.13-1.12 (d, J = 6.8, 3H) 
ppm. 13C NMR (100 MHz, CDCl3): δ, 181.7, 158.7, 144.5, 142.5, 142.4, 139.0, 137.4, 
135.63, 135.56, 130.2, 128.3, 128.2, 128.1, 127.1, 124.5, 124.4, 117.5, 113.4, 86.7, 85.8, 
85.5, 85.4, 74.1, 73.9, 63.4, 63.2, 58.4, 58.2, 55.38, 55.36, 48.0, 43.61, 43.55, 43.4, 41.0, 
24.7, 24.6, 22.9, 21.8, 21.5, 15.6 ppm. 31P NMR (162 MHz, CDCl3): δ, 150.8, 150.2 ppm. 
 
7-Isobutyl-1H-imidazo[4,5c]pyridin-4-amine, trifluoroacetic acid salt (15e) 
This compound was synthesized in similar fashion as 15i. A solution of 
14e (1.3 g, 2.4 mmol) in TFA (20 ml) was placed in a 100 ml pressure 
tube, anisole (1.6 ml, 6 equiv.) was added, and the mixture was heated at 

















under reduced pressure. The residue was coevaporated with toluene (3 x 20 ml) to obtain 





This compound was synthesized in similar fashion as 16i. A solution of 15e 
(ca. 0.8 g, 2.4 mmol) in pyridine (20 ml) was placed in a 100 ml Schlenk 
flask. Tetramethylsuccinic anhydride (M4SA) (0.8 g, 5.1 mmol) and DBU 
(1.5 ml, 10.0 mmol) were added, and the mixture was heated at 120 ˚C 
under argon for 22 h with vigorous stirring. It was cooled and concentrated 
under reduced pressure. The residue was coevaporated with toluene (3 x 20 ml). The 
product was purified by column chromatography on silica gel eluting with 0-5% MeOH in 
CH2Cl2 to give a cream foam. It was taken in SOCl2 (20 ml), heated at 80 ˚C for 2 h, cooled 
and concentrated under reduced pressure. The residue was coevaporated with EtOAc (3 x 
20 ml). The product was purified by column chromatography on silica gel eluting with 0-
8% MeOH in CH2Cl2 to give 16e as a cream foam in 79% yield (0.61 g). HRMS (ESI): 
m/z [M+H]+ calc’d for C18H25N4O2: 329.19777; found: 329.19608. 1H NMR (400 MHz, 
CD3OD): δ, 8.43 (s, 1H), 8.16 (s, 1H), 2.87-2.85 (d, J = 7.6, 2H), 2.11-2.05 (app septet, J 
= 6.8, 1H), 1.37 (bs, 12H), 0.99-0.97 (d, J = 6.4, 6H) ppm. 13C NMR (100 MHz, CD3OD): 










This compound was synthesized in similar fashion as 17i. To a 
solution of 16e (0.585 g, 1.78 mmol) in dry CH3CN (60 ml) in a 
250 ml round bottom flask, 60% NaH in oil (143 mg, 3.57 mmol) 
was added, and the mixture was vigorously stirred at room 
temperature under argon for 35 min. 1-(α)-Chloro-3,5-di-O-(p-
toluoyl)-2-deoxy-D-ribose (1.25 g, 3.21 mmol) was 
subsequently added portionwise over 1 h, and the stirring was 
continued at room temperature for overall 4.5 h. The mixture was filtered through Celite® 
and concentrated. The product was purified by column chromatography on silica gel 
eluting with 0-50% EtOAc in hexanes, and concentrated repeatedly with dichloromethane. 
17e was obtained as a yellowish solid in 38% yield (0.465 g). HRMS (ESI): m/z [M+H]+ 
calc’d for C39H45N4O7: 681.32887; found: 681.32697. 1H NMR (400 MHz, CDCl3): δ, 8.27 
(s, 1H), 8.20 (s, 1H), 7.97-7.95 (d, J = 8.0, 2H), 7.92-7.90 (d, J = 8.0, 2H), 7.30-7.28 (d, J 
= 8.4, 2H), 7.27-7.25 (d, J = 8.4, 2H), 6.59-6.55 (dd, J1 = 5.2, J2 = 8.8, 1H), 5.73-5.72 (m, 
1H), 4.70-4.61 (m, 3H), 2.98-2.92 (dd, J1 = 7.2, J2 = 14.4, 1H), 2.84-2.72 (m, 3H), 2.45 (s, 
3H), 2.42 (s, 3H), 1.98-1.88 (app septet, J = 6.4, 1H), 1.38 (bs, 1H), 1.05-1.03 (d, J = 6.8, 
6H) ppm. 13C NMR (100 MHz, CDCl3): δ, 181.6 (Cq), 166.3 (Cq), 165.9 (Cq), 144.9 (Cq), 
144.4 (Cq), 144.1, 142.2, 139.2 (Cq), 137.7 (Cq), 137.4 (Cq), 129.9, 129.8, 129.54, 129.47, 
126.6 (Cq), 126.3 (Cq), 121.8 (Cq), 85.4, 82.9, 74.9, 64.2 (CH2), 48.0 (Cq), 39.9 (CH2), 























This compound was synthesized in similar fashion as 18i. To a 
solution of 17e (0.46 g, 0.68 mmol) in dry MeOH (7 ml) in a 25 
ml round bottom flask, NaOMe (110 mg, 2.03 mmol) was added. 
The mixture was stirred at room temperature under argon for 2 h 
and concentrated in vacuo. The product was purified by column 
chromatography on silica gel eluting with 0-10% MeOH in 
dichloromethane to obtain 18e as an off-white foam in 85% yield (256 mg). HRMS (ESI): 
m/z [M+H]+ calc’d for C23H33N4O5: 445.24512; found: 445.24381. 1H NMR (400 MHz, 
CD3OD): δ, 8.74 (s, 1H), 8.14 (s, 1H), 6.58-6.55 (dd, J1 = 6.4, J2 = 12.8, 1H), 4.58-4.55 (dt, 
J1 = 3.2, J2 = 6.8, 1H), 4.06-4.04 (app q, J = 3.2, 1H), 3.77-3.73 (app dd, J1 = 3.6, J2 = 12.0, 
1H), 3.72-3.68 (app dd, J1 = 3.6, J2 = 12.0, 1H), 3.06-3.01 (app dd, J1 = 6.8, J2 = 14.4, 1H), 
2.92-2.86 (app dd, J1 = 7.2, J2 = 14.0, 1H), 2.76-2.69 (ddd, J1 = 5.6, J2 = 6.8, J3 = 13.2, 1H), 
2.56-2.51 (ddd, J1 = 3.6, J2 = 6.0, J3 = 9.6, 1H), 2.04-1.94 (app septet, J = 6.8, 1H), 1.37 
(bs, 12H), 1.05-1.03 (d, J = 6.8, 6H) ppm. 13C NMR (100 MHz, CD3OD): δ, 183.4 (Cq), 
146.0 (Cq), 144.0, 140.7 (Cq), 138.5 (Cq), 137.9 (Cq), 124.6 (Cq), 89.4, 87.0, 72.3, 62.8 












This compound was synthesized in similar fashion as 
19i. To a solution of 18e (225 mg, 0.507 mmol) in dry 
pyridine (4 ml), 4,4’-dimethoxytrityl chloride (DMT-
Cl) (240 mg, 0.709 mmol) was added in one portion 
and the mixture was stirred at room temperature 
under argon for 4 h. TLC analysis indicated that a lot 
of starting material remained and then additional 
DMT-Cl (0.120 g, 0.355 mmol) and cat. DMAP (10 
mg) were added.  After 14 h more DMT-Cl (0.120 g, 0.350 mmol), triethylamine (85 μl, 
0.608 mmol), and cat. DMAP (10 mg) were added. After 8 h, another portion as above was 
added, and after 16 h TLC showed no further conversion (overall 42 h). The mixture was 
quenched with 200 μl of MeOH, concentrated in vacuo, the residue was taken in AcOEt 
and filtered, and the filtrate was concentrated in vacuo. The product was purified by column 
chromatography on silica gel (neutralized with triethylamine) eluting with 0-25% acetone 
in dichloromethane to obtain 19e as a colorless foam in 46% yield (175 mg). Further elution 
with 10% MeOH in dichloromethane yielded the recovered starting material 18e as a 
colorless syrup in 45% yield (102 mg). HRMS (ESI): m/z [M+H]+ calc’d for C44H51N4O7: 
747.37582; found: 747.37412. 1H NMR (400 MHz, CDCl3): δ, 8.17 (s, 1H), 8.14 (s, 1H), 
7.40-7.38 (d, J = 8.8, 2H), 7.30-7.20 (m, 7H), 6.82-6.80 (d, J = 8.8, 4H), 6.42-6.38 (dd, J1 
= 6.4, J2 = 12.8, 1H), 4.52-4.51 (m, 1H), 4.10-4.07 (app q, J = 4.4, 1H), 3.77 (s, 6H), 3.38-
3.35 (app dd, J1 = 4.4, J2 = 10.4, 1H), 3.33-3.29 (app dd, J1 = 4.8, J2 = 10.4, 1H), 2.88-2.83 
(app dd, J1 = 7.2, J2 = 14.4, 1H), 2.75-2.70 (app dd, J1 = 6.4, J2 = 14.0, 1H), 2.46-2.41 (m, 
2H), 1.90-1.84 (app quintet, J = 6.4 , 1H), 1.37-1.36 (overlapped s, 12H), 1.01-0.99 (dd, J1 
= 2.4, J2 = 6.4, 6H) ppm. 13C NMR (100 MHz, CDCl3): δ, 181.7 (Cq), 158.7 (Cq), 144.5 
(Cq), 143.6, 142.7, 139.2 (Cq), 137.5 (Cq), 137.4 (Cq), 135.63 (Cq), 135.58 (Cq), 130.1, 
128.2, 128.1, 127.1, 122.2 (Cq), 113.4, 86.8 (Cq), 86.0, 85.0, 72.0, 63.7 (CH2), 55.3, 48.0 













yl)tetrahydrofuran-3-yl (2-cyanoethyl) diisopropylphosphoramidite (20e) 
This compound was synthesized in similar fashion 
as 20i. To a solution of 19e (105 mg, 0.146 mmol) 
in dry CH2Cl2 (5 ml) containing N,N-
diisopropylethylamine (DIEA) (185 μl, 1.07 
mmol), 2-cyanoethyl-N,N-diisopropyl chloro-
phosphoramidite (105 μl, 0.472 mmol) was added 
in one portion and the mixture was stirred at room 
temperature under argon for 4 h (TLC showed complete conversion). The mixture was 
concentrated in vacuo at rt and the product was purified by column chromatography on 
silica gel (neutralized with triethylamine) eluting with 40-60% EtOAc in hexanes 
containing 1% triethylamine, to obtain 20e as a mixture of diastereomers (white foam, Rf 
~0.5 in 50% EtOAc in hexanes, two close spots visible on TLC) in 59% yield (120 mg). 
HRMS (ESI): m/z [M+H]+ calc’d for C53H68N6O8P: 947.48366; found: 947.48314. 1H 
NMR (400 MHz, acetone-d6): δ, 8.43, 8.41 (s, 1H), 8.15 (s, 1H), 7.46-7.41 (m, 2H), 7.33-
7.19 (m, 7H), 6.85-6.81 (m, 4H), 6.62-6.58 (dd, J1 = 6.4, J2 = 13.2, 1H), 4.86-4.81 (m, 1H), 
4.37-4.29 (m, 1H), 3.96-3.82 (m, 1H), 3.77, 3.76 (s, 6H), 3.74-3.66 (m, 2H), 3.39-3.34 (m, 
2H), 3.13-3.09 (m, 1H), 3.03-2.96 (m, 1H), 2.94-2.87 (m, 1H), 2.81 (m, 3H), 2.79-2.76 (t, 
J = 6.4, 1H), 2.68-2.64 (t, J = 6.0, 1H), 1.36, 1.35, 1.30 (bs, 12H), 1.23-1.21, 1.22-1.20, 
1.17-1.16 (d, J = 6.8, 12H), 1.08-1.06 (d, J = 6.8, 3H), 1.05-1.03 (dd, J1 = 1.6, J2 = 6.4, 3H) 
ppm. 13C NMR (100 MHz, acetone-d6): δ, 181.8, 159.6, 145.9, 144.1, 144.0, 139.9, 138.7, 
136.6, 136.5, 131.0, 130.9, 129.0, 128.9, 128.6, 127.6, 123.32, 123.28, 119.0, 114.0, 87.2, 
86.7, 86.1, 86.0, 75.0, 74.9, 74.5, 74.3, 64.5, 59.6, 59.4, 55.5, 48.4, 44.1, 44.0, 40.4, 39.0, 
25.0, 24.9, 24.8, 22.9, 22.5, 22.0, 21.7, 21.4, 20.8 ppm. 31P NMR (162 MHz, acetone-d6): 















7-Phenyl-1H-imidazo[4,5c]pyridin-4-amine, trifluoroacetic acid salt (15a, 3a*TFA) 
This compound was synthesized in similar fashion as 15i. A solution of 
14a (2.09 g, 3.65 mmol) in TFA (20 ml) was placed in a 100 ml pressure 
tube, anisole (2.4 ml, 6 equiv.) was added, and the mixture was heated 
at 70 ˚C for 24 h with vigorous stirring. It was cooled and concentrated under reduced 
pressure. The residue was coevaporated with toluene (3 x 25 ml) to obtain grey-brown 
powder. It was taken in toluene (10 ml) and filtered, washing with toluene (2 x 5 ml), then 
hexane (2 x 5 ml) and dried on air to obtain 15a as a free flowing, light gray powder, 1.13 
g (quantitative). MS (ESI): m/z, 211.3 for [M + H]+. 1H NMR (400 MHz, DMSO-d6): δ, 
8.60 (bs, 2H), 8.52 (s, 1H), 7.82 (s, 1H), 7.70-7.69 (m, 2H), 7.56-7.53 (m, 2H), 7.49-7.46 
(m, 1H) ppm. 13C NMR (100 MHz, DMSO-d6): δ, 159.4, 159.0, 158.7, 158.3, 147.5, 144.3, 




This compound was synthesized in similar fashion as 16i. A solution of 15a 
(0.34 g, 1 mmol) in pyridine (10 ml) was placed in a 100 ml Schlenk flask. 
Tetramethylsuccinic anhydride (M4SA) (0.546 g, 3.5 mmol) and DBU (1.05 
ml, 7 mmol) were added, and the mixture was heated at 120 ˚C under argon 
for 20 h with vigorous stirring. It was cooled and concentrated under reduced pressure. The 
residue was coevaporated with toluene (3 x 25 ml). The product was purified by column 
chromatography on silica gel eluting with 0-5% MeOH in CH2Cl2 to give a colorless syrup. 
It was taken in SOCl2 (12 ml), heated at 80 ˚C for 2 h, cooled and concentrated under 
reduced pressure. The residue was coevaporated with EtOAc (3 x 25 ml). The product was 
purified by column chromatography on silica gel eluting with 0-5% MeOH in CH2Cl2 to 
give 16a as a light brown foam in 92% yield (0.56 g). HRMS (ESI): m/z [M+H]+ calc’d 
for C20H21N4O2: 349.16647; found: 349.16505. 1H NMR (400 MHz, CD3OD): δ, 8.75 (s, 













(100 MHz, CD3OD): δ, 182.5, 147.9, 142.4, 139.6, 135.4, 134.4, 134.3, 130.5, 129.8, 





This compound was synthesized in similar fashion as 17i. To a 
solution of 16a (0.51 g, 1.46 mmol) in dry CH3CN (60 ml) in a 
100 ml round bottom flask, 60% NaH in oil (117 mg, 2.93 mmol) 
was added, and the mixture was vigorously stirred at room 
temperature under argon for 45 min. 1-(α)-Chloro-3,5-di-O-(p-
toluoyl)-2-deoxy-D-ribose (0.368 g, 0.94 mmol) was 
subsequently added portionwise over 1 h, and the stirring was continued at room 
temperature for overall 5 h. The mixture was filtered through Celite® and concentrated. 
The product was purified by column chromatography on silica gel eluting with 0-50% 
EtOAc in hexanes. 17a was obtained as a yellowish syrup in 64% yield (0.64 g). HRMS 
(ESI): m/z [M+H]+ calc’d for C41H40N4O7: 701.29757; found: 701.29626. 1H NMR (400 
MHz, CDCl3): δ, 8.33 (s, 1H), 8.31 (s, 1H), 7.86-7.84 (d, J = 8.0, 2H), 7.75-7.73 (d, J = 
8.0, 2H), 7.46 (bs, 4H), 7.32-7.28 (m, 1H), 7.31-7.29 (d, J = 8.0, 2H), 7.24-7.22 (d, J =  
8.0, 2H), 5.96-5.93 (dd, J1 = 5.2, J2 = 8.8, 1H), 5.46-5.44 (m, 1H), 4.62-4.53 (m, 2H), 4.38-
4.36 (m, 1H), 2.48 (s, 3H), 2.40 (s, 3H), 2.30-2.16 (m, 2H), 1.40 (bs, 12H) ppm. 13C NMR 
(100 MHz, CDCl3): δ, 181.7 (Cq), 166.2 (Cq), 165.6 (Cq), 144.7 (Cq), 144.5 (Cq), 142.9, 
142.7, 138.4 (Cq), 138.0 (Cq), 137.4 (Cq), 134.8 (Cq), 130.0, 129.7, 129.6, 129.3, 129.0, 
128.8, 126.6 (Cq), 126.4 (Cq), 123.5 (Cq), 85.9, 82.8, 74.9, 64.2 (CH2), 48.1 (Cq), 40.1 





















This compound was synthesized in similar fashion as 18i. To a 
solution of 17a (0.44 g, 0.63 mmol) in dry MeOH (6 ml) in a 25 
ml round bottom flask, NaOMe (102 mg, 1.89 mmol) was added, 
and the mixture was stirred at room temperature under argon for 
2 h. It was concentrated in vacuo, and the product was purified by 
column chromatography on silica gel eluting with 0-10% MeOH 
in CH2Cl2 to obtain 18a as a white foam in 58% yield (0.17 g). HRMS (ESI): m/z [M+H]+ 
calc’d for C25H29N4O5: 465.21383; found: 465.21228. 1H NMR (400 MHz, CD3OD): δ, 
8.85 (s, 1H), 8.19 (s, 1H), 7.56 (m, 5H), 5.97-5.94 (t, J=6.0, 1H), 4.37-4.33 (m, 1H), 3.78-
3.65 (m, 3H), 2.35-2.28 (m, 1H), 1.96-1.90 (ddd, J1 = 4.4, J2 = 6.0, J3 = 10.8, 1H), 1.39 (bs, 
12H) ppm. 13C NMR (100 MHz, CD3OD): δ, 183.4 (Cq), 146.5 (Cq), 143.1, 139.4 (Cq), 
138.7 (Cq), 138.6 (Cq), 135.6 (Cq), 130.9, 130.2, 129.9, 126.0 (Cq), 88.9, 87.1, 71.2, 62.3 










The attempted tritylation of 18a was carried forward in similar fashion as for 18i. To a 
solution of 18a (0.15 g, 0.323 mmol) in pyridine (3 ml) under Ar, 4,4’-dimethoxytrityl 
chloride (DMT-Cl) (0.153 g, 0.453 mmol) was added in one portion, and the mixture was 
stirred at room temperature for 4.5 h. TLC analysis indicated that some starting material 
remained, and then additional DMT-Cl was added (0.076 g, 0.225 mmol). After 3.5 h, the 
starting material still remained, and then triethylamine (45 μl, 0.323 mmol), cat. DMAP 
(10 mg) and additional DMT-Cl (44 mg, 0.129 mmol) were added. After 8 h, most of the 
starting material was consumed, and the mixture was concentrated in vacuo, the residue 
was coevaporated with toluene (3 x 10 ml) to remove residual pyridine. A TLC analysis 
indicated that an extensive deglycosylation occurred, indicating the instability of the 
compound which may be ascribed to the electronic character of phenyl group at the position 
3 as suggested by other reports.2 Deglycosylation was also observed to occur upon mild 
heating of the TLC plate in order to remove pyridine before analysis. 
 
7-Phenethyl-1H-imidazo[4,5-c]pyridin-4-amine, trifluoroacetic acid salt (15c) 
This compound was synthesized in similar fashion as 15i. A solution of 
14c (0.327 g, 0.55 mmol) in TFA (8 ml) was placed in a 100 ml pressure 
tube, anisole (0.36 ml, 6 equiv.) was added, and the mixture was heated 
at 70 ˚C for 21 h with vigorous stirring. It was cooled and concentrated 
under reduced pressure. The residue was coevaporated with toluene (3 x 15 ml) to obtain 




This compound was synthesized according to the general procedure.19 A solution of crude 







temperature for 5 h in a closed vessel. The pressure was carefully released 
and the mixture was carefully neutralized with aq. NaHCO3 and diluted with 
Et20 (50 ml). The phases were shaken, and the precipitated solid was 
filtered, washing with water and Et20, and dried on air to obtain 21c as a 
light yellow solid (75 mg, 57% based on 14c). HRMS (ESI): m/z [M+H]+ 
calc’d for C14H14N3O: 240.11369; found: 240.11281. MS (ESI): m/z, 240.3 for [M+H]+, 
262.2 for for [M+Na]+, 501.2 for for [2M+Na]+; 238.3 for [M-H]-. 1H NMR (400 MHz, 
DMSO-d6): δ, 10.9 (bs, 1H), 8.09 (s, 1H), 7.26-7.16 (m, 5H), 6.79 (s, 1H), 2.93-2.89 (m, 
4H) ppm. 13C NMR (100 MHz, DMSO-d6): δ, 156.1, 141.6, 141.2, 128.4, 128.2, 125.8, 
124.9, 110.7, 35.1, 29.7 ppm. 
 
TFA salts 15 were used for synthetic purposes typically without further purification. Pure 
amines could be also isolated as water soluble HCl salts as exemplified below. Free amines 
could be obtained by neutralization of their aqueous solutions with Na2CO3 followed by 
extraction with AcOEt. 
 
7-Phenethyl-1H-imidazo[4,5-c]pyridin-4-amine, hydrochloric acid salt (15c*HCl) 
A solution of 14c (0.173 g, 0.29 mmol) in EtOH/H2O/HCl conc. (8/8/4 
ml) was heated under reflux condenser at 100 ˚C for 23 h. It was cooled 
and EtOH was removed under reduced pressure. It was diluted with aq. 
HCl and washed with Et2O (40 ml, discarded) to remove a precipitated 
oil. The residue was concentrated and dried under vacuum to obtain 15c*HCl (ca. 0.08 g, 
quantitative) as an off-white solid. HRMS (ESI): m/z [M+H]+ calc’d for C14H15N4: 
239.12968; found: 239.12930. MS (ESI): m/z, 239.3 for [M+H]+; 237.3 for [M-H]-, 273.0 
for [M+Cl]-. 1H NMR (400 MHz, D2O): δ, 8.35 (s, 1H), 7.28-7.19 (m, 4H), 7.11-7.09 (m, 
2H), 3.09-3.05 (m, 2H), 2.99-2.96 (m, 2H) ppm. 13C NMR (100 MHz, D2O): δ, 146.6, 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure. B96 13C NMR spectrum of 15c*HCl (D2O, 100 MHz). 
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